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cANcer AND cheMoTherAPy
Cancer is a disease where genetic instability leads to a pathological condition which 
gives normal cells an unlimited growth potential and the ability to disseminate and 
invade other parts of the body. Cancer afflicts millions of people worldwide each year 
and is one of the leading causes of morbidity and mortality. Almost every tissue in 
the human body can give rise to cancer, leading to a range of cancers, each possess-
ing unique features1. The therapeutic corner stones to treat solid tumors are surgery, 
radiotherapy and chemotherapy2-4. Surgery and radiotherapy can provide local control, 
but disseminated disease usually requires systemic therapy. A lack of selectivity and 
specificity of such systemic treatments have led to numerous side effects, decreased 
efficacy due to resistance and suboptimal dosing regimens, which eventually results 
in disease recurrence and metastatic spread. To overcome these limitations, many 
conventional chemotherapeutics have been adapted to cope with drug resistance and 
minimize adverse drug-related effects by creating increasingly specific therapies tar-
geted against cancer.
One of these chemotherapeutics is doxorubicin, a clinically important and often-
used anticancer drug. Clinically, doxorubicin is used in the treatment of several cancers 
including; acute leukemia, breast cancer, gastric cancer, (non-)Hodgkin lymphoma, 
neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue and bone sarcomas, 
thyroid cancer, transitional cell bladder cancer and Wilms tumors5. Doxorubicin was 
first isolated in 1969 from Streptomyces peucetius, and is formed by C-14 hydroxyl-
ation of its precursor, daunorubicin6. The main mechanism of action is the inhibition 
of proliferation by intercalating base pairs of DNA/RNA, which is selective for cells 
with a higher proliferation rate. As a result, the drug is cytotoxic to fast growing cancer 
cells, although the nonspecific activity of the drug also affects normal tissues with high 
proliferation rates such as blood cells, the gastrointestinal tract and hair follicles7. A 
major adverse effect of doxorubicin is its cardiotoxicity, which may lead to congestive 
heart failure8. Doxorubicin-induced cardiotoxicity is probably caused by one or more 
of the following; increased oxidative stress9, decreased antioxidants and sulfhydryl 
groups10,11, inhibition of nucleic acid and protein synthesis12, and decreased cardio-
myocyte-specific gene expression13. Serious adverse effects of doxorubicin and other 
anticancer drugs lead to suboptimal dosing, and in combination with drug resistance, 
often results in discontinuation of the treatment. To solve these problems, anticancer 
drugs need to be delivered more selectively to cancer tissue with minimal exposure to 
healthy tissues.
This can in principal be achieved by using antibody- or ligand-mediated targeting in 
combination with drug carriers, which have the added benefit of lengthening the short 
circulation times of free drugs. The antibodies or ligands would be designed to bind 
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antigens or receptors uniquely present and/or overexpressed on cancer cells. This will 
reduce systemic exposure and increase biodistribution of the encapsulated drug.
LiPoSoMeS
Early phospholipid research led to the description of swollen phospholipids which, 
within years, enabled the production of enclosed phospholipid bilayer structures called 
liposomes14-18. Liposomes are composed of natural phospholipids, which makes them 
biologically inert, less immunogenic, non-toxic and ideal for drug entrapment19,20. 
The combination of a hydrophobic bilayer and an aqueous center makes them ideal 
for encapsulating both lipophilic and hydrophilic drugs, and even compounds with an 
intermediate partition coefficient21. These characteristics facilitate their use as effec-
tive delivery systems, preventing free drug from interacting with the body and thereby 
reducing side effects and immune reactions.
Early liposomal formulations were cleared rapidly from circulation via opsonization22, 
and captured by the mononuclear phagocyte system (MPS)23. To prevent this, long-
circulating liposomes were created by the addition of hydrophilic polymers, such as 
polyethylene glycol (PEG), to the liposome surface24. These polymers can be anchored 
to the liposomal membrane via cross-linked lipids such as pegylated 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine (DSPE-PEG)25. The flexible chain of the polymer 
causes steric hindrance for macromolecules, reduces clearance by macrophages and 
enables long circulation times. In addition, liposomes are not stable in plasma due to 
interactions with high and low density lipoproteins26. Incorporation of cholesterol in 
the lipid bilayer facilitates a bidirectional transfer of phospholipids, which otherwise 
would lead to phospholipid depletion and liposome degradation27-29. Although the use 
of saturated phospholipids also increases the stability of liposomes30, this might lead to 
a decrease in the rate of drug release from the liposomes.
Drug loading of liposomes is highly dependent on the nature of the drug. Like most 
lipid membranes, liposomes have a high permeability to hydrophobic drugs which 
makes drug entrapment difficult31,32. Drug loading progressed significantly with the 
development of pH gradient-dependent or remote drug loading methods33,34. In addi-
tion, some drugs like doxorubicin have the added bonus of precipitation after loading, 
which creates a very stable liposomal drug formulation35. Liposomes can encapsulate 
several thousand drug molecules, ensuring a high drug load delivery, although drug 
loading, retention and release have to be optimized for every nanoparticle formulation. 
This resulted in liposomal doxorubicin (Doxil) being the first liposomal formulation 
to reach clinical trials36,37. Although Doxil has been approved for use against ovarian 
cancer, Kaposi sarcoma and multiple myeloma38; overall the slow release37, lack of 
specificity, and the reliance on passive accumulation via the enhanced permeability and 
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retention (EPR) effect have left room for improvement. Targeting with antibodies or 
other ligands could improve site-specific accumulation and efficacy, whereas triggered 
release tactics can be implemented to avoid the insufficient drug release.
TArGeTeD LiPoSoMeS
Cancer cells have structural and functional differences which can be exploited for tar-
geted therapies. To enhance specificity of liposomal chemotherapy, liposomes can be 
functionalized with a targeting moiety to generate targeted or immunoliposomes. The 
target should have a high density on tumor cells or tumor vasculature, and should pref-
erably not be expressed on other tissues. To this end, liposomes have been formulated 
with ligands to target the tumor itself or its surrounding microenvironment, such as the 
extracellular matrix or the tumor-associated vasculature39-42. The general principle of 
extravasation and binding of targeted liposomes is shown in Figure 1. When using ste-
rically stabilized liposomes, antibodies or antibody fragments can be linked to the end 
of PEG chains with conventional chemical conjugation techniques43,44, while retaining 
an enhanced circulation and decreased uptake in the liver and spleen45,46. Initial stud-
ies investigating antibody-conjugated liposomes suggested that this approach could 
increase the efficacy of liposomal chemotherapy47,48.
D
C
BA
Figure 1. Liposomes extravasate due to enhanced permeability in tumor vasculature (A), 
upon which tumor cell specific binding of targeted liposomes can take place (B). After bind-
ing, liposomes may be internalized (C) resulting in intracellular drug release (D).
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The therapeutic efficacy of targeted liposomes is dependent on the number of antigens 
available for binding on the cell surface49. Heterogeneity in antigen expression within 
a tumor may lead to reduced efficacy; moreover, some antigen-negative cells might 
be affected simply due to their location close to antigen-positive cells. This so-called 
bystander effect might occur when the drug is released from the carriers into the tumor 
interstitial space and can be taken up by other cells, resulting in sometimes unwanted 
cytotoxicity50. Additionally, shedding or downregulation of antigens is counterproduc-
tive, as this might lead to binding competition or loss of specificity, which in the end 
causes loss of efficacy or adverse effects. If non-internalizing ligands are used, the 
liposomes will attach to the cell surface where over time the drug is released and taken 
up as free drug. In contrast, liposomes can be coated with internalizing ligands which 
initiate receptor-mediated endocytosis and help internalize the drug and/or carrier51,52. 
A higher dose of drug will be released into the cell with internalizing ligands, resulting 
in a higher efficacy compared to non-internalizing liposomes53. Some studies have even 
suggested that internalization is a prerequisite for efficient cytotoxicity54-56. Addition-
ally, upon cellular uptake, the drug has to be capable of surviving the endosomes and 
lysosomes it may end up in. Free drugs such as doxorubicin are readily taken up by cells 
via passive diffusion, whereas other drugs can use cell membrane transporters.
Aside from liposomal doxorubicin, various other formulations have made it to the 
clinic or are in preclinical development57. Liposomal vincristine58 and liposomal iri-
notecan59 were approved by the US Food and Drug Administration (FDA) for lympho-
blastic leukemia in 2012 and metastatic pancreatic cancer in 2015, respectively. Others 
remain in clinical trials, and include liposomal formulations containing cytarabine/
daunorubicin60, mitoxantrone, cisplatin, or paclitaxel. Usually after initial FDA approval 
of the nanoparticle, extended approval is sought for additional cancer types or combi-
nation therapies and further optimization of the nanoparticle is performed. Currently, 
HER2-targeted liposomal doxorubicin has reached a phase II clinical trial61. Cationic 
liposomes functionalized with an anti-transferrin receptor antibody are used to deliver 
a wildtype p53 sequence to restore p53 tumor suppressor gene function in humans62. 
PSMA-targeted polymeric nanoparticles containing docetaxel are being used in phase 
I clinical trials for prostate cancer63,64. In addition, other ligands such as RGD, folate 
and transferrin have been used to target cellular adhesion molecules or growth-factor 
receptors, respectively. Despite their lack of specificity due to their ubiquitous expres-
sion, these ligands are currently used in various imaging and treatment regimens65,66.
The use of targeted liposomes has been controversial with studies advocating im-
proved efficacy67,68, and studies showing no improvements in survival due to instabil-
ity of drug loaded liposomes or a lack of liposome internalization69,70. Nonetheless, 
current research remains focused on improving specificity, bioavailability and efficacy 
with the help of targeting ligands. Where targeting ubiquitous ligands, like folate and 
15
Introduction
1
transferrin, has lacked specificity, monoclonal antibodies have been more specific 
towards tumor antigens yet have increased immune related adverse effects. To combine 
the specificity of antibodies with a lesser involvement of the body’s immune system, 
smaller antibody fragments have been generated.
heAvy chAiN ANTiBoDieS
Monoclonal antibodies have been around for quite some time and are used in the 
clinic as therapy against various diseases, including cancer. Normally immunoglobulin-
gamma (IgG) antibodies have two identical heavy chains and two identical light chains 
and it is highly conserved in mammals71. The heavy and light chains which make up 
a full antibody can be divided into domains, four for the heavy chains and two for the 
light chains. The N-terminal domain of both chains is highly variable and is called 
the variable domain. Both variable domains of the heavy and light chain compose the 
antigen-binding site or paratope, with the heavy chain variable region being primarily 
responsible for the binding specificity. The other, more conserved regions are called 
constant domains, where the two last regions of the heavy chain (Fc region) are neces-
sary for the recruitment of immune cells. This happens through binding Fc receptors 
on for example macrophages, which unfortunately leads to high liver and spleen uptake 
of antibody functionalized drugs.
Antibodies targeted against tumor-associated antigens can be useful in a number 
of ways. First of all, diagnosis through imaging and real time imaging of tumors can 
be used to aid surgery or to ascertain efficacy of given anticancer treatment. Secondly, 
antibodies can have an effect via receptor binding and inhibit tumor cell growth and 
proliferation, or induce apoptosis by suppression of signal transduction. Thirdly, anti-
bodies can deliver therapeutic loads via nanoparticles, drug-conjugates or radionuclide 
antibody-conjugates. Currently, 62 monoclonal antibodies have been approved for 
therapy by the FDA and numerous more are in development72. Despite their tremen-
dous contribution to medicine, monoclonal antibodies have some disadvantages. They 
are large molecules (150 kDa, 14.2 x 8.5 nm)73 which have a typical half-life of several 
days74. Although the long exposure is an advantage in some applications, it also leads 
to immune reactions that are counteractive. The majority of monoclonal antibodies are 
produced by generating hybridomas, which involves fusing a tumor myeloma cell with 
an antibody-producing cell from an immunized mouse75. These murine antibodies can 
give rise to human anti-mouse antibodies and immune responses in the patient leading 
to increased clearance, decreased accumulation and adverse effects76. Their large size 
inhibits tumor penetration and biodistribution, impairing successful application as 
an anticancer therapy. To improve pharmacological properties, antibodies have been 
developed with a reduction in size77. One particular type of antibody was discovered in 
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camels as described by Hamers-Casterman et al. in 1993. Camels and other members 
of the biological family Camelidae were found to express antibodies devoid of a light 
chain and lacking the first constant domain (CH1). It has been suggested that an ex-
tended spacer replaces the CH1 region78. Normally, all mammals contain antibodies 
with two heavy chains and two light chains, but in humans with heavy chain diseases79, 
heavy chain antibodies can be produced as a result of a genetic deletion, although these 
antibodies are nonfunctional80,81. In addition, the production of antibodies lacking a 
light chain and CH1 has been observed in nurse sharks, wobbegong, and other spe-
cies82. The expression of heavy-chain antibodies is variable, since conventional IgGs 
are also expressed in camelids. In camels, heavy-chain antibodies can account for up to 
80% of circulating antibodies, whereas in South American camelids (llamas, alpacas) 
it only accounts for 10-25%83. Conventional antibodies are generated by recombina-
tion and selection of V, D, and J elements, each of which are sequentially organized as 
multiples in the gene locus. The variability increases exponentially by selection of dif-
ferently recombined copies and, through further hypermutation of the variable regions, 
a repertoire of antibodies is created, which can be expanded when needed to repel 
invaders. Somatic hypermutations and selection during maturation of the antibodies 
can increase the diversification84. Nucleotide mutations were found upstream of the 
first antigen-binding loop, which create additional somatic hypermutation hotspots. 
These hotspots enable easy mutation of amino acids during the affinity maturation 
process85,86.
The camelid genome contains constant region elements to produce both conventional 
heavy chain and heavy-chain(-only) antibody in the same locus87. To eliminate the CH1 
region, the constant region sequence carries a point mutation that leads to a change 
in RNA splicing and “skipping” of the CH1 region from the mRNA88. Mimicking this 
mutation in mice does not lead to heavy-chain antibodies, but the deletion of the entire 
CH1 exon does lead to the successful generation of heavy-chain antibodies89. Whereas 
conventional antibodies have two domains contributing to the antigen-binding site, 
the heavy-chain antibodies have only one domain and thus a less diverse paratope. The 
two constant domains (CH2 and CH3) of the heavy-chain antibodies are linked by a 
hinge region connecting it to a variable domain (VHH)78. The variable domain of the 
heavy-chain antibody can be isolated relatively easily after immunization of a camelid, 
after which VHHs can be cloned and used for selection through, for example, phage 
display90,91. Phage display and other selection techniques, such as yeast and ribosome 
display, enable selection of high affinity antibodies92. These VHHs are also called single 
domain antibodies or nanobodies, due to their size in the nanometer range.
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NANoBoDieS
VHHs contain four conserved framework regions interspersed with three hypervariable 
complementary-determining regions (CDR), which are complementary to the epitope 
surface and play a major role in antigen recognition and binding93. The hypervariable 
regions form loops, which in conventional antibodies can be structured to recognize 
small molecules, linear peptides or large proteins by formation of a cavity, groove or 
flat surface94. In the absence of a light chain, highly conserved hydrophilic amino acids 
(usually) replace four hydrophobic amino acids that are normally used for binding to 
the light chain and promote solubility of the heavy-chain antibody95,96. To compensate 
for the loss of the variable light chain domain, the loops in the variable domain of heavy-
chain antibodies can be longer than conventional antibodies85. It can be expected that 
a longer loop is more flexible, yet has a lower binding capacity. Therefore the loops in 
VHHs are constrained with disulfide bonds97. Especially, the first and third antigen-
binding loops have more cysteine residues to facilitate inter- and intraloop disulfide 
bonds than its conventional antibody counterparts98,99. The loop increases the potential 
antigen-binding surface by protruding from the rest of the binding site100. When heavy-
chain antibodies are generated in mice the variable domains are very similar in length 
compared to regular antibodies. Nanobodies (only the variable domain; 15 kDa, 4.2 
x 2.5 nm)93 are much smaller than monoclonal antibodies and have protruding CDR 
loops to interact with antigens with CDR3 being responsible for 60-80% of antigen 
binding101,102. The three-dimensional shape of a nanobody is prolate (rugby ball-like) 
and thus exposes a convex paratope, which enables easier access to difficult to reach 
epitopes102.
Although nanobodies are derived from the Camelidae family, it has been reported 
that for application in humans, the immunogenicity is low and anti-drug antibodies are 
absent103-107. This is probably a result of the large sequence homology with the human 
VH III gene family108,109. Nevertheless, a discourse continues, with groups reporting 
significant immune adverse events and the presence of autoantibodies110-112. This has 
led to humanization strategies of amino acids differing between human and camelid 
variable domains113. After in vivo administration of nanobodies, these small molecules 
distribute throughout the body, penetrating most tissues114. Although, with a size below 
the renal molecular weight cut-off, nanobodies will be rapidly cleared115. When labeled 
with a radionuclide or fluorophore, these characteristics make nanobodies ideal as in 
vivo imaging tools106,116. Additionally, the use of an alpha or beta emitting radionuclide 
conjugated to the nanobodies can be used for targeted radionuclide therapy or so-called 
radioimmunotherapy (RIT)117. The high specificity of nanobodies is combined with a 
high dose of radiation which damages the cancer cells and causes minimal damage to 
healthy tissue. One major disadvantage is kidney retention of nanobodies, although 
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this can be reduced by removing the His-tag from nanobodies, by co-injection of the 
positively charged plasma-expander GeloFusin118, or by generation of His-tag free 
nanobodies.
In the treatment of cancer, nanobodies can be used in a similar manner as monoclonal 
antibodies; for the imaging of tumors, direct antagonistic effects via receptor binding 
or as targeting modality for drug delivery systems. Nanobodies are very efficient for 
the imaging of tumor cells, due to a homogeneous distribution in most tumors119. As 
antagonists, nanobodies are less efficacious, since they lack an Fc domain and can-
not initiate the complement immune system120. Despite this, nanobodies have been 
developed which inhibit tumor growth by targeting EGFR121, HGF122, CXCR7123, and 
VEGF-A124 and VEGFR2125. Finally, nanobodies can be used to functionalize nanopar-
ticles or drug-conjugates to specifically target tumor cells126. In this case, the small size 
and low immunotoxicity of the nanobodies works together with the nanoparticles’ 
capability to deliver large drug doses, while protecting the body against systemic toxic-
ity. Although the large size of the nanoparticles impairs tumor penetration compared to 
nanobodies alone, the prolonged circulation time enables sufficient accumulation via 
the EPR effect, which includes poor lymphatic drainage127,128. A number of drug delivery 
systems have been described using nanobodies for targeting. For example, IGF-1R ki-
nase inhibitor-loaded liposomes were targeted against EGFR to facilitate simultaneous 
blocking of both receptors129. EGFR-targeted micelles loaded with doxorubicin were 
effective inhibitors of tumor growth130. Polymersomes have been developed containing 
nanobodies targeted against HER2 and PlexinD1131,132. Besides the use in anticancer 
therapy, nanobodies can be used in the treatment of infections, inflammations, and in 
neurodegenerative diseases, as has been reviewed elsewhere133.
There are some downsides to the use of nanobodies instead of conventional antibod-
ies. Partially due to their monovalent nature, most nanobodies have a lower affinity/
avidity than bivalent antibodies. In some instances this is a benefit, for example if the 
binding site barrier effect is taken into account, but in general, higher affinities are 
preferable. Luckily, affinity maturation processes have been developed to improve 
antibody affinities134. For instance an error-prone PCR can be applied on the desired 
nanobody to generate a highly diversified nanobody library135. In addition, the reduced 
affinity of nanobodies can be compensated with the use of nanoparticles. Depending 
on the size of the antibody fragment, up to hundreds of antibodies can be attached 
to the surface of a nanoparticle. This in turn will lead to a high affinity of targeted 
nanoparticles. Although, studies have also shown that a higher affinity does not always 
lead to a higher accumulation136. In addition, tumor penetration will be impaired due 
to the binding-site barrier effect where the first target encountered will bind the anti-
body permanently137-139. A second downside, is the relatively expensive immunization 
of camelids, although transgenic mice have been developed expressing hybrid human 
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or llama antibody loci where conventional antibody development is blocked by using 
endogeneous heavy (and light) chain knockout mice89,140,141.
Recent developments show major improvements on the use of conventional antibod-
ies and novel antibody formats have enabled the production of highly specific and low 
immunogenic anticancer therapies, in addition to several other applications.
The eNhANceD PerMeABiLiTy AND reTeNTioN effecT
First described in 1986, the enhanced permeability and retention (EPR) effect is based 
on observations that most solid tumors have a defective blood vessel architecture and 
usually produce various vascular permeability factors142. Newly formed tumor blood 
vessels have an abnormal architecture, defective endothelial cells, lack of a smooth 
muscle layer and an irregular vascular alignment143,144. Tumor vessels show an enhanced 
vascular permeability, which ensures the tumor of sufficient nutrients and oxygen 
needed for rapid growth. In addition, an impaired lymphatic system was observed that 
increased retention of macromolecules in the tumor142,145. Increased permeability of 
tumor blood vessels facilitates increased extravasation of macromolecules compared to 
normal blood vessels. The tumor vessels lack tight junctions between their endothelial 
cells146,147. The gaps in tumor vessels range from 100-600 nm148, enabling extravasation 
of almost all nanoparticles into the interstitial space. However, the impaired lymphatic 
system in tumors may increase osmotic pressures within large tumors, resulting in an 
impaired accumulation or even an outflow of nanoparticles149. The EPR effect is highly 
dependent on the molecular size, which needs to be larger than the renal clearance 
threshold (> 40 kDa) to enable longer circulation times and slow body clearance. The 
size of the drug or nanoparticle has a large effect on tumor penetration, which is highly 
heterogeneous150-153. Clearance from circulation by macrophages, Kupffer cells or scav-
enger receptors is just as important as size, where more biocompatible molecules have 
a longer plasma half-life and eventually a bigger chance of extravasation.
Tumors show a high degree of morphological heterogeneity, which means that the 
EPR effect is not always present in the entire tumor or in every stage of tumor pro-
gression. Larger tumors often have a hypovascular or necrotic core which reduces the 
chance of nanoparticle extravasation154, whereas small early stage tumors often show a 
high vascular density (hypervasculature)155. Tumor tissue is surrounded by the extracel-
lular matrix (ECM), which in addition to facilitating tumor-associated angiogenesis, 
promotes metastasis and the generation of a tumorigenic microenvironment. It is also 
a major bottleneck for macromolecular drugs, since the ECM in tumors is abnormally 
structured and more dense than in normal tissues156,157.
Extravasation of nanomedicine is the rate-limiting step of liposomal accumulation 
and is dependent on the EPR effect. The presence or degree of the EPR effect relies 
Chapter 1
20
on many parameters within the tumor and tumor microenvironment, and predictors 
remain to be elucidated. Therefore the promise of liposomal accumulation in the tumor 
via the EPR effect has been discussed controversially150,158, yet it is clear that targeting 
modalities are ineffective without access to the tumor tissue. Luckily, vascular perme-
ability can be increased by the use of chemicals, hyperthermia and other methods, 
which allow enhanced liposomal accumulation in tumors159,160.
MiLD hyPerTherMiA
The goal of increasing the in vivo stability of liposomes has led to an undesirable side 
effect; the drug remains encapsulated and is released slowly from the liposomes which 
results in decreased bioavailability. To circumvent this issue, modes of triggered drug 
release have been extensively investigated and includes the use of heat, ultrasound and 
pH, among others161-166. Here we will focus on triggered drug release upon applica-
tion of heat, which has the added benefit of increasing liposomal accumulation in the 
tumor by enhancing vascular permeability (Figure 2)160,167. Release of the drug from 
liposomes based on mild hyperthermia (40-43°C) was first described by Yatvin and 
Weinstein168,169, and liposomes capable of hyperthermia triggered release are termed 
thermosensitive liposomes. The goal of thermosensitive liposomes is to minimize 
HyperthermiaNormothermia
Figure 2. Increased liposomal extravasation after pretreatment of the tumor with mild 
hyper thermia.
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unwanted drug leakage during circulation at physiological temperatures and a quick 
drug release upon application of mild hyperthermia.
Thermosensitive formulations are based on the melting phase transition temperature 
(Tm) of the lipids, which indicates the temperature at which the lipids transfer from a 
solid gel phase to a liquid-crystalline phase. The original formulation used by Yatvin et 
al. was made with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, Tm = 41.4°C) 
and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Tm = 54.9°C) in a molar ratio of 
3:1168. The composition of lipids determines the permeability to water and hydrophilic 
drugs, where the liposomes are more permeable in the liquid-crystalline phase170-172. 
In addition, it has been suggested that permeability is highest around the transition 
temperature, due to the formation of grain boundaries between solid and liquid phase 
areas173-175. Continued heating past the transition temperature leads to a reduction 
in the interfacial areas and eventually into a pure liquid phase which is accompanied 
by a reduction in permeability171. Thermosensitive liposomes can also be formulated 
using lysolipids, a product of phospholipid hydrolysis which can act as detergents in 
the presence of lipid membranes and have been reported to create hydrophilic pores 
along liquid-solid boundaries171,176. A further development has been the incorporation 
of cholesterol and PEG lipids to generate stealth thermosensitive liposomes, which 
circumvents the low circulation times of conventional liposomes177,178.
ThermoDox is a lysolipid thermosensitive liposomal formulation encapsulating 
doxorubicin that releases the drug upon a mild hyperthermia treatment of 42°C179. 
Clinical studies in ovarian cancer (phase I) and breast cancer (phase I/II) are underway. 
In a clinical phase III trial (HEAT study) it was shown that a combination of image-
guided radiofrequency ablation (RFA) with ThermoDox did not produce a therapeutic 
doxorubicin concentration in primary liver cancer, although it was suggested that 
a standardized dwell time of more than 45 min might increase clinical efficacy of 
ThermoDox (ongoing OPTIMA study)180. For this drug the mechanism of intravascular 
release is used, where prior to administration the tumor site is heated so that the release 
of doxorubicin occurs within the tumor blood vessels damaging perivascular tumor 
cells and tumor associated endothelial cells181. It was shown that thermosensitive lipo-
somes release their drug intravascularly upon application of localized hyperthermia181. 
As a result a high dose of free drug was able to penetrate the tumor tissue deeper than 
controls with free drug or Doxil. It is important to note that the higher dose of drug 
delivered to the tumor might also be attributed to an increase in vascular permeability 
as a consequence of the hyperthermia treatment182.
Thermosensitive liposomes have been developed further and are currently equipped 
with targeting moieties to enhance specificity183,184. In recent years, thermosensitive 
liposomes targeted against HER2185, CD13186, and the folate receptor187 have been re-
ported. Although the use of hyperthermia and other triggered release systems is clearly 
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beneficial in that it enables the localized delivery of a high drug dose to the tumor, its 
application remains limited to superficial or otherwise accessible tumors. Disseminated 
metastatic disease remains the major cause of cancer related mortality and thus there 
is an urgent need to improve on current drug delivery systems to enhance targeted drug 
delivery. Current research is therefore focused on enhancing specificity and bioavail-
ability of liposomal chemotherapy.
AiMS AND ScoPe of ThiS TheSiS
There still is an urgent need for the development of effective treatments against various 
unresectable and metastatic cancers. This thesis explores the development of targeted 
nanoparticles that could overcome current challenges in anticancer therapies, such as 
drug resistance, adverse drug-related effects and limited drug accumulation in the tu-
mor. In addition, we have tried to elucidate the factors influencing the aforementioned 
issues.
Chapter 2 describes the production and characterization of novel heavy-chain anti-
bodies against the cell surface antigen MUC1.
In Chapter 3, we applied novel anti-PSMA nanobodies as a tool to image prostate 
cancer by site-specific labeling with indium-111.
In Chapter 4, the anti-PSMA nanobodies were used as a targeting moiety by conju-
gation with doxorubicin-loaded liposomes. The efficacy of targeted and non-targeted 
liposomes was determined with and without hyperthermia to increase vessel perme-
ability.
Chapter 5 investigates the impact of the enhanced permeability and retention (EPR) 
effect on the accumulation of liposomes in various tumor types and attempts to eluci-
date the factors regulating this effect.
In Chapter 6, the efficacy of thermosensitive liposomes after 1- and 2-step hyper-
thermia protocols was investigated before further studies into the effect of tumor 
morphology on liposomal accumulation.
Chapter 7 discusses the results of these studies in light of current developments in 
nanomedicine, antibody research and imaging.
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iNTroDucTioN
Heavy-chain antibodies are produced naturally in the Camelidae species, where in the 
absence of a light chain, the antigen binding site is completely formed by the single 
heavy chain variable domain78,188. Camelid variable domains may display surface loops 
longer than conventional human antibodies85. To avoid cumbersome immunization 
of Camelids, transgenic mice have been generated, which are able to generate antigen 
specific humanized heavy-chain antibodies (HCAbs) upon immunization89. The first 
generated transgenic mice contained two llama variable regions (VHH), while later 
generation transgenic mouse lines utilizes human variable regions (VH). All trans-
genic mouse lines are made in a mouse heavy-chain knockout background to prevent 
rearrangement and expression of endogenous mouse immunoglobulins189. Antibody 
production is maintained by long-lived antibody producing cells migrating to survival 
niches within the bone marrow and spleen190-192.
MUC1 is a large transmembrane mucin protein which, when glycosylated, extends 
200-500 nm above the cell membrane193. The extracellular region of MUC1 is com-
posed of a variable number of 20 amino acid repeats that are enriched in serine, 
threonine and proline residues. It is overexpressed in epithelial cancer cells where it is 
abnormally glycosylated with short oligosaccharides194-196. MUC1 is usually expressed 
on the apical surface of epithelial cells, yet in tumor cells it is expressed over the entire 
cell surface197. Increased MUC1 levels have been reported in the blood of patients with 
breast cancer198,199 and ovarian cancer200, and is associated with metastatic competence 
and poor prognosis201,202. MUC1 mediated signaling influences metabolic pathways, 
which support tumor cell growth and invasiveness203.
The aim of this study was to generate high affinity MUC1-specific antibodies and 
conjugate them to liposomes as a drug delivery system to MUC1-overexpressing cancer 
cells. To this end, transgenic mice were immunized with a peptide representing the 
20-amino acid tandem repeat present in the extracellular region of MUC1. Using direct 
cloning of plasma cell repertoires into eukaryotic HCAbs vectors yielded a HEK cell an-
tibody library. Screening of the library resulted in a number of antigen specific HCAbs 
that recognize the peptide used for immunization, but also the MUC1 expressed on the 
surface of MUC1 positive cancer cells. These will be used for conjugation to liposomes 
and further cell binding experiments. In future studies, this antibody-liposome plat-
form can be used for targeted delivery of chemotherapeutics to MUC1-positive tumors.
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MATeriALS AND MeThoDS
immunization
All animal experiments were approved by the Committee on Animal Research of the 
Erasmus MC (Rotterdam, the Netherlands). Transgenic mice were immunized with 
MUC1 tandem repeat peptide, PDTRPAPGSTAPPAHGVTSA, conjugated to keyhole 
limpet hemocyanin (KLH) (Bio-Synthesis Inc. Lewisville, TX) dissolved in PBS using 
Stimune adjuvant (Thermo Fisher Scientific Inc., Waltham, MA). Mice were injected 
s.c. with 20 μg of peptide conjugate, 6 times with two weeks intervals. 4 d after the last 
i.p. injection, mice were sacrificed and plasma cells were isolated from the spleen and 
bone marrow.
Plasma cell isolation and library construction
A single cell suspension was made in 0.5% BSA, 2 mM EDTA in PBS, from the spleen, 
femurs and tibias of the transgenic mice. Magnetic cell sorting of CD138-positive cells 
was performed using a mouse CD138+ plasma isolation kit (Miltenyi Biotec GmbH, 
Germany), which first depletes non-plasma cells (by indirect labeling of CD49b and 
CD45R) and then enables selection of plasma cells (by direct labeling of CD138). 
Plasma cells eluted from the column were centrifuged and resuspended in 400 μL 
Ultraspec TM RNA reagent (Biotecx Laboratories Inc, Houston, TX). Total RNA was 
prepared according to manufacturer’s instructions and dissolved in dH2O before first 
strand cDNA synthesis using SuperScript TM II RT (Invitrogen, Carlsbad, CA) using 
oligo dT priming. RT-PCR was performed using specific primers, forward from leader 
sequences and reverse from G2/G3 hinge region, and high fidelity DNA polymerase 
Phusion (Finnzymes, Finland) with an annealing temperature of 68°C and 35 cycles in 
total. PCR products were cut with PvuII/BstEII and cloned into pCAGhygroG2 vector 
containing an Ampicillin resistance gene for bacterial selection and a Hygromycin B 
(Thermo Fisher Scientific Inc.) resistance gene for eukaryotic selection. Ligations were 
performed o/n at 16°C.
Preparation and transfection into HEK293 cells
1 μL of 5x diluted ligation product was used to transform electrocompetent MegaX 
DH10B T1R cells (Invitrogen) according to manufacturer’s instructions. The result-
ing product was plated on 2xTY/Amp agar plates and 1920 individual colonies were 
picked and incubated o/n in 1.5 mL of 2xTY/Amp medium in 96-well format. DNA 
plasmid preparations were made using NucleoSpin 96 Plasmid (Macherey-Nagel 
GmbH, Germany). An estimated 200 ng of DNA was used for transfection into HEK293 
cells. HEK cells were plated in 96-well plates and transfected using Lipofectamine 2000 
Transfection Reagent (Thermo Fisher Scientific Inc.) according to the manufacturer’s 
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instructions. The next day, hygromycin B (final concentration of 200 μg/mL) medium 
was added to the medium (DMEM medium supplemented with non-essential amino 
acids (NEAA, Lonza, Belgium), 10% fetal bovine serum (FBS) and penicillin and strep-
tomycin (P/S; Lonza). After 4 d, 50 out of 200 μL of medium was taken per well to 
perform an antigen specific ELISA.
Antigen specific screening ELISA and sequencing
ELISA plates were coated o/n at 4°C with 10 μg/mL MUC1-peptide conjugated to BSA. 
Plates incubated with BSA alone were used as a negative control. After washing with 
PBS/Tween 0.5% and PBS, the plates were blocked for 1 h with 2% milk in PBS (w/v). 
Plates were further washed three times with PBS/Tween 0.5% and PBS. 50 μL of the 
HEK cells supernatant were added to the plates with 50 μL of 4% milk in PBS (w/v) 
and incubated for 2 h at room temperature. After another washing step, 50 μL of goat 
anti-human IgG peroxidase (1:5000) in 2% milk in PBS was added to the wells and 
incubated for 1 h. A final washing step was performed before addition of 50 μL BM 
Blue POD substrate (Roche). The reaction was stopped with H2SO4 and the plate was 
analyzed on an ELISA plate reader. Sequencing of positive DNA clones was done using 
the primer VH3-23 leader 5’-TACACCGGTCCACCATGGAGT- 3’.
Purification, cell binding and affinity measurements
Positive clones were stably transfected into HEK293 cells and these were used for pro-
duction of specific heavy-chain antibodies against MUC1. In short, 4 x 106 cells were 
seeded in 145 mm culture dishes and grown in DMEM + 10% FBS till semi-confluent. 
The medium was changed to serum free production medium, OptiMEM Glutamax 
(Thermo Fisher Scientific Inc.). The production medium was harvested and cell free 
medium was used to purify HCAbs on Protein A agarose (Sigma Aldrich). HCAbs were 
eluted with 3 M KCN and dialyzed 3 times against PBS, before use in other experiments.
The pancreatic cell line, CFPAC-1, was used to test the specificity of the generated 
MUC1 HCAbs and was obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). Cell culture reagents, unless otherwise specified, were obtained from 
Sigma-Aldrich, St. Louis, MO. CFPAC-1 was grown in Dulbecco’s Modified Eagle Me-
dium (DMEM) supplemented with 10% FBS and P/S, and was routinely cultured in a 
well humidified incubator at 37°C and 5% CO2.
Cell binding was established with flow cytometry analysis, for which cells were har-
vested by trypsinization and resuspended in cold PBS (Sigma-Aldrich) containing 1% 
BSA (Sigma-Aldrich). Cell suspensions were incubated with HCAbs at a concentration 
of 50 μg/mL for 30 min at 4°C. Post incubation, the cells were washed twice with cold 
PBS/1% BSA and incubated with a secondary antibody against human IgG conju-
gated to FITC (goat-anti-human IgG FITC, Anogen Biotech Laboratories Ltd., Toronto, 
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Canada) After a second wash, the cells were subjected to flow cytometry analysis using 
the LSRFortessa cell analyzer (BD Biosciences, Franklin Lakes, NJ). Data analysis was 
performed using the FlowJo software (TreeStar Inc, Ashland, OR).
Affinity measurements were performed using the Octet QK (Forte Bio, Menlo Park, 
CA). Briefly, after pre-hydration anti-human IgG Fc coated tips (FortéBio) were dipped 
in PBS for 300 s to obtain a stable baseline signal. The tips were loaded with anti-MUC1 
HCAbs for 180 s in a concentration range from 0 to 20 μg/mL in PBS, before another 
baseline step of 600 s in PBS. Then association with MUC1 peptide (10 μg/mL) was 
ascertained over 600 s before dissociation over 900 s in PBS. The association and dis-
sociation curves were fitted to a 1:1 binding model and the dissociation constant (Kd) 
was calculated using Octet software.
reSuLTS AND DiScuSSioN
Generation of heavy-chain antibodies
The immunized transgenic mice successfully produced HCAbs, which are lacking a 
CH1 region (Figure 1A). The entire procedure from immunization up to screening of 
antigen-specific HCAbs is depicted in Figure 1B. From the MUC1 specific ELISA screen, 
150 clones were found positive based on comparison with a negative control (BSA 
coated plates). The corresponding cDNA was sequenced, which showed a certain de-
gree of homology between various antibodies. Out of 150 clones 73 were unique (data 
not shown), and based on the CDR3 regions, the HCAbs were classified into distinct 
groups of which 18 clones were selected for further testing (Figure 2). These antibodies 
were generated and produced in a relatively short period of time (circa 2-3 months), 
in comparison to other techniques, such as hybridoma production or phage display 
selection followed by bacterial or yeast expression. Further expansion and production 
of antibodies can be done in mammalian cells in a limited time span.
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A
V regions D regions J regions Cγ2 Cγ3
B
Immunization
Extraction of RNA and generation of cDNA
Isolation of plasma cells from 
spleen and bone marrow
VH specific amplification PCR 
& 
transformation into E. coli
Picking of E. coli colonies
& 
plasmid DNA isolation
HEK cell transfection
&
antibody production
ELISA screen of supernatant
Figure 1. Human HCAb locus construct used for transgenesis, containing human V, D and 
J regions and constant regions lacking the CH1 domain (A). Schematic overview of the ex-
perimental procedure followed to obtain heavy-chain antibodies from transgenic mice (B).
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CDR1 CDR2 CDR3
6C2:  EVQLVESGG.GVVQPGRSLRLSCAAS GFTF....SSYG MHWVRQAPGKGLEWVAV IWYD..GSNK YYADSVK.GRFTISRDNSTNTLYLQMNSLRAEDTAVYYC AREGTMVRGAL----------DY WGQGTLVTVSS
5C6:  EVQLVESGG.GVVQPGRSLRLSCAAS GFTF....SRYG MHWVRQAPGKGLEWVAV IWYD..GSNK YYADSVK.GRFTISRDNSKNTLFLQMNSLRAEDTAVYYC ARESYCGGGACYF--------DY WGQGTLVTVSS
4D11: EVQLVESGG.GVVQPGRSLRLSCAAS GFTF....STYG MHWVRQAPGKGLEWVAV IWYD..GSNK HYADSVK.GRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARGGYERYYYYYYGM------DV WGQGTTVTVSS
5F7:  EVQLVASGG.GVVQPGRSLRLSCAAS GFTF....SSYG MRWGRQAPGKGLEWVAI IWHD..GINK NYADSVK.GRFTISRDNSKNTVYLQMNSLRAEDTAVYYC ARDISTDPF------------DY WDQGTLVTVSS
5B5:  EVQLQESGP.GLVNPSETLSLTCAVS GHSIS...SGYY WGWIRQPPGKGLEWIGS INHS...GST YYNPSLK.SRVTISVDTSKNQFSLKLSSVTAADTAVYYC ARVRLRFYYGM----------DV WGQGTTVTVSS
5F6:  EVQLQESGP.GLVNPSETLCLTCAVS GHSIS...SGYY WGWIRQPPGKGLEWIGS INHS...GST YYNPSLK.SRVTISVDTSKNQFSLKLSSVTAADTAVYYC ARVRLRFYYGM----------DV WGQGTTVTVSS
3G9:  EVQLQESGP.GLVKPSETLSLTCTVS GGTI....SSSY WSWIRQSPGKGLEWIGR IPSP...PST NYNPSLK.SRVTISVDTSKNQFSLKLSSVTAADTAVYYC ARGYCTRTSCEGV--------DY WGQGTLVTVSS
3F6:  EVQLQESGP.GLVKPSETLSLTCTVS GGSI....SSYY WSWIRQPPGKGLEWIGY IYYS...GST RYNPSLR.SRVTISIDTSKNQFSLKLNSVTAADTAVYYC ARGYCSRTSCEGV--------DY WGQGTLVTVSS
8G2:  EVQLQESGP.RLVKPSETLSLTCTVS GGSI....SSYY WSWIRQPPGKGLEWIGY IYYS...GST RYNPSLR.SRVTISIDTSKNQFSLKLNSVTAADTAVYYC ARGYCNKTSCEGV--------DY WGQGTLVTVSS
4D8:  EVQLQESGP.GLVKPSETLSLTCTVS GGSI....SSYY WSWIRQSPGKGLEWIGK ISYS...GST IYNPSLK.SRVTISVDTSKNQFSLKLTSVTAADTAVYYC ARGYCSTPSCKGV--------DY WGQGTLVTVSS
5G12: EVQLQESGP.GLVKPSETLSLTCTVS GGSI....SSYY WSWIRQSPGKGLEWIGK ISSS...GTT LYNPSLK.SRVTISIDTSKNQFSLKLTSVTAADTAVYYC ARGTCSRTSCKWV--------DY WGQGTLVTVSS
3G8:  EVQLQESGP.GLVKPSETLSLTCTVS GGSI....SSYY WSWIRQSPGKGLEWIGK ISYS...GST IYNPSLK.SRVTISVDTSKNQFSLKLTSVTAADTAVYYC ARGYCSRTSCKGV--------DY WGQGTLVTVSS
8F6:  EVQLQESGP.GLVRPSETLSLTCTVS GGSL....SSYY WSWIRQSPGKGLEWIGY IHDT...GST YYNPSLK.SRVTISVDTSKNQFSLKLSSVTAADTAVYYC ARGYCTRTSCAGV--------DY WGQGTGVTVSS
7A8:  EVQLQESGP.GLVKPSETLALTCTVS GGSI....SSYY WSWIRQFPGKGLEWIGK ISYS...GNT MYNPSLK.SRVTISVDTSKNQFSLKLNSVTAADTAVYYC ARGTCSITSCEWV--------DY WGQGTLVTVSS
3F5:  EVQLQESGP.GLVKPSETLSLTCTVS GGTI....SGYY WSWIRQSPGKGLEWIGR IYNS...GST DYNPSLK.SRVSISVDTSKNQFSLRLSSVTAADTAVYYC ARGYCSRTTCAWV--------DH WGQGTLVTVSS
5C2:  EVQLQESGP.GLVKPSETLSLTCTVS GGTL....SGYY WSWIRLSPGKGLEWIGR ISSS...GST NYNPSLQ.SRVTISVDTSKNQFSLRLNSVTAADTAVYYC ARGYCSRTSCAGV--------DY WGQGTLVTVSS
5F2:  EVQLQESGP.GLVKPSETLSLTCTVS GGTL....SGYY WSWIRLSPGKGLEWIGR ISSS...GNT NYNPSLQ.SRVTISVDTSKNQFSLRLNSVTAADTAVYYC ARGYCSRTSCAGV--------DY WGQGTLVTVSS
6B2:  EVQLQESGP.GLVKPSETLCLTCTVS GGTL....SGYY WSWIRLSPGKGLEWIGR ISSS...GST NYNPSLQ.SRVTISVDTSKNQFSLRLNSVTAADTAMYYC ARGYCSRTSCAGV--------DY WGQGTLVTVSS
Figure 2. Sequence alignment of 18 selected antibodies, which tested positive on the ELISA 
screen against the MUC1 peptide. Conserved regions in the CDR3 (blue) are shown with 
somatic hypermutations (red, yellow).
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Figure 3. Cell binding of heavy-chain antibodies (HCAbs, blue) compared to background 
(red) in MUC1 positive cell line CFPAC-1 depicted for four HCAbs. Cells were incubated 
with 50 μg/mL of HCAbs for 30 min followed by incubation with goat anti-human IgG-FITC 
secondary antibody (1:40). Y-axis, cell count; X-axis, FITC fluorescence.
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Affinity and cell binding
Flow cytometry experiments were performed to assess binding of the HCAbs to the 
MUC1-positive cell line CFPAC-1 (Figure 3, Table 1). Based on the mean fluorescence 
intensity we conclude that at least 4 antibodies show a moderate to good binding to 
CFPAC-1 cells. The moderate binding to CFPAC cells may be a result of the internaliza-
tion of MUC-1, before recycling to the surface of the cells with 0.9% of receptors being 
recycled per minute204.
Table 1. Cell binding of heavy-chain antibodies to CFPAC-1
Heavy-chain antibody MFI
6C2 4.7 (2.5 - 6.0)
5C6 4.0 (3.5 - 4.5)
4D11 34.7 (26.5 - 45.0)
5F7 12.3 (9.5 - 14.0)
5B5 68.3 (57.0 - 81.5)
5F6 2.0 (2.0 - 2.0)
3G9 2.7 (2.5 - 3.0)
3F6 2.5 (2.2 - 2.7)
8G2 4.7 (4.0 - 5.0)
4D8 2.0 (2.0 - 2.0)
5G12 2.3 (2.0 - 2.5)
3G8 30.3 (20.5 - 36.5)
8F6 24.7 (18.0 - 29.0)
7A8 17.0 (14.5 - 20.0)
3F5 7.3 (6.5 - 8.0)
5C2 7.7 (7.0 - 8.5)
2F2 4.3 (2.0 - 5.5)
6B2 3.3 (3.0 - 3.5)
Median fluorescence intensity is shown with 25th and 75th percentiles. All experiments 
have been performed 3 times.
These antibodies were tested for further binding on the Octet system, to determine avid-
ity between HCAbs and the MUC1 peptide (Figure 4). Nanomolar dissociation constants 
(Kd) were reached; 4D11 = 2.25 ± 0.49 x 10−9 M, 5B5 = 3.54 ± 0.21 x 10−9 M, which in-
dicates moderate strength binding antibodies. This might be a benefit, since it has been 
shown that diabodies with low affinity scFv are more effective in accumulating in the 
tumor than higher affinity antibodies205. This might be explained by inhibition of tumor 
penetration due to irreversible association with peripheral antigen presenting cells206,207.
By generating HCAbs with human variable domains, we offer clinically interesting 
therapeutics with the benefits of antibody fragments. These are the more economical 
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production, easy conjugation techniques to develop therapeutics, and reduced im-
munogenicity103. Human single variable heavy chain domains obtained from classical 
antibodies showed affinities comparable to the parent antibody, but had poor solubility 
and aggregation problems208. The heavy-chain antibodies generated in this study retain 
their structure and remain highly soluble and functional, because they are generated in 
mice and isolated by expression cloning which selects against insoluble antibodies. It 
has been suggested that nanomedicine in a size range of 10 to 50 nm is ideal for an ef-
ficient biodistribution209,210. The size of HCAbs might facilitate rapid tissue penetration 
and rapid blood clearance211,212, while remaining high target retention due to affinities 
comparable to conventional antibodies99.
Further research is aimed at combining these MUC1-specific antibodies with nano-
medicine to deliver large quantities of drugs to antigen-presenting cells. The generated 
heavy-chain antibodies can be used to produce human single variable domain only 
proteins, or nanobodies, targeted against MUC1. Provided that affinity and stability 
remain, these could be used for diagnostic purposes in combination with radionuclides 
or for image-guided drug delivery in combination with drugs or drug carriers.
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Figure 4. Octet binding analysis of HCAbs showing association (left) and dissociation 
(right) curves. 10 μg/mL HCAbs were loaded onto anti-human IgG-Fc tips and assessed for 
binding using a dilution range of MUC1 peptide.
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ABSTrAcT
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and 
a promising target for molecular imaging and therapy. Nanobodies are the smallest 
antibody-based fragments possessing ideal molecular imaging properties, such as high 
target specificity and rapid background clearance. We developed a novel anti-PSMA 
nanobody (JVZ-007) for targeted imaging and therapy of prostate cancer. Here, we 
report on the application of the indium-111 (111In) radiolabeled nanobody for SPECT/
CT imaging of prostate cancer. A nanobody library was generated by immunization 
of a llama with four human prostate cancer cell lines. Anti-PSMA nanobodies were 
captured by biopanning on PSMA-overexpressing cells. JVZ-007 was selected for evalu-
ation as an imaging probe. JVZ-007 was initially produced with a c-myc-hexahistidine 
(His-)tag allowing purification and detection, which was subsequently replaced by 
a single cysteine at the C-terminus, allowing site-specific conjugation of chelates for 
radiolabeling. JVZ-007-c-myc-His was conjugated to 2-(4-isothiocyanatobenzyl)-
diethylenetriaminepentaacetic acid (p-SCN-DTPA) via lysines, whereas JVZ-007-cys 
was conjugated to maleimide-DTPA via the C-terminal cysteine. PSMA targeting was 
analyzed in vitro by cell binding experiments using flow cytometry, autoradiography, 
and internalization assays with various prostate cancer cell lines and patient-derived 
xenografts (PDXs). The targeting properties of radiolabeled nanobodies were evaluated 
in vivo with SPECT/CT imaging experiments, using nude mice bearing PSMA-positive 
PC-310 and PSMA-negative PC-3 tumors. JVZ-007 was successfully conjugated to 
DTPA for radiolabeling with indium-111 at room temperature. 111In-JVZ007-c-myc-His 
and 111In-JVZ007-cys internalized in LNCaP cells and bound to PSMA-expressing PDXs 
and, importantly, not to PSMA-negative PDXs and human kidneys. Good tumor target-
ing and fast blood clearance were observed for 111In-JVZ-007-c-myc-His and 111In-JVZ-
007-cys. Renal uptake of 111In-JVZ-007-c-myc-His was initially high, but was efficiently 
reduced by coinjection of gelofusine and lysine. The replacement of the c-myc-His-tag 
by the cysteine contributed to a further reduction of renal uptake without loss of target-
ing. PC-310 tumors were clearly visualized by SPECT/CT with both tracers, with low 
renal uptake (< 4% injected dose per gram) for 111In-JVZ-007-cys already at 3 h after 
injection. We developed an indium-111 radiolabeled anti-PSMA nanobody, showing 
good tumor targeting, low uptake in nontarget tissues, and low renal retention, allow-
ing excellent SPECT/CT imaging of prostate cancer within a few hours after injection.
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iNTroDucTioN
Prostate cancer is the second leading cause of cancer-related death among men in 
the western world. Early detection and accurate staging of prostate cancer is crucial 
because the survival rate decreases dramatically when the cancer has spread beyond the 
prostate213. Because of the heterogeneity of prostate cancer, and the lack of specificity 
of conventional imaging techniques, there is currently no universal imaging method 
approved for detection of early prostate cancer lesions. PSMA is an interesting target for 
molecular imaging of prostate cancer, as it is overexpressed in 90-100% of local prostate 
cancer lesions, as well as on cancerous lymph nodes, and bone metastases214,215, with 
some reports suggesting PSMA expression levels are further enhanced in high-grade, 
metastatic, and castration-resistant prostate cancer216,217. PSMA is also expressed in 
other tissues including normal prostate epithelium, small intestine, renal tubular cells, 
and salivary glands, but the expression in these organs is 100–1,000 fold less than in 
prostate cancer218.
PSMA, also referred to as glutamate carbopeptidase II (GPCII), N-acetyl-α-linked 
acidic dipeptidase I (Naaladase I), or folate hydrolase, is a type II transmembrane 
glycoprotein exhibiting glutamate carboxypeptidase and folate hydrolase enzymatic 
activity. The first clinical tracer for imaging PSMA was based on the murine anti-PSMA 
antibody 7E11, binding to an epitope on the intracellular domain of PSMA. The in-
dium-111 labeled version of 7E11, 111In-capromab, commonly known as ProstaScint 
(Cytogen Corp.), was approved by the Food and Drug Administration in 1997 for detec-
tion of soft-tissue metastases and recurrence of prostate cancer219. Its use for staging 
primary prostate cancer is suboptimal, with an average sensitivity and specificity of 
60% and 70%, respectively220. 111In-capromab was also not reliable for the detection 
of bone metastases, which are often the initial site of metastasis in advanced prostate 
cancer221. After the discovery of 7E11, next-generation monoclonal antibodies (mAbs) 
binding to the extracellular domain of PSMA were developed, including mAb J591. 
Initially developed for therapeutic purposes, J591 was also evaluated for SPECT imag-
ing in clinical trials, showing characteristics superior to 111In-capromab, revealing most 
soft-tissue and bony metastases222,223. Despite improved targeting of J591 and next-
generation PSMA mAbs, the major disadvantage of the use of antibodies for imaging is 
the slow clearance from nontarget tissues, often requiring several days between tracer 
administration and imaging.
An interesting alternative for molecular imaging of PSMA is the development of 
small-molecule PSMA inhibitors. Because PSMA possesses an enzymatic site in its extra-
cellular domain that cleaves endogenous substrates such as N-acetylaspartylglutamate 
and poly-γ-glutamyl folic acid, a series of substrates has been designed. These small-
molecule PSMA inhibitors consist of zinc-binding compounds attached to a glutamate 
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moiety. Several radiolabeled PSMA small-molecule inhibitors have been synthetized, 
starting with phosphonate and phosphate inhibitors, followed by phosphoramidate-, 
thiol-, and urea-based inhibitors, which are discussed in an extensive review by Mease 
and colleagues224. Some have shown promising results in early clinical studies, such 
as 123I-MIP-1072, 123I-MIP-1095225, N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18F-
fluorobenzyl-L-cysteine226, 68Ga-HBED-CC227, and BAY1075553228. These compounds 
localize rapidly to tumor lesions, including soft-tissue and bone metastases, but also 
show high uptake in kidneys and salivary glands, attributed to PSMA expression in 
these organs.
Another approach aiming at circumventing the long circulation time of mAbs is 
the use of antibody fragments, such as single-domain antibodies (VHH). Nanobodies 
display attractive features for molecular imaging, including fast nontarget tissue clear-
ance, good tumor penetration capability, and recognition of unique epitopes that are 
less accessible for mAbs229. In this study, we describe the development of a nanobody 
targeting PSMA and showing good tumor targeting and fast blood clearance, result-
ing in impressive tumor-to-background ratios within a few hours after injection. The 
nanobody was conjugated to a diethylenetriaminepentaacetic acid (DTPA) chelator, al-
lowing facile and stable radiolabeling with indium-111 at room temperature in a 1-step 
procedure. The structure of the nanobody was optimized to minimize renal retention 
using a novel method for production and labeling of cys-tagged nanobodies. We report 
on the production and radiolabeling of anti-PSMA nanobodies as well as in vitro and in 
vivo evaluation in patient-derived prostate cancer xenograft models.
MATeriALS AND MeThoDS
immunization and vhh-library construction
A llama (Lama glama) was immunized subcutaneously at 1, 30, 60 and 90 d with a 
mixture of four androgen-responsive human-derived prostate cancer cell lines (LNCaP, 
PC346C, VCaP, and MDA PCa 2b) (33 x 106 cells per cell line) to generate a VHH li-
brary targeting prostate cancer. Blood was collected after the third immunization and 
peripheral blood lymphocytes were isolated. Library construction was performed as 
previously described230. Briefly, RNA was isolated and cDNA was synthetized with re-
verse transcriptase. VHH (variable domains of camelid heavy-chain antibodies) genes 
were amplified by PCR introducing NotI and SfiI restriction enzyme sites (forward and 
backward primers). VHH fragments were isolated from a 1% agarose gel, digested with 
Sfil and Notl, ligated into the pHEN1-6HISGS phagemid and transformed into TG1 
Escherichia coli cells to generate a library of 3.3 x 109 transformants (L1P4 library). The 
VHH library was kindly provided by Dr. Patrick Chames (IBISA).
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Selection and screening by phage display
A phage display library was produced by infecting the nanobody library with M13 
K07∆pIII hyperphages (Progen Biotechnik). PSMA-specific nanobodies were captured 
by three rounds of biopanning. Each round consisted of a negative selection using wild-
type B16 cells followed by a positive selection on B16-PSMA transfected cells. Briefly, 1 
x 107 B16 cells were scraped in PBS with 10% FCS. B16 cells and phages were incubated 
in PBS with addition of 10%FCS and 2% protivar milk (Nutrica) for 30 min at RT. B16 
cells were incubated with 2 x 1011 phages in PBS/10% FCS/2% protivar milk for 45 
min at RT. Meanwhile, B16-PSMA cells were scraped in PBS/10% FCS and incubated 
in PBS/10% FCS/2% protivar milk (Nutrica) for 30 min at RT. B16 cells were then 
spun down, and the supernatant containing unbound phages was incubated with 107 
B16-PSMA transfected cells in PBS/1% BSA/2% protivar milk for 45 min at RT. Cells 
were washed ten times with PBS/1% BSA/2% protivar milk and two times with PBS. 
Phages bound to PSMA-transfected B16 cells were eluted with 200 mM triethylamine 
(Sigma) and reamplified in TG1 cells. Colonies were grown on 2xTY (16 g/L tryptone, 
10 g/L yeast extract and 5 g/L NaCl)/ampicillin (100 μg/mL)/glucose (2%) agar plates. 
Colonies were scraped from the 2xTY plates, and stored at –80°C in the presence of 
20% glycerol. Selected single clones were plated in 100 μl 2xTY/ampicillin (100 μg/
mL)/glucose (2%) broth in 96-well plates and shaken overnight at 30°C. From each 
well, 5 μl was replated in 150 μl 2xTY/ampicillin (100 μg/mL)/glucose (2%) broth and 
shaken for 2.5 h at 37°C. Phages presenting a VHH were produced by adding 0.5 x 109 
M13 K07∆pIII helper phage to each well and incubating for 30 min at 37°C. Plates were 
centrifuged (1700 rpm, 10 min). Bacterial pellet was resuspended in 2xTY/ampicillin 
(100 μg/mL)/kanamycin (25 μg/mL) and grown under vigorous shaking overnight at 
30°C. Phage-containing supernatants were tested for binding to PSMA by ELISA using 
B16 and B16-PSMA cells. Briefly, B16 and B16-PSMA cells were collecting by scraping 
in PBS containing 1% bovine serum albumin (BSA). Cells were incubated with phage 
supernatant for 1.5 h at room temperature, shaking. Binding of phages to PSMA was 
detected with a horseradish peroxidase (HRP)-conjugated anti-M13 mouse antibody 
(27-9421-01, GE Healthcare). Cells were then incubated with OPD substrate (Sigma) 
and measurement was done at OD 490 nm. Clones found positive in cell ELISA were 
further analyzed by FACS analysis. Binding of phages was detected with an anti-M13 
mouse antibody (GE Healthcare), followed by a phycoerythrin (PE)-conjugated 
anti-mouse goat antibody (550589, BD Biosciences). Fluorescence was measured on 
a FACScan (BD).
Nanobody sequencing, production and purification
Selected clones were sequenced, and distinct nanobody clones were identified. The 
sequence of JVZ-007 clone is shown in Figure 1. Clones were produced as c-myc-His–
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tagged proteins to facilitate purification by affinity chromatography and detection by 
flow cytometry. The plasmid containing JVZ-007 sequence was isolated from the TG1 
cells (JetStarTM 2.0 plasmid purification MIDI kit, Genomed) and transformed into 
HB2151 cells. Production in HB2151 cells was performed overnight at 37°C in 2xTY 
(16 g/L tryptone, 10 g/L yeast extract and 5 g/L NaCl) medium supplemented with 
100 μg/mL ampicillin and 0.1% glucose. Cells were collected by centrifugation for 30 
min at 4000 rpm, washed with PBS and lysed by freeze-thaw cycles in lysis buffer (50 
mM KPO4 pH 7.8, 400 mM NaCl, 100 mM KCl, 10% glycerol, 0.5% Triton X-100). The 
lysate was centrifuged and filtered (40 μm filter), and c-myc-His-tagged nanobodies 
were trapped on a HisTrap FF column (GE Healthcare) on a ÄKTA preparative protein 
purification system (GE Healthcare) and eluted with 500 mM imidazole. Buffer was 
changed for phosphate-buffered saline (PBS) using a Vivaspin sample concentrator (5-
kDa cut-off, GE Healthcare). C-myc-His-tagged nanobody purity was assessed with re-
ducing SDS-PAGE and western blot analysis with anti-c-myc mouse antibody (M4439, 
Sigma), followed by HRP-anti-mouse goat antibody (p0447, Dako) and visualized with 
a Chemiluminescence kit (Thermo Fisher Scientific Inc). The protein concentration 
was determined using a BCA protein assay kit (Thermo Fisher Scientific Inc).
Additionally, JVZ-007 nanobody was cloned from the pHEN vector, introducing 
a cysteine at the C-terminus, and expressed as a fusion protein to SUMO3 (Smt3 
ubiquitin-like protein) using the pETM11-SUMO3GFP vector (kindly provided by 
EMBL). The nanobody sequence was cloned from the pHEN vector using two primers. 
The forward primer contains a restriction enzyme site AgeI and two glycine molecules, 
necessary for SenP2 digestion (5’ ACT ATG ACC GGT GGA GAG GTG CAG CTG GTG 
3’). The backward primer contains a cysteine sequence, a stop sequence and a HindIII 
restriction enzyme site (3’ TCA GTA AAG CTT TCA ACA TGA GGA GAC GGT GAC 
5’). The nanobody was ligated into the pETM11-SUMO3GFP vector after digestion 
with AgeI and HindIII. After expression of the recombinant plasmid in BL21 bacteria 
and protein extraction, JVZ-007-cys-SUMO3 was isolated with a HisTrap column. The 
SUMO3 protein was cleaved off by a SUMO-specific protease, Sentrin-specific protease 
2 (SenP2, provided by Guy Salvesen, Addgene)231. Digestion was performed overnight 
1        10        20        30        40        50
|        |         |         |         |         |
EVQLVESGGGLVQPGGSLTLSCAASRFMISEYSMHWVRQAPGKGLEWVSTINPAGTTDY
60       70        80        90        100       110
|        |         |         |         |         |
AESVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCDGYGYRGQGTQVTVSS
Figure 1. Amino acid sequence of JVZ-007 nanobody.
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at 4°C with a ratio of 1:10 (w/w) of SenP2 to JVZ-007-cys-SUMO3. His-tagged SenP2 
and SUMO3 were removed with a HisTrap FF column (GE Healthcare). JVZ-007-cys 
nanobody purity was assessed with reducing SDS-PAGE.
flow cytometry
PSMA-specific binding was assessed by flow cytometry on PC-346C, LNCaP, and PC-3 
cells. Briefly, cells were collected by scraping in polypropylene tubes and incubated 
with the c-myc-His-tagged nanobody for 60 min at 4°C, followed by incubation with 
an anti-c-myc mouse antibody (M4439, Sigma) for 30 min, and finally PE-conjugated 
anti-mouse goat antibody (550589, BD Biosciences) for 30 min. As negative control, 
cells were incubated using the same procedure, without the nanobody. As positive con-
trol, cells were incubated with anti-PSMA mouse antibody (SAB4200257, Sigma), and 
PE-conjugated goat anti-mouse antibody (550589, BD Biosciences). Flow cytometry 
was performed using a BD FACScan system (Becton Dickinson).
conjugation to DTPA and radiolabeling
JVZ-007-c-myc-His was incubated with a 5-fold molar excess of p-SCN-Bn-DTPA 
(Macrocyclics) in 0.1 M sodium carbonate buffer (pH 9.5) for 2.5 h at room tempera-
ture. JVZ-007-cys was reduced with 1 mM 2-mercaptoethylamine-HCl in phosphate-
buffered saline (PBS), 5 mM ethylenediaminetetraacetic acid for 90 min at 37°C. 
Reduced JVZ-007-cys was then incubated with 5 mM maleimide-DTPA for 2 h at 37°C. 
Conjugated nanobodies were then dialyzed for 3 d in a Slide-A-Lyzer (3.5-kDa cutoff; 
Life Technologies) against 0.25 M ammonium acetate (NH4Ac), pH 5.5.
Nanobody-DTPA conjugates were labeled with 111InCl3(Covidien) in 20 mM sodium 
acetate, pH 5.0, for 30 min at room temperature. Radioprotectants (3.5 mM ascorbic 
acid, gentisic acid, and methionine) were used to prevent radiolysis. Labeling efficiency 
was assessed by instant thin-layer chromatography using silica gel–coated paper (Var-
ian Inc.) and 0.1 M citrate buffer, pH 5.0, as the mobile phase. After incubation, an 
excess of DTPA (final concentration, 0.15 mM) was added to complex free 111InCl3.
Cell culture, autoradiography and internalization
Cell lines were purchased from the American Type Culture Collection. B16-PSMA was 
kindly provided by Marco Colombatti (University of Verona). Cell cultures media and 
reagents were obtained from Lonza unless stated otherwise. LNCaP, VCaP and PC-3 
cells were cultured in RPMI 1640 medium containing 10% (5% for PC-3) fetal calf 
serum (FCS). PC-346C cells were cultured in Dulbecco’s modified Eagle’s F12 medium 
supplemented with 2% FCS, 0.01% BSA (Boehringer-Mannheim), 1% insulin-transfer-
rin-selenium (Life Technologies), 0.1 μg/mL fibronectin (Alfa Aesar), 0.1 nM R1881 
androgen, 10 ng/mL epidermal growth factor, 0.5 μg/mL dexametason, 1 nM triio-
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dothyronine, 0.1 mM phosphoethanolamine, 50 ng/mL cholera toxin and 20 μg/mL 
fetuin (all from Sigma). B16 cells were cultured in Dulbecco’s modified Eagle’s medium 
containing 10% FCS, 10 mM HEPES (Sigma), 20 μM 2-mercaptoethanol (Sigma) and 2 
mM glutamine. For B16-PSMA, 1200 μg/mL geneticin (G418, Gibco) was added to this 
medium. MDA PCa 2b cells were grown in Ham’s F12 medium containing 15% FCS, 25 
ng/mL cholera toxin, 10 ng/mL epidermal growth factor, 5 μM phosphoethanolamine, 
120 pg/mL hydrocortisone and 1% insulin-transferrin-selenium. Penicillin (100 units/
mL), and streptomycin (100 µg/mL) were added to cell culture media. Cells were grown 
in tissue culture flasks at 37°C in a humidified atmosphere containing 5% CO2.
Binding of 111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys to frozen cryostat section 
of PDXs and kidneys (mouse/human) was evaluated using autoradiography, as de-
scribed previously232. Tissue sections were incubated for 1 h with 111In-JVZ-007-c-myc-
His or 111In-JVZ-007-cys (10−9 M). In saturation binding experiments, concentrations 
ranging from 10−6 to 10−12 M of 111In-JVZ-007-c-myc-His were used.
The internalization of 111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys was assessed 
using LNCaP and PC-3 cells. Cells were trypsinized and incubated with 111In-JVZ-007-
c-myc-His or 111In-JVZ-007-cys (10−10 M) in RPMI 1640/GlutaMAX (Life Technolo-
gies)/20 mM N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)/1% bovine 
serum albumin (pH 7.4) for 90 min at 37°C or 4°C. JVZ-007-c-myc-His was used for 
blocking (10−6 M). After incubation, the cells were centrifuged and washed 2x with PBS. 
Cell surface–bound nanobodies were eluted using a solution of 50 mM glycine/100 
mM NaCl (pH 2.8), and cells were washed with PBS. Cells were then lysed in 1 M so-
dium hydroxide to collect internalized nanobody. Membrane-bound and internalized 
fractions were counted in a γ counter. Binding was expressed as percentage of added 
amount of radioactivity per number of cells.
Biodistribution and SPecT/cT imaging
Male NMRI nu/nu mice (8-week-old) were transplanted with PC-310 tumor fragments 
near the left shoulder and injected subcutaneously near the right shoulder with PC-3 
cells (3 × 106 cells, 200 μL, 66% RPMI, 33% Matrigel [BD Bioscience]). Three to four 
weeks after inoculation, when tumor size averaged 200 mm³, mice were injected intra-
venously with radiolabeled nanobody (200 μL). Radiolabeled nanobody was diluted in 
PBS containing 0.1% v/w bovine serum albumin. When coinjection of lysine (20 mg) 
and gelofusine (4 mg) was performed, radiolabeled nanobody was mixed 1:1 with a 
solution of lysine (400 mg/mL), and 100 μL of this solution were coinjected with 100 
μL of gelofusine (40 mg/mL).
Mice were injected with 0.7 MBq of radiolabeled nanobody (amount ranging from 1 
to 100 μg) and euthanized 4 or 24 h after injection for biodistribution studies. Blood, 
tumor, and relevant organs and tissues were collected, weighed, and counted in a γ 
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counter (Perkin-Elmer) with a counting time of 60 s per sample with an isotope-specific 
energy window and a counting error not exceeding 5%. The percentage injected dose 
per gram (%ID/g) was determined for each tissue sample.
For SPECT/CT imaging experiments, mice were injected with 30 MBq of 111In-JVZ007-
c-myc-His (10 μg) or 15 MBq of 111In-JVZ007-cys (10 μg). Mice were scanned under 
isoflurane/O2 anesthesia at 3 and 24 h after injection on a small-animal nanoSPECT 
scanner (Mediso) with heated bed. SPECT emission scans were acquired for 30-42 min, 
with a matrix of 256 x 256 and 20 projections (120 s per projection). Multi-pinhole 
mouse collimators with 9 pinholes (1.4 mm diameter) per head were used. SPECT scans 
reconstruction and processing were performed with InVivoScope/VivoQuant software 
2.0 (inviCRO). All animal experiments were approved by the Animal Experiments 
Committee under the Dutch Experiments on Animal Act and adhered to the European 
Convention for Protection of Vertebrate Animals used for Experimental Purposes (Di-
rective 86/609/EEC).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.01 (San Diego, CA, 
USA). Biodistribution data are represented as the mean %ID/g ± SD, with group sizes of 
4 mice. Statistical analysis of biodistribution data was performed using a 1-way ANOVA 
with Bonferroni post-hoc test, and the level of significance was set at p < 0.05.
reSuLTS
Generation of anti-PSMA nanobodies
A prostate cancer specific nanobody library was generated by immunization of a 
llama with four prostate cancer cell lines (LNCaP, PC346C, VCaP, and MDA PCa 2b). 
PSMA-specific nanobodies were retrieved by biopanning using phage display for three 
positive and negative selection rounds with B16-PSMA and B16 cell lines, respectively. 
Selection on PSMA-expressing cells was preferred rather than using the recombinant 
PSMA protein, to increase the chance of capturing nanobodies binding to an accessible 
epitope on the extracellular domain of PSMA. Several distinct PSMA-specific nanobod-
ies were isolated and sequenced (data not shown). Selected clones were produced as 
c-myc-His–tagged proteins to facilitate purification by affinity chromatography and 
detection by flow cytometry. PSMA-specific binding was assessed by flow cytometry on 
PC-346C, LNCaP, and PC-3 cells. Results of flow cytometry analysis of a few selected 
nanobodies are displayed in Figure 2. JVZ-005, JVZ-007, and JVZ-012 all bound to 
PSMA-expressing LNCaP and PC346C, as shown by the increase in the geometric mean 
of the fluorescence intensity. No binding was observed on the PSMA-negative PC-3 
cells, showing the specificity of the nanobodies for PSMA. JVZ-007, showing the high-
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est binding, was selected for further evaluation as the imaging probe. Its sequence is 
indicated in Figure 1. JVZ-007-c-myc-His and JVZ-007-cys were successfully produced 
in bacteria using the pHEN and pETM11-SUMO3GFP expression vectors, respectively.
Labeling and in vitro binding studies
JVZ-007-c-myc-His was conjugated to p-SCN-Bn-DTPA via lysine residues, to allow 
radiolabeling with indium-111 for SPECT imaging of prostate cancer. JVZ-007-cys was 
site-specifically conjugated with DTPA by reacting it with maleimide-DTPA. JVZ-007-
cys formed dimers via cysteine bridging, and mild reduction was necessary to free the 
thiol in the cysteine. Indium-111 radiolabeling was performed, with specific activities 
up to 60 MBq/nmol, whereas the labeling efficiency always exceeded 90%. No release 
of indium-111 was observed at 4°C up to 72 h after radiolabeling. Binding to frozen sec-
tions of PDXs and kidney using autoradiography is shown in Figure 3. Binding affinity 
of 111In-JVZ-007-c-myc-His was estimated by saturation binding on the PSMA-positive 
PC-310 tumor, resulting in an equilibrium dissociation constant value of 27.4 nM 
(14.1–40.7, 95% confidence interval). 111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys 
showed high binding to all PSMA-expressing tumor sections (PC310, LNCaP, PC82, 
 
Figure 2. Flow cytometry analysis of JVZ-005, JVZ-007 and JVZ-012 on LNCaP (A), PC346C 
(B) and PC-3 cells (C). Green, in the presence of nanobody; red, in the presence of PSMA-
antibody (PSMA-Ab); black, control, in the absence of nanobody; x-axis, fluorescence in-
tensity; y-axis, number of events. Binding was observed with the PSMA-positive LNCaP and 
PC346C cells, while no binding was observed with the PSMA-negative PC-3 cells.
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and PC295), with lower binding to the weakly PSMA-positive PC346c. The absence of 
binding was observed on the PSMA-negative tumors (PC-3 VCaP, PC133, PC339, and 
PC324). These results are in line with previous PSMA RNA expression data of these 
PDXs (Affymetrix data not shown). Binding to mouse and human kidneys was low 
(< 1%) in comparison with PSMA-positive tumors.
Cell binding assays on PSMA-positive LNCaP cells (Figure 4) showed 30% and 37% 
internalization after 90 min at 37°C, for 111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys, 
 
Figure 3. Saturation binding of 111In-JVZ-007-c-myc-His on PC-310 frozen sections using 
autoradiography (A). Binding of 111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys to tumor 
and kidney frozen sections using autoradiography (B). High binding is observed with PSMA-
expressing tumor sections (PC310, PC346c, LNCaP, PC82 and PC295) while no binding is 
observed with the PSMA-negative tumors PC-3 VCaP, PC133, PC339, PC324) and kidneys 
(mouse or human).
 
Figure 4. Internalization of 111In-JVZ-007-c-myc-His in LNCaP and PC-3 cells, after incu-
bation for 90 min at 37°C and 4°C (A). Comparison of internalization of 111In-JVZ-007-c-
myc-His and 111In-JVZ-007-cys in LNCaP cells after incubation for 90 min at 37°C (B). 111In-
JVZ-007-c-myc-His and 111In-JVZ-007-cys internalized in PSMA-expressing LNCaP cells at 
37°C, while no internalization was observed at 4°C, or in PSMA-negative PC-3 cells.
Chapter 3
48
respectively. Cell binding of both tracers was blocked in the presence of an excess of 
unlabeled JVZ-007-c-myc-His, confirming target specificity. Internalization of 111In-JVZ-
007-c-myc-His was confirmed by the strongly reduced amount of radioactivity in the in-
ternalized fraction (0.05% of total binding) observed at 4°C. Low binding (< 1% relative 
to LNCaP cells) and absence of internalization of 111In-JVZ-007-c-myc-His was observed 
for the PSMA-negative cell line PC-3, confirming nanobody specificity for PSMA.
Biodistribution and SPecT/cT imaging
The PSMA-targeting properties of 111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys were 
evaluated further in mice bearing PC-310 and PC-3 tumors. Biodistribution studies are 
displayed in Figure 5, showing good tumor targeting, with low background intensity 
except for the kidneys. Four hours after injection, the uptake of 111In-JVZ-007-c-myc-
His in the PC-310 tumor was 3.91 ± 1.13% injected dose per gram. Uptake in the 
 
Figure 5. Biodistribution studies in mice bearing PC-310 and PC-3 tumors. Effect of co-
injection of gelofusine and lysine (A) and dose (B) on biodistribution of 111In-JVZ-007-c-
myc-His (10 μg) at 4 h after injection (A). Biodistribution at 4 h and 24 h after injection of 
111In-JVZ-007-cys (10 μg) with co-injection of gelofusine and lysine (C). Tumor-to-organ 
ratios at 4 h after injection of 111In-JVZ-007-c-myc-His (10 μg) or 111In-JVZ-007-cys (10 μg) 
with co-injection of gelofusine and lysine (D).
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A
B
Figure 6. SPECT/CT images of mice bearing PC-310 (left shoulder) and PC-3 (right shoul-
der) tumors. Images acquired 3 h after injection of 111In-JVZ-007-c-myc-His (A) with co-
injection of PBS (left) or gelofusine and lysine (right). Images acquired 3 h (left) and 24 h 
(right) after injection of 111In-JVZ-007-cys (B). Scale from 0 to 0.2 kBq (A); 0 to 0.015 kBq 
(B, left); 0 to 0.005 (B, right). PSMA-expressing PC-310 tumor could be clearly visualized 
with high contrast on the left shoulder, while no uptake was observed in PC-3 tumor on the 
right shoulder.
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kidneys was 110.89 ± 7.35% injected dose per gram, but could be reduced to 27.77 ± 
2.02% injected dose per gram by coinjection of gelofusine and lysine. Increasing doses 
of JVZ-007-c-myc-His showed a slight decrease in tumor uptake. Similarly, 111In-JVZ-
007-cys in combination with gelofusine and lysine showed uptake in PC-310 and PC-3 
tumors of 3.70 ± 0.29 and 0.18 ± 0.05% injected dose per gram at 4 h after injection, 
respectively. Importantly, kidney uptake was approximately 10-fold lower than that of 
JVZ-007-c-myc-His, with values of only 3.13 ± 0.30 and 0.61 ± 0.20% injected dose per 
gram, at 4 and 24 h after injection, respectively. Moreover, 111In-JVZ-007-cys showed 
higher tumor-to-background ratios at 4 h after injection than 111In-JVZ-007-c-myc-His, 
with a tumor-to-muscle ratio of 104.8 ± 27.4 and tumor-to-kidney ratio of 1.2 ± 0.1. 
The tumor-to-blood ratio was significantly lower for 111In-JVZ-007-cys (48.1 ± 5.1) 
than for 111In-JVZ-007-c-myc-His.
SPECT/CT images of mice bearing PC-310 and PC-3 tumors 3 h after injection of 
111In-JVZ-007-c-myc-His and 111In-JVZ-007-cys are shown in Figure 6. PSMA-express-
ing PC-310 tumor could be clearly visualized with high contrast on the right shoulder, 
whereas no uptake was observed in PC-3 tumor on the left shoulder. Signal intensity 
in kidneys after injection of 111In-JVZ-007-c-myc-His was very high but could be ef-
ficiently reduced by a coadministration of gelofusine and lysine. Importantly, kidney 
signal intensity of 111In-JVZ-007-cys was markedly lower.
DiScuSSioN
Development of PSMA-based imaging tracers for prostate cancer has increased tre-
mendously in the past few years. After the approval of the PSMA mAb 111In-capromab 
as an imaging agent in 1997, a panel of novel PSMA-targeted imaging agents was 
developed, including next-generation antibodies, antibody fragments, aptamers, and 
PSMA inhibitors224. PSMA small-molecule inhibitors localize rapidly to tumor lesions, 
including soft-tissue and bone metastases, but also show a high uptake in the kidneys 
and salivary glands. The high uptake of PSMA inhibitors in these organs was attributed 
to PSMA expression, although the expression of PSMA in these organs was shown to 
be 100- to 1,000-fold lower than in prostate cancer218. This lower PSMA expression in 
normal organs may suggest that other (receptor-mediated) processes may be involved 
in tracer uptake in normal organs as well.
In parallel to these developments, alternative strategies have been pursued using 
smaller variants of mAb, such as antigen-binding fragments (Fab) and F(ab′)2233, and 
minibodies or diabodies234,235, aiming to circumvent the long circulation time of mAb. 
These antibody fragments have shown fast target recognition and rapid blood clearance, 
but also show unspecific accumulation in the liver and kidneys. A more recent approach 
is the use of nanobodies (VHH), the smallest antibody-based fragments (12–15 kDa), 
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offering ideal characteristics for molecular imaging. Because of their small size below 
the renal threshold for glomerular filtration (60 kDa), they are mainly cleared via the 
renal pathway. Moreover, it is possible to humanize nanobodies for clinical translation 
using the recently described universal humanized nanobody scaffold technique113. 
Nanobodies targeting PSMA were developed, showing moderate tumor targeting, low 
liver uptake, and high kidney uptake236. Retention of tracers in the kidneys might be 
the result of a combination of different factors, including glomerular filtration by the 
kidneys, PSMA-specific binding, and trapping of metabolites in the lysosomes of renal 
tubular cells. Tracer retention in the kidneys is not desirable, because it may interfere 
with visualization of small tumor lesions in the vicinity of the kidneys and especially 
with staging of prostate cancer. Renal tracer retention also limits the application of the 
PSMA tracer for radionuclide therapy by inflicting a high dose to the kidneys. We have 
developed a nanobody (JVZ-007) that shows good tumor targeting in PSMA-expressing 
PC-310 PDX tumors. JVZ-007 was initially produced with a c-myc-His-tag and conju-
gated to p-SCN-Bn-DTPA via the lysine residues, to allow radiolabeling with indium-111 
for SPECT imaging of prostate cancer. 111In-JVZ-007-c-myc-His was internalized in 
LNCaP cells and showed high binding on all PSMA-expressing PDX sections in vitro, 
whereas low binding to the PSMA-negative PDX sections was observed and 50-fold 
lower binding to the human kidney than the PC-310 tumor, indicating the markedly 
lower expression levels of PSMA in the kidney. 111In-JVZ-007-c-myc-His was evaluated 
further in mice bearing PC-310 tumors, showing good tumor targeting as early as 4 h 
after injection, with low background intensity, except for the kidneys. It was recently 
described that renal retention of an anti–epidermal growth factor receptor nanobody 
could be reduced by coinjection of gelofusine and lysine237. Indeed, efficient reduc-
tion of renal uptake of our anti-PSMA nanobody was obtained when gelofusine and 
lysine were coadministered. These results support that high renal uptake may be due to 
reabsorption in the renal promixal tubule after glomerular filtration. Moreover, studies 
from D’Huyvetter et al. have also shown that the His-tag plays a major role in the high 
retention of radiolabeled nanobodies in the kidneys117. Therefore, we have engineered a 
new nanobody construct, based on JVZ-007, in which the c-myc-His-tag was removed. 
In addition, we introduced a cysteine at the C-terminus for site-specific coupling to 
maleimide-DTPA. For this purpose we used the pETM11-SUMO3GFP expression vec-
tor, allowing production of a protein with a C-terminal cysteine and retrieval of the 
protein by cleavage of SUMO3 by a specific protease. 111In-JVZ-007-cys showed similar 
binding on PSMA-expressing cells and PDXs. More importantly, a further drop in renal 
uptake to 3% injected dose per gram was observed at 4 h after injection, without loss 
of tumor targeting. In comparison, these renal uptake values in mice were superior to 
those found with other PSMA tracers: 100% injected dose per gram for 68Ga-HBED-
CC-PSMA (1 h)238 and 111In-D2B-Fab fragments (4 h)233. Kidney uptake of 78 and 36% 
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injected dose per gram was reported for 123I-MIP-1095 and 123I-MIP-1072 (4 h), respec-
tively239. Tumor-to-blood and tumor-to-muscle ratios obtained with 111In-JVZ-007-cys 
at 4 h after injection were superior to those obtained with 111In-D2B-Fab fragments
233 
and comparable to those obtained with 123I-MIP-1095239, in LNCaP xenograft mice (4 
h). The novel method described here for production and site-specific labeling of cys-
tagged nanobodies could have a significant impact for the clinical implementation of 
a wide range of nanobodies. The site-specific coupling offers a well-defined labeling 
procedure, while the absence of the c-myc-His-tag limits reabsorption in renal tubular 
cells. This minimal renal retention also broadens the applicability of this nanobody to 
radionuclide therapy.
coNcLuSioN
We developed a specific anti-PSMA nanobody containing a cysteine for site-specific 
conjugation to radioactive labels. The indium-111 radiolabeled anti-PSMA nanobody 
shows good tumor targeting and fast blood clearance, allowing SPECT/CT imaging 
within a few hours after injection. Unlike most radiolabeled small-molecule PSMA 
inhibitors, anti-PSMA nanobody JVZ-007 displays a low kidney uptake. These results 
warrant further evaluation of anti-PSMA nanobody JVZ-007 for detection and radionu-
clide therapy of metastatic lesions in PSMA-expressing prostate cancer, for which few 
treatment options are currently available.
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ABSTrAcT
Advanced prostate cancer remains difficult to treat, yet combining hormonal therapy 
with chemotherapy has resulted in improved overall survival. Chemotherapy with 
docetaxel has been used as first-line treatment of advanced castration-resistant prostate 
cancer since 2004, however intrinsic and acquired resistance to docetaxel, and serious 
adverse effects limit the use of the drug. To circumvent these problems and increase 
specific drug uptake in the tumor, nanobody-targeted liposomes against prostate spe-
cific membrane antigen (PSMA) were prepared and investigated. The PSMA-specific 
targeting of these liposomes was analyzed in vitro and in vivo using flow cytometry and 
SPECT/CT imaging, respectively. Efficacy of drug-loaded liposomes was tested on cell 
lines, and in cell line and patient-derived xenografts. The distribution of liposomes in the 
tumor was investigated with whole tumor microscopy. Pretreatment with hyperthermia 
was used to alleviate restrictive vascular permeability in these slow-growing xenografts. 
Targeted liposomes had an increased cytotoxic effect on PSMA-positive cell lines. A 
twofold increase in liposomal accumulation was observed in LNCaP xenografts after 
injection of targeted liposomes. Efficacy experiments with targeted and non-targeted 
doxorubicin-loaded liposomes showed no difference, and whole tumor microscopy 
revealed limited extravasation and retention in the perivascular space. Pre-treatment 
of tumors with hyperthermia enhanced liposomal accumulation, with a maximum 
of 11.58% ± 3.75% injected dose per cm³ of PSMA-targeted liposomes at 24 h after 
injection. This study shows that tumor-targeting modalities can increase accumulation 
of nanoparticles, although limited extravasation and retention may prevent maximal 
efficacy. The use of hyperthermia in conjunction with targeted liposomes appears to be 
a promising combination.
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iNTroDucTioN
Prostate cancer is one of the most prevalent cancers among men with an annual in-
cidence of more than 180,000 new cases and with over 26,000 deaths in the United 
States alone240. First-line therapy of advanced disseminated prostate cancer starts with 
androgen deprivation therapy, although within a few years the disease progresses to 
castration-resistant prostate cancer (CRPC)241,242. Since 2004, docetaxel is the first-line 
chemotherapy of CRPC243-245, and currently novel androgen receptor-targeting agents 
such as enzalutamide and abiraterone are being evaluated in pre- and post-docetaxel 
settings246,247. Clinical trials have evaluated the use of docetaxel before or in combina-
tion with hormone therapy and these trials showed remarkable benefit of docetaxel248, 
although the drug also provoked severe adverse effects such as alopecia, nausea and 
neutropenia249. In order to use docetaxel in early stage disease, such issues need to be 
addressed. Moreover, intrinsic resistance to docetaxel is another major problem, since 
more than half of the patients do not show a biochemical response244. This may be 
caused by cross-resistance between microtubule-regulated androgen receptor traffick-
ing250, reduced drug influx251, increased cellular metabolism252, and/or an unfavorable 
tumor microenvironment (aberrant vasculature, high interstitial fluid pressure, hypox-
ia) leading to reduced intratumoral drug levels253 and resulting in patient withdrawal. 
Therefore, strategies that address docetaxel resistance and reduce severe drug-induced 
toxicities are needed, and to this end several nanomedicines have been developed254.
Targeted nanoparticles have been developed with the aim of reducing adverse effects 
by shielding the drug from interactions during circulation, decreasing exposure to non-
target tissues and increasing accumulation at the target site. The rationale for using 
nanoparticles as anti-cancer treatment is based on the discovery that macromolecules 
accumulate in solid tumors due to the enhanced permeability and retention (EPR) 
effect142. This phenomenon is based on observations that solid tumors have a leaky 
and dysfunctional vasculature; macromolecules leak into the tumor where they remain 
present due to poor drainage by an impaired lymphatic system. One of the most well-
known nanoparticles developed is Doxil, a doxorubicin-loaded liposome approved by 
the FDA in 1995, which has been proven effective in the clinic255. Doxil reduces side 
effects that are seen after administration of free doxorubicin256,257, and facilitates an in-
creased accumulation of drug in solid tumors258. Delivery of docetaxel with liposomes 
has shown high specific release and decreased resistance compared to free docetaxel ad-
ministration259. To improve drug delivery to prostate tumors and reduce adverse effects, 
targeted antibody conjugated liposomal docetaxel formulations are being developed260.
Prostate cancer cells express high levels of prostate-specific membrane antigen 
(PSMA), allowing targeted nanoparticles to show improved specific targeting and 
receptor mediated endocytosis, internalization and intracellular release261,262, yet pre-
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venting multi-drug resistance263. PSMA is a membrane-bound glycoprotein expressed 
by almost all prostate cancers and is upregulated in advanced stages of the disease264. 
Its expression is independent from androgen265 and therefore remains a valid target 
in hormone-refractory cells after androgen ablation treatment. Moreover, it has been 
suggested to be upregulated after surgical or hormonal ablation217. PSMA is currently 
one of the most promising targets for prostate cancer with clinical implementation of 
PSMA-targeted imaging and developments in radionuclide therapy266. Targeting agents 
against PSMA have been reviewed extensively267-269, and include the recently developed 
nanobodies118, which combine the avidity of monoclonal antibodies with the ease of 
production and efficient biodistribution of peptides. Nanobodies, or single domain 
antibodies, were isolated after the discovery of functional heavy-chain antibodies in 
camelidae78,270 and are considered the smallest naturally derived antibodies retaining 
sufficient antigen binding98.
In this study we report on the delivery, tumor accumulation and efficacy of chemo-
therapeutics via anti-PSMA nanobody targeted liposomes using doxorubicin as a refer-
ence drug. The resulting PSMA-targeted liposomes were evaluated for targeting and 
therapeutic benefit both in vitro and in vivo, using different PSMA positive and negative 
prostate cancer cell lines, and cell-based and patient-derived xenograft (PDX) models. 
The use of nanobody-targeted liposomes created a highly specific platform for prostate 
cancer treatment which, in combination with hyperthermia, could further enhance 
tumor-specific accumulation.
MATeriALS AND MeThoDS
Anti-PSMA nanobody
The production and characterization of the anti-PSMA nanobody targeting the extra-
cellular domain of PSMA has been described elsewhere118.
Liposome preparation, drug loading and radiolabeling with indium-111
Liposomes were composed of hydrogenated soy phophatidylcholine (HSPC; Lipoid 
GmbH, Ludwigshaven, Germany), cholesterol (Sigma-Aldrich, St. Louis, MO), 
1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy(polyethylene gly-
col)-2000] (ammonium salt) (18:0 PEG2000 PE; Lipoid GmbH), 1,2-distearoyl-sn-
glycerol-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (ammo-
nium salt) (DSPE-PEG(2000)-Maleimide; Avanti Polar Lipids Inc., Alabaster, AL), and 
1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-diethylenetriaminepentaacetic 
acid (ammonium salt) (18:0 PE-DTPA; Avanti Polar Lipids Inc.) in a molar ratio of 
57:38:4:1:0.1 and were dissolved in chloroform/methanol 9:1 (vol/vol) before lipid film 
hydration and extrusion271.
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Doxorubicin-loaded liposomes were prepared with ammonium sulfate to enable ac-
tive loading of doxorubicin at 60°C with a 1:0.15 lipid to drug molar ratio. After drug 
loading, the functional PEG-maleimide groups in the liposomes were used to couple 
the anti-PSMA nanobody in a molar ratio of 1:100 of total lipid to nanobody. The size 
distribution of the liposomes was measured with a Zetasizer NanoSeries (Malvern In-
struments Ltd., Worcestershire, United Kingdom). The total amount of phospholipid 
was determined by phosphate assay, as described before272.
Radiolabeling of the liposomes with 111In was performed for the in vivo localization 
studies and has been described before127. Briefly, approximately 30 MBq of 111In was 
coupled to 1 μmol of liposomes before i.v. injection.
cell lines and culture conditions
Cell culture reagents, unless otherwise specified, were obtained from Sigma-Aldrich. 
Human prostate cancer cell lines LNCaP, PC-3, MDA PCa 2b and DU145 were obtained 
from the American Type Culture Collection (ATCC, Manassas, VA). The transfected 
murine melanoma cell line B16-PSMA was kindly provided by Marco Colombatti (Uni-
versity of Verona, Italy). LNCaP, PC-3 and DU145 were propagated using Roswell Park 
Memorial Institute (RPMI) 1640 medium supplemented with penicillin and strepto-
mycin (P/S; Lonza, Basel, Switzerland), and 5% fetal bovine serum (FBS). MDA PCa 2b 
was cultured in Ham’s F12 medium (Lonza) supplemented with 15% FBS, 25 ng/mL 
cholera toxin, 10 ng/mL epidermal growth factor (EGF), 5 μM phosphoethanolamine, 
120 pg/mL hydrocortisone and 1% insulin-transferrin-selenium (Thermo Fisher Sci-
entific, Waltham, MA). B16-PSMA was cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS under selection of 1.2 mg/mL geneticin (G418; 
Thermo Fisher Scientific). All cell lines were routinely cultured in a humidified incuba-
tor at 37°C and 5% CO2. LNCaP, MDA PCa 2b
273 and B16-PSMA are positive for PSMA, 
whereas PC-3 and DU145 are PSMA negative274.
fAcS analysis
Cells were harvested after trypsinization and resuspended in cold PBS (Sigma-Aldrich) 
containing 1% BSA (Sigma-Aldrich). The cell suspensions were incubated with targeted 
and non-targeted liposomes containing rhodamine B (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl; Avanti Polar Lipids Inc.) 
for 30 min at 4°C. After incubation, cells were washed twice with cold PBS/1% BSA 
and subjected to flow cytometric analysis using the LSRFortessa cell analyzer (BD Bio-
sciences, Franklin Lakes, NJ). Data analysis was performed using the FlowJo software 
(TreeStar Inc, Ashland, OR).
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cytotoxicity assay
Cells were plated in 96-well cluster plates at 5,000 cells (PC-3 and DU145) or 10,000 
cells (LNCaP and MDA PCa 2b) per well in 100 μL of their respective medium. To 
determine sensitivity to doxorubicin and doxorubicin liposomes, cells were exposed to 
concentrations ranging from 10−5 to 102 μM doxorubicin or empty liposomes as control 
with comparable lipid concentration for 24, 48 and 72 h. At each time point, cells were 
fixed with 10% trichloroacetic acid (TCA, Sigma-Aldrich) after which cell viability was 
assessed using the Sulphorhodamine B (Sigma-Aldrich) colorimetric assay.
In vivo imaging
All animal experimentation procedures were approved by the Animal Welfare Commit-
tee of the Erasmus Medical Center in Rotterdam, the Netherlands. Immune competent 
C56Bl/6 mice (for B16-PSMA) and NMRI nu/nu (for LNCaP, PC-3, MDA PCa 2b) 
were purchased from Envigo (Cambridgeshire, UK). Athymic NMRI nu/nu mice were 
obtained from Taconic (Ry, Denmark) for experiments with patient-derived xenografts. 
LNCaP, PC-3, MDA PCa 2b cells were resuspended in High Concentration Matrigel (BD 
Biosciences, San Jose, CA) at a concentration of 5 x 106 cells/100 μL. B16-PSMA was 
reconstituted at a concentration of 1 x 106 cells/100 μL PBS. Cell suspensions (100 μL) 
were injected subcutaneously in the right flank of 9-week old mice. Patient-derived 
xenografts, PC-295 and PC-310, were propagated subcutaneously in NMRI nu/nu mice 
which were supplemented with testosterone (Sigma-Aldrich)275 through silastic im-
plants. When tumors reached approximately 200 mm³ in size, mice were injected with 
radiolabeled liposomes (1 μmol of liposomes in 200 μL) for SPECT/CT (nanoSPECT/CT; 
Mediso Medical Imaging Systems) imaging. Imaging was performed using the following 
settings: SPECT static scan with 20 projections, 60 s/projection, and a quality factor of 
0.8. APT1 apertures were in place with 1.4 mm diameter pinholes (FOV 24 + 16 mm). 
For CT, 240 projections were made using 24 kVp tube voltage and 500 ms exposure. 
T = 0 scans were followed by scans at 4, 8, 24, 48, 72 and 96 h after liposomal injection. 
Analysis of SPECT/CT scans was performed using InVivoScope/VivoQuant software 
(inviCRO), where three-dimensional regions of interest were drawn over the tumor to 
calculate the amount of radiolabeled liposomes (%ID/cm³) taken up by the tumor.
In vivo efficacy
To assess antitumor efficacy, LNCaP and PC-3 xenografts were established as described 
above. When tumors were established (circa 200 mm³), mice were randomized into 
3 groups of at least 5 animals and treated with unloaded liposomes, doxorubicin-
loaded non-targeted liposomes, or doxorubicin-loaded PSMA-targeted liposomes 
by intravenous injection of 5 mg/kg doxorubicin (or comparable lipid concentration 
for the unloaded liposomes) once every 3 d for 4 consecutive times. Body weight and 
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tumor size were measured every 2 d. Tumor volumes were calculated with the following 
formula: Volume = height x width x depth x 0.4, where the day before the first injection 
(t = 0) was set at 100%.
hyperthermia to enhance ePr and improve liposomal uptake
MDA PCa 2b tumor grafts (circa 10 mm³ fragments), harvested from donor mice, were 
xenografted subcutaneously on the right hind leg of NMRI nu/nu mice. Tumors were al-
lowed to grow till 100 mm³, after which the tumor was subjected to mild hyperthermia 
for 1 h at 41°C, followed by an intravenous injection of unloaded PSMA-targeted and 
non-targeted 111In-labeled liposomes. Liposomal uptake was followed with SPECT/CT 
imaging using the same settings as described above.
Microscopic evaluation of intratumoral liposomal localization
Mice were inoculated with LNCaP cells. When the tumors had reached approximately 
200 mm³, mice were injected i.v. with 1 μmol of drug-loaded PSMA-targeted liposomes 
4 h before sacrifice. Xenograft tumors were excised and imaged with an Leica SP5 AOBS 
upright confocal microscope with multiphoton laser (Leica, Wetzlar, Germany) using a 
water immersion objective (HCX APO L 20x/1.0 W, Leica) with a ceramic front. Imme-
diately after excision, tumors were submerged in PBS and imaged using the following 
settings: pixel size 1.4 μm for 512 x 512 pixel images and 0.7 μm for 1024 x 1024 pixel 
images, 300 μm stacks with a 10 μm step size. Rhodamine liposomes were imaged with 
pinhole at 2 Airy units, excitation 561 nm and emission BP 570-620 nm, and the tumor 
was imaged using reflectance microcopy with pinhole at 2 Airy units, excitation 633 nm 
and emission BP 630-636 nm.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (version 5.01; GraphPad 
Software). All statistical tests were two-tailed, and a p value lower than 0.05 was con-
sidered statistically significant.
reSuLTS
characterization of Liposomes
Empty liposomes were generated using lipids and cholesterol in the ratio as described. 
These empty liposomes were subsequently coupled with anti-PSMA nanobody and 
loaded with doxorubicin or labeled with 111In. Empty liposomes were obtained with 
an average size of 82.69 ± 1.47 nm and polydispersity index (PDI) of 0.026 ± 0.013. 
PSMA-targeted liposomes had an average size of 87.71 ± 4.02 nm and PDI of 0.038 ± 
0.018. Loading with doxorubicin did not result in an increase in the size of liposomes, 
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since doxorubicin-loaded liposomes were 82.45 ± 1.63 nm, PDI of 0.030 ± 0.018, and 
PSMA-targeted doxorubicin liposomes were 87.88 ± 3.27 nm, PDI of 0.052 ± 0.021. 
The radiolabeling efficiency of liposomes with 111In was > 99%. On average the lipo-
somes were labeled with 32.52 ± 4.41 MBq 111In per µmol liposomes.
In vitro specificity of anti-PSMA nanobody targeted liposomes
Flow cytometry analysis was performed to confirm targeting specificity of the PSMA-
targeted liposomes using several PSMA positive and negative prostate cancer cell lines. 
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Figure 1. Representative graphs depicting binding of non-targeted (red) versus targeted 
empty liposomes (blue) in PSMA positive cell lines B16-PSMA, LNCaP, MDA PCa 2b and 
PSMA negative cell line PC-3.
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Table 1 shows the comparison of the median fluorescence intensity for unloaded non-
targeted and targeted liposomes. Non-targeted liposomes showed aspecific binding to 
all cell lines irrespective of the presence of PSMA, which was similar for all cell lines 
(comparable to a background mean fluorescent intensity of 1.13 ± 0.94). The targeted 
liposomes showed increased binding to the PSMA positive cell lines, B16-PSMA, LN-
CaP and MDA PCa 2b as compared to the non-targeted liposomes, confirming the 
specific binding of these liposomes (Figure 1). Based on these results PSMA expressing 
LNCaP cells and PSMA negative PC-3 cells, as negative control cell line, were selected 
for further efficacy experiments.
cytotoxicity of targeted and non-targeted doxorubicin liposomes
To determine the sensitivity of prostate cancer cells to free and liposomal doxorubicin, 
cells were exposed to the various treatments and cell viability was calculated using the 
SRB assay. EC50 values for the prostate cancer cell lines LNCaP, MDA PCa 2b (PSMA-
positive) and PC-3, DU145 (PSMA-negative) after treatment with free doxorubicin, 
drug-loaded targeted and non-targeted liposomes are shown in Table 2. For all cell 
lines tested, free doxorubicin was more effective than both targeted and non-targeted 
liposomal doxorubicin. Encapsulated doxorubicin showed a lesser efficacy and higher 
Table 1. Cell binding of PSMA-specific liposomes
Cell line MFI (non targeted) MFI (anti-PSMA)
B16-PSMA 3.21 (0.64 - 3.85) 59.1 (27.4 - 112.7)
DU-145 1.28 (1.28 - 1.28) 1.28 (1.28 - 1.28)
LNCaP 3.85 (2.57 - 4.17) 195.0 (165.3 - 269.3)
MDA-PCa-2b 3.85 (2.57 - 3.85) 310.0 (310.0 - 339.0)
PC-3 3.85 (2.57 - 3.85) 2.57 (1.28 - 5.13)
VCaP 3.85 (3.85 - 3.85) 2.57 (1.60 - 2.57)
Median fluorescence intensity is shown with 25th and 75th percentiles. All experiments 
have been performed for a minimum of 3 times.
Table 2. Cytotoxicity of free and liposomal doxorubicin
Cell line EC50 free dox (in μM) EC50 DL (in μM dox) EC50 TDL (in μM dox)
DU-145 0.011 a,b 3.834 a 3.030 b
LNCaP 0.092 a,b 4.021 a,c 0.361 b,c
MDA-PCa-2b 0.012 a,b 1.026 a 0.282 b
PC-3 0.122 a,b 40.02 a 22.26 b
Statistical test used: two-tailed one-way ANOVA with Bonferroni multiple comparison test. 
a Free doxorubicin versus Doxil is significant at p < 0.05 level; b Free doxorubicin versus 
Doxil-A7 is significant at p < 0.05 level; c Doxil versus Doxil-A7 is significant at p < 0.05 level.
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EC50 values compared to free doxorubicin, which can be explained by the slow release 
of doxorubicin from liposomes. Figure 2 shows cytotoxicity of LNCaP and PC-3 cells af-
ter treatment with free doxorubicin, non-targeted doxorubicin liposomes and targeted 
doxorubicin liposomes. The increased cytotoxicity of targeted liposomes was most sig-
nificant for LNCaP, with an EC50 for targeted and non-targeted liposomes of 0.361 μM 
and 4.021 μM doxorubicin, respectively. MDA PCa 2b cells showed an EC50 of 0.282 
μM and 1.026 μM, for targeted and non-targeted liposomes. As expected, no additional 
benefit of the targeted liposomes was observed for the PSMA negative PC-3 cells.
Accumulation of indium-111 labeled liposomes in prostate tumor xenografts
While in vitro experiments showed that targeted liposomes can be cytotoxic to cells, 
in vivo uptake and accumulation of (targeted) liposomes in the tumor is very much 
determined by the EPR effect, which is influenced by a number of different factors127. 
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Figure 2. Cell viability after treatment with free doxorubicin (red), doxorubicin liposomes 
(orange) or targeted doxorubicin liposomes (blue). The left panels show the PSMA positive 
cell lines LNCaP and MDA PCa 2b (A, C), the right panels show the PSMA negative cell 
lines PC-3 and DU145 (B, D). Data represents mean ± SEM of 3 independent experiments 
performed in duplicate.
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Different xenografts, both patient-derived (PDX) and cell line-based were selected 
representing PSMA-negative and PSMA-positive tumors, to assess the uptake of 
111In-labeled liposomes. Surprisingly, the high PSMA-expressing PDXs, PC-295 and 
PC-310, did not show an enhanced uptake of the targeted liposomes as compared to 
non-targeted liposomes (Figure 3A). In contrast, the PSMA-positive cell line-based 
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Figure 3. Graphs depicting tumor uptake after injection with indium-111 labeled empty 
liposomes, both non-targeted (square) and targeted (circle) with anti-PSMA nanobodies. 
PDXs derived from prostatic carcinomas PC-295 and PC-310 (A); Transfected B16-PSMA 
and MDA PCa 2b xenografts (B); LNCaP and PC-3 xenografts (C). * statistical significance 
p < 0.05 with unpaired two-tailed t-test. Data represents mean ± SD of 3 or more animals.
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xenografts showed higher accumulation of the PSMA-targeted liposomes: B16-PSMA 
tumors showed a relatively high uptake both with targeted (max. at 48 h with 4.80% 
injected dose per cm³) and non-targeted liposomes (max. at 24 h at 4.17% injected 
dose per cm³) compared to the PDXs (Figure 3B, left panel) and MDA PCa 2b showed 
a 2-fold increase in tumor uptake of targeted liposomes over non-targeted liposomes 
with a maximum uptake of 3.57% injected dose per cm³ at 48 h (Figure 3B, right panel). 
LNCaP tumors showed the largest increase in tumor uptake with targeted liposomes 
(max. 4.59% injected dose per cm³ at 24 h) when compared to non-targeted liposomes 
(Figure 3C, left panel). No difference between targeted and non-targeted liposomal ac-
cumulation was observed for the PSMA-negative PC-3 tumors, confirming the absence 
of significant amounts of PSMA in this model (Figure 3C, right panel). Based on these 
results, we decided to continue with efficacy experiments on the LNCaP xenografts, 
using PC-3 xenografts as non-target controls.
In vivo efficacy of non-targeted and PSMA-targeted doxorubicin liposomes
PSMA-expressing LNCaP and PSMA-negative PC-3 tumor bearing mice were injected 
with doxorubicin-loaded liposomes to ascertain inhibitory effects of the liposomal 
formulations on tumor growth. A treatment schedule was chosen with 4 subsequent 
injections of 5 mg/kg doxorubicin encapsulated in PSMA-targeted or non-targeted 
liposomes. Tumor growth arrest was immediately induced after the first injection with 
both PSMA-targeted and non-targeted liposomal doxorubicin and continued for at 
least 30 d after the last injection for both cell lines (Figure 4). Empty PSMA-targeted 
liposomes served as control and showed no inhibitory effect. The already high efficacy 
of liposomal doxorubicin did not allow a discrimination between a potential effect of 
targeted liposomes over the non-targeted liposomes.
Ex vivo localization of doxorubicin-loaded liposomes
To gain insight into the lack of effect of the PSMA-targeted doxorubicin liposomes, LN-
CaP tumors were harvested intact and imaged immediately. Liposomes were observed 
in and around blood vessels and accumulating to a certain degree in the cytoplasm of 
tumor cells. In general, the penetration of PSMA-targeted liposomes in the tumor was 
limited and large areas of the LNCaP tumor remained void of liposomes (Figure 5).
Localization and uptake of empty liposomes after mild hyperthermia
To enhance liposomal accumulation in the tumor, PSMA-expressing subcutaneously 
xenografted MDA PCa 2b tumors were preheated locally. Hyperthermia pretreatment 
did not diminish the ratio between accumulation of targeted and non-targeted lipo-
somes originally seen in non-heated xenografts, which leads to a high accumulation of 
targeted liposomes after hyperthermia. Whereas tumors showed significantly improved 
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accumulation for targeted versus non-targeted liposomes (3.23 ± 0.94 and 2.00 ± 
0.18% injected dose per cm³ at 24 h) (Figure 3), after pretreatment with hyperthermia, 
accumulation increased to 11.24 ± 3.34 and 7.10 ± 1.55% injected dose per cm³ at 24 
h for targeted and non-targeted liposomes, respectively (Figure 6).
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Figure 4. Tumor growth of PC-3 (A) and LNCaP (B) xenografts after 4 subsequent injec-
tions with empty liposomes (triangle), doxorubicin liposomes (square) and targeted doxoru-
bicin liposomes (circle). Data represents mean ± SD of 5 or more animals.
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Figure 5. Whole tumor microscopy showing liposomal distribution in tumors. Represen-
tative maximum projections of an LNCaP xenograft injected with targeted doxorubicin li-
posomes. Area showing targeted liposomes within the tumor vasculature and those that 
have extravasated and accumulated in the tumor cells (A), indicating internalization. Poorly 
vascularized area within the same tumor with lower permeability where the liposomes are 
confined to the vessels (B). Scale bars = 100 μm.
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Figure 6. Tumor accumulation of injected indium-111 labeled empty liposomes in MDA-
PCa-2b xenografts after 1 h of hyperthermia (41°C applied locally to the tumor), both non-
targeted (square) and targeted (circle) with anti-PSMA nanobody. Statistical significance * = 
p < 0.05 and ** = p < 0.01 with Mann Whitney test. Data represents mean ± SD of > 5 animals.
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DiScuSSioN
The principle of highly specific targeted drugs has always been appealing, since these 
personalized targeted drugs would theoretically only accumulate in the target region 
resulting in decreased side effects and an increased therapeutic effect. Targeting would 
be especially interesting in combination with nanomedicines, which shield the drugs 
during long circulation and have the capability to deliver large quantities of drugs into 
the cell. While the targeting of nanoparticles is primarily aimed to improve localiza-
tion to the target tissue, added advantages are an increased internalization and target 
tissue retention260. Studies with targeted liposomes have provided mixed results276, but 
it seems that internalizing targeting moieties, like the one used in this study, are more 
effective as therapy56.
We have previously reported the generation of a highly specific PSMA nanobody 
which is capable of accumulating in PSMA-expressing xenografts. Here we conjugated 
the nanobody to liposomes and we showed that PSMA-targeted liposomes can specifi-
cally bind to PSMA-positive cells and tumors, yet we could not show an added therapeu-
tic benefit of these targeted liposomes in vivo. The chosen dosing regimens may have 
been too frequent for long circulating liposomes, as it has recently been shown that 
dosing every other day can diminish the added benefit of targeting moieties, whereas 
a once-weekly dosing schedule showed targeted nanoparticles to be more efficacious 
than non-targeted nanoparticles277. It has been suggested that frequent administra-
tion causes a continuous supply to the tumor, rendering targeting irrelevant or even 
a factor reducing efficacy. Therefore, it seems that the higher dose intensity in this 
study resulted in an efficacy too high to elucidate an added effect of targeted liposomes. 
Furthermore, there may be additional reasons for the absence of a difference between 
PSMA-targeted and non-targeted liposomes. The difference in accumulation between 
targeted and non-targeted liposomes was limited (average Δ = 1.37 ± 0.43% injected 
dose per cm³), which might not be enough to elucidate a difference in efficacy.
Despite these findings, benefits of encapsulated drugs as alternative treatment op-
tions have led to the generation of several new nanoparticles against prostate cancer in 
(pre)clinical trials. For example, Cellax, is a self-assembled nanoparticle composed of 
docetaxel conjugated to PEG-acetylated carboxymethylcellulose278, and BIND-014, is a 
nanoparticle where docetaxel is encapsulated in biodegradable polymer based particles 
targeted against PSMA with S,S-2[3[5-amino-1-carboxypentyl]-ureido]-pentanedioic 
acid63,279,280. The results of these nanomedicines are hopeful, and continued investiga-
tion of barriers in tumor morphology and physiology may further enhance the efficacy 
of nanomedicine.
Targeted liposomes tend to bind to the first barrier of target-positive cells which 
strongly reduces the penetration of liposomes throughout the tumor and hence may 
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reduce efficacy. This so-called binding site barrier effect may act as a bottleneck, where 
high avidity antibodies bind the first possible antigen and effectively are stopped at 
the periphery of the target site207,281,282. Another issue is the limited extravasation or 
accumulation in the perivascular space as has been investigated before as an important 
aspect of the EPR effect127 and indeed extravasation from the tumor vasculature has 
been recognized as the rate-limiting step for tumor accumulation52. It is known that 
the penetration depth for liposomes is limited to a few dozen μm283. To counteract this, 
we have shown in this study that liposomal accumulation can be enhanced with the 
use of mild hyperthermia, which possibly widens the restrictive gaps in the endothelial 
layer to enhance extravasation182, supporting the notion that limited extravasation of 
liposomes is a major restrictive factor in nanoparticle delivery. In this study, the differ-
ence between tumor accumulation of targeted and non-targeted liposomes remained 
significant, which may warrant a follow-up study where efficacy of targeted liposomes 
in combination with hyperthermia is investigated.
coNcLuSioN
We used a highly specific anti-PSMA nanobody to functionalize doxorubicin loaded 
liposomes. The anti-PSMA targeted liposomes showed high specificity for PSMA-pos-
itive cell lines and xenografts, although we were unable to show enhanced therapeutic 
efficacy. Additional studies revealed that limited extravasation and/or a restrictive pen-
etration of the tumor tissue is a major limiting factor, resulting in the accumulation of 
liposomes in the (peri)vascular space rather than the tumor. Nonetheless, extravasation 
from the tumor blood vessels could be enhanced with the application of mild hyper-
thermia resulting in a more than 3-fold increase in liposomal accumulation, proving to 
be an interesting option to enhance drug delivery to the tumor site and improve drug 
efficacy.
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ABSTrAcT
Liposomal chemotherapy offers several advantages over conventional therapies, includ-
ing high intratumoral drug delivery, reduced side effects, prolonged circulation time, 
and the possibility to dose higher. The efficient delivery of liposomal chemotherapeutics 
relies, however, on the enhanced permeability and retention (EPR) effect, which refers 
to the ability of macromolecules to extravasate leaky tumor vessels and accumulate in 
the tumor tissue. Using a panel of human xenograft tumors, we evaluated the influence 
of the EPR effect on liposomal distribution in vivo by injection of pegylated liposomes 
radiolabeled with indium-111. Liposomal accumulation in tumors and organs was 
followed over time by SPECT/CT imaging. We observed that fast-growing xenografts, 
which may be less representative of tumor development in patients, showed higher 
liposomal accumulation than slow-growing xenografts. Additionally, several other pa-
rameters known to influence the EPR effect were evaluated, such as blood and lymphatic 
vessel density, intratumoral hypoxia, and the presence of infiltrating macrophages. 
The investigation of various parameters showed a few correlations. Although hypoxia, 
proliferation, and macrophage presence were associated with tumor growth, no hard 
conclusions or predictions could be made regarding the EPR effect or liposomal uptake. 
However, liposomal uptake was significantly correlated with tumor growth, with fast-
growing tumors showing a higher uptake, although no biological determinants could 
be elucidated to explain this correlation.
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iNTroDucTioN
Almost all nanocarriers, including liposomes15, and many other anticancer drugs rely 
on the enhanced permeability and retention (EPR) effect for accumulation in tumor 
tissue. The EPR effect is defined as the process of extravasation of large molecules from 
leaky tumor vasculature, leading to accumulation in tumor tissue142. The EPR effect 
is dependent on many biological parameters, with the development of the abnormal 
tumor vasculature playing a major role, although other parameters such as the com-
position of the surrounding stroma, absence of functional lymphatics, and presence 
of tumor infiltrating macrophages also play an important role284. Abnormally upregu-
lated growth factors affect the vasculature of the tumor151 and lead to large endothelial 
junctions at the luminal surface, resulting in a leaky vasculature285. In addition, ves-
sels lack smooth muscle cell layers and supporting cells286, and the fast recruitment 
of blood vessels results in tumor neovasculature that is not hierarchically organized, 
causing a heterogeneous spatial distribution151,287,288. Finally, tumors overexpress many 
permeability-enhancing factors, which contribute to an enhanced EPR effect289. These 
observations suggest that most tumors may be susceptible to nanoparticle treatment, 
but thus far such particles show only a limited effect in vivo due to various barriers such 
as the mononuclear phagocyte system, extracellular matrix, low pH, low oxygenation, 
and high interstitial fluid pressure290-292. The intra- and intertumoral heterogeneity are 
major factors influencing the EPR effect, especially in patients, where tumor growth 
and vessel development are slower150. The Food and Drug Administration–approved 
liposomal doxorubicin (Doxil or Caelyx; Janssen Products, LP) is one of the most suc-
cessful nanoparticle drugs for several cancer types293-296. Unfortunately, Doxil has a lim-
ited effect on overall survival when compared with conventional chemotherapy284, as 
has been shown in various clinical trials294,297,298. This and previous results suggest that 
tumor physiology influences the efficacy of nanoparticle drugs, possibly due to varia-
tions in the EPR effect299. Because the EPR effect is essential for the efficacy and mode 
of action of liposomes in vivo, the aim of this study was to investigate major parameters 
influencing EPR and their effects on liposomal uptake in tumor xenografts. To this end, 
we injected unloaded, long-circulating, pegylated Doxil-like liposomes to determine 
liposomal tumor accumulation. Various human xenograft tumor models, including 
squamous cell carcinoma, breast cancer, and pancreatic cancer, were selected on the 
basis of tumor growth rate, taking into consideration that slow-growing tumors are 
more representative of tumor growth in patients. Our results show that it is difficult to 
elucidate single determinants of the EPR effect and we therefore suggest that liposomal 
uptake and distribution in tumors is a multifactorial process involving physiological 
and morphological parameters.
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MATeriALS AND MeThoDS
Preparation of unloaded Doxil liposomes
Doxil liposomes were prepared by the lipid film hydration and extrusion method300. 
A mixture containing hydrogenated soy phosphatidylcholine (HSPC; Lipoid GmbH, 
Ludwigshaven, Germany), cholesterol (Sigma-Aldrich, Zwijndrecht, the Netherlands), 
1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)- 
2000] (ammonium salt) (18:0 PEG2000 PE; Lipoid GmbH), 1,2-distearoyl-sn-glycer-
ol-3-phosphoethanolamine-Ndiethylenetriaminepentaacetic acid (ammonium salt) 
(18:0 PE-DTPA; Avanti Polar lipids, Alabaster, AL) in a molar ratio 57:38:5:0.1 was dis-
solved in chloroform/methanol 9:1 (vol/vol). After the addition of 0.1 mol% 1,2-di-
palmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(ammonium salt) (Rhodamine-PE; Avanti Polar lipids), the solvent was evaporated in 
vacuo using a rotary evaporator (Büchi Rotavapor R-210, Büchi Labortechnik, Flawil, 
Switzerland) until a homogeneous lipid film was formed. The lipid film was hydrat-
ed in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline (10 
mM HEPES, 135 mM NaCl, pH 7.4). The newly formed vesicles were extruded at 60°C 
through a high-pressure Lipex thermoline extruder (Northern Lipids Inc, Vancouver, 
Canada) by passing through Nucleopore polycarbonate membrane filters (Whatman, 
Newton, MA) with pore diameters of 200, 100, 80, and 50 nm (5 extrusions per fil-
ter). The average diameter and size distribution (polydispersity index) of the liposomes 
were determined by dynamic light scattering using a Zetasizer Nano (Malvern Instru-
ments, Worcestershire, United Kingdom). Total phospholipid content was determined 
by phosphate assay, as described elsewhere272.
cell lines
Established human cell lines were obtained from the American Type Culture Collection, 
among which: one squamous cell carcinoma cell line (A431), four pancreatic adenocar-
cinoma (AsPC-1, BxPC-3, CFPAC-1, HPAF-II), one epithelioid carcinoma (PANC-1), 
two breast adenocarcinoma (MDA-MB-231, MDA-MB-468), and one primary ductal 
breast carcinoma (UACC-893). Cell culture reagents were purchased from Lonza 
(Breda, the Netherlands). A431, CFPAC-1, and PANC-1 were grown in Dulbecco’s 
Modified Eagle Medium with glutamine supplemented with 10% fetal bovine serum; 
AsPC-1, BxPC-3, MDA-MB-231, MDA-MB-468, and UACC-893 were grown in Roswell 
Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum; 
HPAF-II was grown in Roswell Park Memorial Institute 1640 medium with glutamine 
supplemented with 5% fetal bovine serum.
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Indium-111 labeling of liposomes
Liposomes contained 0.1 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
diethylenetriaminepentaacetic acid (DTPA-PE) lipid (Avanti Polar Lipids, Inc.), which 
enabled conjugation with 111InCl (Mallinckrodt Medical B.V.). Approximately 30 MBq 
indium-111 was incubated per µmol of liposomes for 15 min at room temperature; 
2.5 M sodium acetate was used to set the pH at 5.0. Instant thin-layer chromatography 
silica gel (silica gel–coated paper [Varian Inc.]; 0.1 M sodium citrate, mobile phase) 
was performed to ascertain complete labeling301. Because of the molar excess of DTPA 
lipid over indium-111, lipid labeling efficiencies of greater than 99% were achieved. 
Before injections, the volume was adjusted to 200 µL per µmol of liposomes with N-(2-
hydroxyethyl)piperazine-N-(2-ethanesulfonic acid) (HEPES)–buffered saline (10 mM 
HEPES, 135 mM NaCl, pH 7.4).
In vivo biodistribution studies
NMRI nu/nu mice were obtained from Harlan (Horst, the Netherlands). All experiments 
were performed according to the guidelines for research animals and approved by the 
Animal Welfare Committee of the Erasmus Medical Center. 9-week-old male NMRI 
nu/nu mice were injected subcutaneously in the right flank with 3-5 x 106 cells in 100 
μL phosphate buffered saline. Mice were anesthetized with the inhalation anesthetic 
isoflurane during injection of cells and SPECT/CT imaging. Tumors were measured by 
caliper every other day till grown to an average size of 200 mm³. Tumor volumes were 
calculated using the formula: V = 0.4 ∗ (a ∗ b ∗ c), where a, b and c represent the 
length, width and depth of the tumor, respectively. Mice were injected intravenously 
(tail) with 1 µmol of liposomes labeled with indium-111. Immediately after injection, 
the animal was scanned (t = 0), using the following settings: SPECT (nanoSPECT/CT; 
Mediso Medical Imaging Systems) static scan with 20 projections, 60 s per projection, 
and a quality factor of 0.8. APT1 apertures were used with 1.4 mm diameter pinholes 
(FOV 24 + 16 mm). The following were the CT scan settings: 240 projections, 45 kVp 
tube voltage, and 500 ms exposure. The t = 0 scan was followed by scans at 4, 8, 12, and 
24 h after injection. SPECT/CT analysis was performed using InVivoScope/VivoQuant 
software (inviCRO). Three-dimensional regions of interest were drawn over the heart 
(blood pool) and tumor to calculate uptake of indium-111 liposomes at the selected 
time points, after which they were corrected for volume (%ID/cm³). Representative 
figures were made with the same software after correction for indium-111 decay.
Ex vivo biodistribution
Tumors and tissue samples (blood [cardiac puncture], heart, lung, liver, spleen, pancre-
as, kidney, stomach, duodenum, caecum, colon, tail, and muscle) were harvested and 
weighed. Radioactivity was determined with a γ counter (Perkin Elmer), and liposomal 
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accumulation was calculated as percentage injected dose per gram of tissue (%ID/g) 
and corrected for radioactive decay of indium-111 (half-life, 2.81 d). The injected dose 
was calculated by measuring the syringe before and after injection.
immunohistochemical staining
After the final scan, pimonidazole (60 mg/kg of body weight) was injected intraperito-
neally and allowed to circulate for 4 h before dissection of tumor and organs. Harvested 
tumors were snap-frozen in liquid nitrogen, and frozen tumor sections (10 µm thick) 
were mounted on Superfrost++ slides (VWR, Radnor, PA). The slides were fixed with 
acetone at 4°C for 10 min and stained for the following morphological parameters: 
blood vessels (Rat-anti-mouse CD31, 1:100; Becton Dickinson, Franklin Lakes, NJ), 
PEGylated liposomes (Rabbit-anti-PEG, 1:100; Abcam, Cambridge, United Kingdom), 
macrophages (Rat-anti-mouse CD11b, 1:100; eBioscience, San Diego, CA), lymphatic 
vessels (rabbit-anti-LYVE1, 1:100; Abcam) and vessel integrity (Rabbit-anti-Collagen 
IV, 1:100; Millipore, Billerica, MA). Hypoxia was detected with a rabbit-anti-pimoni-
dazole antibody (1:200, Hypoxiprobe, Burlington, MA). Secondary antibodies were 
species-specific donkey-antibodies conjugated with AF488 or AF647 (1:500) (Mo-
lecular Probes, Waltham, MA) in appropriate combinations. Tile scans of fluorescently 
stained tumor sections were acquired using an LSM 510 Meta confocal microscope 
(Carl Zeiss B.V.) with a Plan-Neofluar 10x objective. Quantifications were performed 
with ImageJ (National Institutes of Health), using manual thresholding (range, 0–255) 
for density analysis and a colocalization threshold tool to ascertain the ratio between 
PEG and CD31, and collagen IV and CD31. To avoid regional bias, all quantifications 
were performed on whole tile scans of tumor sections.
In vitro stability assay
Liposomes were made and radiolabeled with indium-111 as described before. These 
liposomes were incubated in 100% fetal bovine serum at 37°C for 24, 48, 72, 96 h. 
The solution was eluted over a size exclusion chromatography column (PD-10, GE 
Healthcare, Buckinghamshire, United Kingdom) and fractions of 1 mL were collected. 
After elution the column was washed with 25 mL phospate buffered saline to check for 
free 111In-DTPA.
In vivo stability assay
Mice were injected with 1 µmol 111In-labeled liposomes and were followed over time. 
After 24 and 96 h the mice were used for biodistribution experiments as described 
before.
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Statistical analysis
Statistical analyses were performed using GraphPad Prism (version 5.01; GraphPad 
Software). The differences between fast-, intermediate-, and slow-growing xenografts 
were evaluated using 1-way ANOVA with nonparametric Kruskal–Wallis H test and 
Dunn’s multiple comparison post-test. Comparisons between the high- and low-uptake 
groups were performed using the 2-tailed Mann–Whitney U test. Correlation analysis 
between the various parameters evaluated in this study was performed using the Spear-
man rho test. All statistical tests were 2-sided, and a p value of lower than 0.05 was 
considered statistically significant.
reSuLTS
characterization of liposomes
Lipids and cholesterol were used in the ratio as described for preparing liposomes com-
parable to Doxil. The addition of cholesterol increases liposome stability in plasma and 
pegylation provides a long circulation half-life by creating a steric barrier against opso-
nization302. Doxil is one of the few liposomal drugs approved for clinical use in breast 
cancer295, ovarian cancer293, multiple myeloma, and HIV-related Kaposi’s sarcoma294,296. 
The formulation used here was not loaded with doxorubicin, as the principal objective 
was to assess the distribution behavior of the liposomes in vivo. All other characteristics 
are similar to Doxil, such as an average size of 83.13 ± 2.69 nm and polydispersity index 
of 0.036 ± 0.016. To perform image-guided delivery, the liposomes were labeled with 
indium-111 for SPECT imaging. The radiolabeling efficiency with indium-111 after 15 
min labeling at room temperature was greater than 99%. The indium-111 conjugated 
F1 F2 F3 F4 FT
0.0
0.1
0.2
0.3
0.4
24 h
48 h
72 h
96 h
A
ct
iv
ity
 (M
B
q)
Figure 1. Indium-111 liposomes were incubated in 100% fetal bovine serum at 37°C for t = 
24, 48, 72, 96 h, after which the sample was used for size exclusion chromatography (PD-10 
column). Retention activity in MBq is depicted of fractions (F1-F4 = 1 mL) collected during 
size exclusion chromatography and after washing the column (FT = 25 mL).
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liposomes were tested for stability for up to 96 h as shown in Figure 1. On average the 
liposomes were labeled with 34.54 ± 1.04 MBq of indium-111 per µmol of liposomes.
Tumor characterization
After inoculation tumor volume was measured every other day until a size of 200-300 
mm³ was reached. Figure 2 shows the growth rate of individual s.c. xenografts subdivid-
ed in groups of fast (Figure 2A), intermediate (Figure 2B), and slow growing xenografts 
(Figure 2C). The squamous cell carcinoma A431, and pancreatic adenocarcinoma’s 
CFPAC-1 and HPAF-II are fast growing tumors, which grew to the target size within 
1 month. Pancreatic adenocarcinomas AsPC-1, BxPC-3, and breast adenocarcinoma 
MDAMB-231 needed 1.5-2.5 months, whereas slow growing tumors, such as primary 
ductal carcinoma UACC-893, epithelioid carcinoma PANC-1, and breast adenocarci-
noma MDA-MB-468 needed 3-6 months. With few exceptions (e.g. MDA-MB-231), 
Table 1. Correlation between morphological parameters and tumor growth
Characteristics
(median, IQR)
Fast growing 
xenografts
(n = 9)
Intermediate 
growing 
xenografts (n = 9)
Slow growing 
xenografts
(n = 8)
pa pb pc
Time in days 21
(18 - 25)
60
(44 - 67)
79
(72 - 145)
< 0.05 < 0.001 ns
Morphological parameters
PEG percentage 4.98
(2.51 - 7.24)
3.55
(2.35 - 8.53)
2.26
(0.88 - 3.84)
ns ns ns
CD31 percentage 3.63
(2.56 - 4.36)
2.30
(2.06 - 4.42)
2.69
(1.85 - 5.60)
ns ns ns
Pimonidazole 
percentage
26.18
(16.32 - 37.21)
41.19
(32.28 - 47.58)
37.74
(30.09 - 44.70)
< 0.05 ns ns
Ki67 percentage 6.10
(5.24 - 9.21)
5.55
(5.09 - 7.83)
10.36
(8.3 - 12.58)
ns < 0.05 < 0.05
LYVE-1 percentage 0.37
(0.15 - 0.79)
0.17
(0.10 - 1.02)
0.22
(0.07 - 0.28)
ns ns ns
CD11b percentage 0.44
(0.28 - 1.03)
1.60
(1.23 - 2.97)
1.43
(0.27 - 3.64)
< 0.05 ns ns
Collagen 
percentage
18.45
(10.84 - 19.87)
14.58
(8.36 - 16.57)
13.81
(8.88 - 19.45)
ns ns ns
Liposomal uptake
Liposomes (in vivo) 4.00
(2.92 - 5.01)
2.25
(1.74 - 3.77)
2.04
(1.48 - 2.25)
ns < 0.01 ns
Liposomes (ex 
vivo)
4.24
(2.58 - 7.06)
2.70
(2.12 - 3.79)
1.97
(1.54 - 2.48)
ns < 0.01 ns
Abbreviations: IQR = inter quartile range, ns = not significant; Statistical test used: one-way 
ANOVA test, two-tailed Kruskal-Wallis test; a = fast growing versus intermediate; b = fast 
versus slow; c = intermediate versus slow growing
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the tumors showed a predictable and reproducible growth pattern. This subdivision 
was used to compare various parameters thought to be involved in the EPR effect and 
uptake of liposomes. Table 1 shows an increased liposomal uptake in vivo and ex vivo, 
in fast growing xenografts compared to slow growing xenografts (p < 0.01). However, no 
other parameter could be clearly identified as being involved in liposomal uptake with 
this subdivision of xenografts.
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Figure 2. Human tumor cells (3-5 x 106) were inoculated s.c. in the right flank of NMRI nu/
nu mice. Tumor growth was followed over time and measured three times a week. Individual 
mice are depicted with the following symbols: mouse 1 = ○, mouse 2 = □, mouse 3 = △). 
The tumor xenografts were ordered according to their growth in vivo: fast growing (A); in-
termediate growing (B); slow growing (C). Vertical axis shows tumor size (mm³); horizontal 
axis days after inoculation.
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In vivo stability assay
Biodistribution experiments (Figure 3) showed that liposomes are cleared from the 
blood over time, whereas they are retained in liver and spleen, which are known to be 
involved in the clearance of liposomes. This data shows that most other organs show 
liposome-specific activity due to perfusion at 24 h, which is cleared after several days.
24 h p.i.
Bl
oo
d
He
art
Lu
ng
Liv
er
Sp
lee
n
Pa
nc
rea
s
Ki
dn
ey
St
om
ac
h
Du
od
en
um
Ca
ec
um
Co
lon
Mu
sc
le
0
5
10
15
%
ID
/g
96 h p.i.
Bl
oo
d
He
art
Lu
ng
Liv
er
Sp
lee
n
Pa
nc
rea
s
Ki
dn
ey
St
om
ac
h
Du
od
en
um
Ca
ec
um
Co
lon
Mu
sc
le
0
5
10
15
%
ID
/g
Figure 3. Percentage of injected dose per gram (%ID/g) depicted per mouse after biodistri-
bution at 24 and 96 h post injection (p.i.).
In vivo localization of indium-111 labeled liposomes in human tumor 
xenografts
All mice were injected intravenously with 1 µmol of liposomes labeled with indium-111 
for SPECT imaging. A volume of interest was drawn to quantify liposomal accumulation 
in the tumor and heart (blood pool). Figure 4A shows accumulation of liposomes in 
the tumor over time (0, 4, 8, 12, and 24 h after injection) as a percentage injected dose 
corrected for tumor volume (%ID/cm³). The EPR effect ensured accumulation of lipo-
somes in the tumors over time, whereas the heart showed clearance of liposomes from 
circulation. In the heart, liposomes still accounted for 6.28 ± 1.50% injected dose per 
cm³ (SD) after 24 h, which was confirmed by t1/2β of 16.99 ± 1.81 h (SEM). Figure 4B 
shows representative mice depicting high liposomal uptake (HPAF-II tumor) and low 
liposomal uptake (PANC-1 tumor). The SPECT/CT scans show radiolabeled liposomes 
in circulation, visible in the heart, aortic arch, aorta, and continuing downstream into 
axillary, hepatic, splenic, renal, and femoral arteries. The liposomes in circulation 
diminished over time and accumulated in the liver, spleen, and, to varying degrees, the 
tumor. The liposomes were slowly cleared via the liver and spleen (mononuclear phago-
cytic system), whereas they were retained in the tumor because of the EPR effect303. 
Spleen macrophages and hepatic Kupfer cells can ingest liposomes and are responsible 
for liposome accumulation in these organs. Liver fenestrations (100 nm) and spleen 
lumina (up to 5 µm) will further contribute to this accumulation304. Figure 5 shows all 
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studied tumor types 12 h after injection with radiolabeled liposomes. In addition to dif-
ferences in total uptake, early variations in intratumoral localization were clearly visible 
and were probably caused by perfusion differences305,306. For example, MDA-MB-231 
showed a clear uptake in certain regions of the tumor periphery, whereas other regions 
remained clear. Other tumors such as CFPAC-1 showed a more homogeneous distribu-
tion of liposomes. Importantly, the circulation of liposomes and accumulation in liver 
and spleen were comparable between different tumor models, as confirmed later by 
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Figure 4. Average tumor uptake in percentage injected dose per cubic centimeter tumor 
(%ID/cm³) was calculated and is depicted at t = 0, 4, 8, 12, and 24 h post injection (A). 
Representative SPECT/CT scans, adjusted for indium-111 half-life, of HPAF-II or PANC-1 
tumor (white circle) bearing mice at different time intervals after injection with indium-111 
liposomes show uptake of liposomes over time to a higher (HPAF-II) and lesser (PANC-1) 
degree (B).
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the biodistribution data. Liposomes are degraded in the liver after 12–24 h, causing a 
release of free 111In-DTPA, as detected by low levels of radioactivity in the kidney and 
bladder, because free 111In-DTPA is rapidly cleared from circulation307.
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Figure 5. Representative SPECT/CT scans of fast, intermediate, and slow growing tumors 
12 h after injection. The scans have been set to the same threshold (in kBq) to compensate 
for indium-111 half-life. Tumors are circled in white and show uptake of liposomes to vari-
ous degrees.
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Ex vivo organ biodistribution
Radioactivity uptake was measured after resection of the tumors and other relevant 
tissues and is shown per tumor type in Figure 6 and in more detail for all analyzed 
organs, including the tumor, in Figure 7. The tumors are again arranged from fast to 
slow-growing, with levels of uptake ranging from PANC-1 (1.51 ± 0.11% injected dose 
per gram) on the low end to CFPAC-1 (7.99 ± 3.59% injected dose per gram) on the 
high end. A trend was observed between tumor growth and liposomal uptake (Table 2, 
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Figure 6. Tumor accumulation of indium-111 in percentage injected dose per gram (%ID/g 
tumor) at 24 h after i.v. injection ordered from fast to slow growing tumor xenografts show-
ing some association with speed of tumor growth.
Table 2. Correlation between morphological parameters and liposomal tumor uptake
Characteristics (median, IQR) High uptake (n = 9) Low uptake (n = 17) p value
Liposomal uptake
Liposomes (in vivo) 4.16 (3.67 - 5.01) 2.12 (1.50 - 2.45) < 0.0001*
Liposomes (ex vivo) 4.24 (3.95 - 7.06) 2.26 (1.76 - 2.62) < 0.0001*
Time in days 25 (21 - 43) 70 (52 - 79) 0.0104*
Morphological parameters
PEG percentage 5.64 (4.92 - 11.77) 2.50 (0.97 - 4.07) 0.0018*
CD31 percentage 2.84 (2.08 - 3.98) 2.87 (2.12 - 5.57) 0.5899
Pimonidazole percentage 37.13 (24.12 - 40.72) 33.49 (27.23 - 45.19) 0.6276
Ki67 percentage 7.63 (5.32 - 9.21) 7.79 (5.52 - 11.39) 0.4188
LYVE-1 percentage 0.37 (0.15 - 0.79) 0.21 (0.06 - 0.41) 0.2465
CD11b percentage 1.01 (0.31 - 2.26) 1.40 (0.39 - 2.53) 0.4834
Collagen percentage 18.56 (12.23 - 20.23) 13.72 (8.31 - 16.46) 0.0524
Abbreviation: IQR = inter quartile range; Statistical test used: two-tailed Mann-Whitney U 
test; * significant at p < 0.05 level.
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p = 0.0104), although outliers, such as A431, BxPC-3, and MDA-MB-468, indicate 
that other factors are important and may be influencing liposomal accumulation. The 
reason for this was investigated in more detail using immunohistochemical stainings, 
but it is, for example, known that the presence of necrotic or poorly vascularized tumor 
cores in fast-growing tumors may inhibit liposomal uptake154. Most of the liposomes 
accumulate in the liver, spleen, and tumor, after which they are cleared. Biodistribution 
data up to 96 h after injection are shown in Figure 3, showing clearance of liposomes 
from most organs. Liposomal uptake in vivo was compared with other modalities used 
to detect liposomal uptake and the morphological parameters thought to influence the 
EPR effect and nanoparticle accumulation. To this end, the tumors were subdivided 
into high- and low-uptake groups; the high-uptake group included CFPAC-1, HPAF-II, 
and MDA-MB-231 xenografts. Table 2 shows that the difference in uptake between 
these groups can be detected with all tested modalities: in vivo SPECT/CT imaging, ex 
vivo biodistribution, and the anti-PEG antibody staining (p value < 0.0001, < 0.0001, 
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Figure 7. Percentage of injected dose per gram (%ID/g) depicted per mouse and tumor type 
shows a high uptake in liver, spleen, and other highly perfused tissues. Tumor measurements 
have been indicated by red arrow.
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and = 0.0018, respectively). In addition, there was a significant difference in tumor 
growth, that is, the time required for the tumors to reach 200 mm³ (p = 0.0104). We 
did not observe a statistically significant correlation with any other morphological 
parameter evaluated.
immunohistochemistry
To further investigate the underlying mechanisms of the EPR effect and to find possible 
explanations for the observed variations in liposomal tumor uptake, several morpho-
logical parameters were investigated using immunohistochemistry (Table 2). In Figure 
8A, the percentage of total tumor areas positive for liposomal content was calculated 
using an anti-PEG antibody. This shows a significant correlation with the in vivo and ex 
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Figure 8. Percentage of liposome uptake calculated from immunohistochemical staining of 
PEG, which shows a comparable uptake as in vivo/ex vivo quantifications (A). Representative 
images of tumor periphery and center indicate that uptake in the periphery is higher in both 
high and low uptake tumors (B). Extravasated liposomes calculated for all tumors based on 
the total PEG (red) minus PEG colocalized (yellow) with blood vessels (CD31, green), lead-
ing to a final composite figure showing the colocalized (yellow) and extravasated (red) lipo-
somes (C, D). The degree of extravasation is relatively high in all tumors. All quantifications 
were performed on whole tile scans of the tumor sections. Scale bars = 100 μm.
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vivo quantifications (Table 3; p = 0.007 and < 0.001, respectively). Unfortunately, the 
aforementioned subdivision into slow-, intermediate-, and fastgrowing xenografts did 
not result in significant correlations (Table 1). Figure 8B shows HPAF-II and PANC-1 
frames to demonstrate the difference of liposome localization in tumors with high and 
low uptake, respectively. Additionally, the intratumoral localization of the liposomes 
was determined in relation to blood vessels (CD31) showing that most liposomes had 
indeed extravasated from the vessels (Figure 8C), although the distance traveled from 
the vessels is minimal. The percentage of extravasated liposomes was calculated by 
subtracting the amount of CD31-colocalized liposomes from the total amount of lipo-
somes present in the area. This is depicted in Figure 8D, in which an example is given 
of a CD31 staining (green), total PEG staining (red), and the calculated colocalized 
liposomes (PEG in; yellow), which shows liposomes within and extravasated from these 
vessels (shown in PEG composite in yellow and red, respectively). Although nanopar-
ticle distribution and accumulation is undeniably related to the presence of blood ves-
sels308, Figure 9A shows that the number of vessels (depicted in percentage mean vessel 
density) cannot be used to predict the degree of liposomal uptake. For example, AsPC-1 
and UACC-893 have a similar uptake of liposomes, depicted with in vivo, ex vivo, and 
immunohistochemical quantifications, but the mean vessel density of UACC-893 is 3 
times higher than that of AsPC-1. As mentioned before, the factors influencing the EPR 
effect and the uptake of liposomes are more complex. The mononuclear phagocytic 
system also has a major influence on the delivery of liposomes, although detection by 
the mononuclear phagocytic system may be reduced by pegylation309,310. Monocytes 
internalize liposomes, after which the drug may be released, resulting in toxic effects 
to the monocytes. Figure 9B shows that the percentage of macrophages in the tumor 
tissue is in general relatively low, with the exception of MDA-MB-468 (5.70% ± 2.26%). 
This might explain why a slow growing tumor (5 months) with a poor mean vessel 
density (1.79% ± 0.42%) still has a considerable liposomal uptake (2.87% ± 1.05%). 
Hypoxia is usually correlated with poor vascularization and indicative of poor drug 
uptake. Because of unrestrained tumor growth, cells move beyond the distance over 
which oxygen can diffuse (circa 150 µm), and drugs targeting fast-dividing cells will 
usually be less effective311,312. All tumors show a comparable degree of hypoxia (Figure 
9C), suggesting that this aspect plays a minor role in these tumor models. Representa-
tive scans of the aforementioned stainings are shown in Figure 10. The functionality of 
both blood and lymphatic vessels is thought to be of great importance to the EPR effect 
and eventual uptake of macromolecules142. We therefore incorporated a lymphatic 
marker (LYVE-1) and a collagen IV antibody to measure lymphatic vessel density and 
collagen IV support of blood vessels. The lymphatic vessels (Figures 11A and 11B) are 
important for drainage of the tissue, and the result suggests that the high presence of 
these vessels caused lower accumulation in BxPC-3 tumors. The intermediate-growing 
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Figure 9. Mean vessel density in tumors based on anti-CD31 staining (A). Macrophages 
are stained with anti-CD11b antibody (B), and a high percentage is seen in MDA-MB-468 
tumors. Hypoxia percentage (C) in different tumors, which was calculated on the basis of 
presence of pimonidazole after intraperitoneal injection. Degree of hypoxia is comparable 
for all tumors. All quantifications were performed on whole tile scans of tumor sections.
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BxPC-3 has a high lymphatic vessel density, 1.52% ± 0.86%, and a lymphatic–to–blood 
vessel ratio of 0.35 ± 0.11, with a well-developed mean vessel density, 5.19% ± 0.92%, 
and still showed a relatively poor liposomal accumulation. In addition, BxPC-3 tumor 
cells grew in tight clusters, which may be an additional factor contributing to the lower 
uptake, because the tissue is less permeable to liposomes. Most tumors have blood 
vessels supported with collagen IV matrix, apart from MDA-MB-468 tumors (Figures 
11C and 11D). To decipher possible associations between liposomal uptake and the 
A
B
C
UACC-893 AsPC-1
MDA-MB-468 PANC-1
BxPC-3 A431
BxPC-3 AsPC-1D
BxPC-3 A431
CFPAC-1 A431
UACC-893 MDA-MB-468
E
F
G
Figure 10. Immunohistochemical stainings showing, mean vessel density (MVD) (A), 
macrophage density (B), hypoxia based on the presence of pimonidazole (C), LYVE-1 stain-
ing for lymphatic vessels (D), lymphatic vessel (LYVE-1, red) to blood vessel (CD31, green) 
ratio, indicative of the supply and drainage of tumor tissue (E), collagen IV density (F), colo-
calization of collagen IV and blood vessels (CD31) (G). Scale bars = 100 μm.
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various morphological parameters tested, we performed a correlation analysis (Table 
3). Although there was a significant correlation between the percentage PEG and the 
liposomal uptake in vivo, no further significant correlations related to other tested 
morphological parameters could be found. A multivariate analysis requiring a much 
larger dataset may in the future enable elucidation of multiple factors contributing to 
the EPR effect.
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Figure 11. LYVE-1 staining indicates the presence of lymphatic vessels in the different tu-
mors (A), which can be used to interpret possible drainage of the tumor. For example, BxPC-
3 has a highly developed lymphatic system, which might explain the relatively low liposomal 
uptake. Lymphatic vessel (LYVE-1) to blood vessel (CD31) ratio (B), indicative of the supply 
and drainage of tumor tissue. Collagen IV is important for the support of blood vessels and is 
used as a marker for mature blood vessels (C). The degree of collagen is comparable between 
tumors. Colocalization of collagen IV and blood vessels (CD31) (D) supports the observa-
tion that most tumor vessels are mature and supported by collagen, with the exception of 
MDA-MB-468. All quantifications were performed on whole tile scans of the tumor sections. 
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DiScuSSioN
The EPR effect, first described by Matsumura and Maeda in 1986142, shows tumor-
specific accumulation of large molecules and is dependent on the following parameters: 
the size of the molecules should be larger than the renal clearance threshold (7 nm) to 
prevent fast clearance; the molecules should have characteristics that ensure a long 
circulation time to increase the chance for extravasation; and the nature of the tumor 
has to be such that it will ensure retention of these molecules, usually ranging from 
days to weeks, leading to enhanced efficacy. These properties distinguish the EPR effect 
needed for therapeutic purposes from targeting of low-molecular-weight molecules 
with a short half-life and fast clearance, which are more suited for imaging purposes313. 
By utilizing the EPR effect, pegylated liposomes such as Doxil have been successful in 
the treatment of certain cancers.
This study has consolidated that pegylated liposomes can accumulate in various 
solid tumors, although considerable differences in uptake were observed. Uptake levels 
ranged from PANC-1 to CFPAC-1 at the low to high end, respectively. There was a trend 
between liposome accumulation and the speed of tumor growth. Although tumors, 
Table 3. Correlation coefficients between various morphological parameters
PEG % CD31 %
PEG % Correlation Coefficient 1.000 0.154
p value (two-tailed) 0.454
CD31 % Correlation Coefficient 0.154 1.000
p value (two-tailed) 0.454
Pimonidazole % Correlation Coefficient 0.179 −0.123
p value (two-tailed) 0.383 0.550
Ki67 % Correlation Coefficient −0.128 0.204
p value (two-tailed) 0.534 0.317
LYVE-1 % Correlation Coefficient 0.280 0.452
p value (two-tailed) 0.166 0.020*
CD11b % Correlation Coefficient 0.185 −0.060
p value (two-tailed) 0.366 0.772
Collagen % Correlation Coefficient 0.164 −0.142
p value (two-tailed) 0.424 0.490
Liposomes (in vivo) Correlation Coefficient 0.516 0.069
p value (two-tailed) 0.007* 0.739
Liposomes (ex vivo) Correlation Coefficient 0.623 0.065
p value (two-tailed) < 0.001* 0.754
Statistical test used: two-tailed Spearman’s rho test; * significant at p < 0.05 level.
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such as squamous cell carcinoma A431, showed very fast tumor growth but had limited 
liposomal accumulation in the tumor. This could be explained by the high growth rate 
and relatively large size of these tumors. Angiogenesis is increased during tumor growth 
and the tumor will grow exponentially until sufficient vascularization can no longer be 
sustained314. This leads to hypoxic or necrotic tumor cores, which are more difficult to 
reach with anticancer drugs. Before this point is reached, the chaotic development of 
tumor vasculature together with the obstruction and collapse of lymphatic vessels at the 
tumor core will lead to an enhanced EPR effect and possibly an increased accumulation 
of nanoparticles142. Lymphatic vessel density evaluation revealed that most tumors had 
an impaired lymphatic system aiding liposome accumulation. The exception was the 
intermediate-growing BxPC-3, which had a high lymphatic vessel density and a well-
developed mean vessel density, resulting in a relatively poor liposomal accumulation. 
Although it has been hypothesized that normalization of the vasculature, extracellular 
matrix, and lymphatic vessels would lead to better delivery of drugs315, this may not 
always hold true for liposomal drugs. Normalization of vessels will lead to a less leaky 
vasculature, which might impair the EPR effect.
It has also been shown that mean vessel density correlates with the degree of liposome 
accumulation308, but we did not observe this correlation in our study. The liposomes 
were still in circulation after 24 h. Various degrees of colocalization of blood vessels and 
liposomes were observed, but most liposomes had extravasated from tumor vessels. 
Unfortunately, high levels of extravasation do not always result in high efficacy, due 
to the poor penetration characteristics of liposomes. The liposomes did not penetrate 
further than the perivascular space, confirming that smaller particles (12 nm) can 
penetrate a tumor heterogeneously up to 80 µm, but particles of 60 nm and larger do 
not leave the perivascular space or even the vessel152. Several additional barriers such 
as high interstitial fluid pressure, low oxygenation, and the extracellular matrix need to 
be overcome292.
Various other variables can influence the uptake of liposomes and the EPR effect in 
addition to the important role of the vasculature. For example, associated inflamma-
tion316 and interactions with monocytes317 can play a major role to increase the lipo-
somal uptake in the tumor. This may explain why MDA-MB-468 had an intermediate 
liposomal uptake even though the mean vessel density was low. The monocyte staining 
to determine the involvement of the immune system showed a high presence of macro-
phages in MDA-MB-468 as opposed to the other tumors.
This study supports the notion that the EPR effect is a highly complex, multifactorial, 
heterogeneous phenomenon, which is possibly much larger in animal tumors than in 
human tumors150. Because tumors are usually faster-growing in animal models, it is to 
be expected that they will have a higher degree of vascularization and a lesser developed 
vascular environment, leading to a high EPR effect. For this reason, we also investi-
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gated slowgrowing tumors with a lower vessel density to explore pegylated liposomes 
in a more clinically relevant setting. Especially the pancreatic tumor models are more 
representative for the clinical setting, in which human tumors grow over long periods 
of time318. Slow growing tumors, such as prostate and pancreatic tumors, are known 
to have more normalized vessels and are usually difficult to treat with nanomedicine. 
Here, we showed that even within the pancreatic tumor models, there is a wide range 
in liposomal uptake and EPR effect, which accentuates the importance of selecting the 
appropriate tumor model for preclinical studies. In addition, it is crucial to include an 
imaging modality in studies investigating the effects of nanoparticle accumulation in 
vivo and to intervene if the therapy is inhibited by poor access to the tumor. Fortunately, 
an increasing number of methods to enhance the EPR effect in tumors have been de-
veloped, both in preclinical and clinical settings, including the use of heat to increase 
vessel permeability and induce extravasation of nanomedicines319-322.
coNcLuSioN
The EPR effect can be used to predict liposomal accumulation into tumors or explain 
limited uptake. In this study, we investigated several parameters and our results suggest 
that the EPR effect, and thus liposomal uptake, is a complex, multifactorial, and hetero-
geneous phenomenon. This is caused by tumor (microenvironment) variability, which 
therefore should be taken into account when considering liposomes as an anticancer 
therapy.


CHAPTER 6
Investigation of Particle Accumulation, 
chemosensitivity and Thermosensitivity 
for Effective Solid Tumor Therapy 
using Thermosensitive Liposomes and 
hyperthermia
Wouter J.M. Lokerse, Michiel Bolkestein, Timo L.M. ten Hagen, Marion de Jong, 
Alexander M.M. Eggermont, Holger Grüll, Gerben A. Koning
Adapted from Theranostics, 2016
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ABSTrAcT
Doxorubicin loaded thermosensitive liposomes (TSLs) have shown promising results 
for hyperthermia-induced local drug delivery to solid tumors. Typically, the tumor is 
heated to hyperthermic temperatures (41-42°C), which induced intravascular drug 
release from TSLs within the tumor tissue leading to high local drug concentrations 
(1-step delivery protocol). Next to providing a trigger for drug release, hyperthermia 
(HT) has been shown to be cytotoxic to tumor tissue, to enhance chemosensitivity and 
to increase particle extravasation from the vasculature into the tumor interstitial space. 
The latter can be exploited for a 2-step delivery protocol, where HT is applied prior to 
i.v. TSL injection to enhance tumor uptake, and again after 4 h to induce drug release. 
In this study, we compare the 1- and 2-step delivery protocols and investigate which 
factors are of importance for a therapeutic response. In murine B16 melanoma and 
BFS-1 sarcoma cell lines, HT induced an enhanced doxorubicin uptake in 2D and 3D 
models, resulting in enhanced chemosensitivity. In vivo, therapeutic efficacy studies 
were performed for both tumor models, showing a therapeutic response for only the 
1-step delivery protocol. SPECT/CT imaging allowed quantification of the liposomal 
accumulation in both tumor models at physiological temperatures and after HT treat-
ment. A simple two compartment model was used to derive respective rates for liposo-
mal uptake, washout and retention, showing that the B16 model has a twofold higher 
liposomal uptake compared to the BFS-1 tumor. HT increases uptake and retention of 
liposomes in both tumors models by the same factor of 1.66, maintaining the absolute 
differences between the two models. Histology showed that HT induced apoptosis, 
blood vessel integrity and interstitial structures are important factors for TSL accu-
mulation in the investigated tumor types. However, modeling data indicated that the 
intraliposomal doxorubicin fraction did not reach therapeutic relevant concentrations 
in the tumor tissue in a 2-step delivery protocol due to the leaking of the drug from its 
liposomal carrier providing an explanation for the observed lack of efficacy.
99
Hyperthermia and thermosensitive liposomes
6
iNTroDucTioN
Classical chemotherapy for treatment of solid tumors typically employs cytotoxic drugs 
with low molecular weight that have sizes below 1 nm. The latter allows the drugs to 
efficiently extravasate upon injection from the vascular compartment into the tumor 
tissue in order to reach their targets. However, as extravasation is not restricted to the 
tumor tissue, toxicity imposed on healthy tissues is limiting the therapeutic window. 
One approach to limit off-target toxicity is the encapsulation of cytotoxic drugs into 
nanoparticles, such as liposomes with sizes in the range of 50-200 nm, which reduces 
side effects observed for free drugs. In contrast to healthy tissues, tumors exhibit a 
poorly organized vascular system323,324 with endothelial gaps146,325 that allow extravasa-
tion and accumulation of nanoparticles up to several hundred nanometers323,326. In 
addition, as tumors often lack a functional lymphatic system, which impedes efficient 
clearance of nanoparticles, substantial retention of long circulating nanoparticles 
is observed327,328. This enhanced permeability and retention (EPR) effect was first 
described for macromolecules by Matsumura and Maeda and is a prerequisite for 
liposomal drug targeting142. Today, several lipomosal drug formulations are clinically 
approved, mostly due to their improved toxicity profile328. One example is Doxil, a long 
circulation liposomal formulation of doxorubicin37,310. While liposomal encapsulation 
reduces off-site toxicity, it unfortunately reduces bioavailabity of the parent drug. Drug 
release from the liposomal carrier is slow as it is based on passive diffusion of the drug 
across the liposomal lipid bilayer, which strongly reduces peak concentrations329. An 
alternative approach is heat-triggered drug delivery using a drug that is encapsulated in 
the aqueous core of a temperature sensitive liposome (TSL), as first proposed by Yatvin 
and Weinstein168. A TSL retains the drug at body temperature, but rapidly release their 
payload at mild hyperthermic temperatures (40-43°C). Heating the targeted tissue to 
these temperatures, for example using radiofrequency or high intensity focused ultra-
sound, leads to rapid intravascular release with subsequent substantial drug deposition 
in the tumor, which is investigated in numerous preclinical179,330-333, yet also clinical 
studies334,335.
Next to providing a trigger for drug release, hyperthermia (HT) exposure can induce 
multiple other changes on cellular as well as tissue level336,337. HT can cause direct cyto-
toxicity in vitro and in vivo338, which depends on the absolute temperature and exposure 
time, but also on the type of cell or tissue339,340. Secondly, HT can increase chemosen-
sitivity341,342 due to a synergistic effect between HT- and drug-induced cytotoxicity or 
due to an increased drug uptake as HT enhances cell membrane permeability343,344. 
On tissue level, preclinical studies have shown that HT increased liposomal uptake in 
tumors178,322,345-347. However, clinical trials using Doxil in combination with HT showed 
variable therapeutic outcomes, highlighting the clinical need for a liposomal formula-
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tions that could more effectively release the drug348,349. The latter inspired the design 
a 2-step drug delivery scheme, where first HT is applied to enhance the EPR effect 
followed by injection of TSLs. After accumulation of TSLs in the tumor, drug release is 
triggered with a second application of HT to ensure bioavailability of the drug.
In a previous study, Li et al. performed a comparative study with doxorubicin loaded 
TSL using the aforementioned 2-step drug delivery scheme versus a 1-step intravascu-
lar HT-drug delivery scheme in a murine BLM melanoma model350. The conclusion of 
that study was that a 1-step treatment was more efficacious in treating a solid tumor 
than the 2-step approach. Here we provide a follow-up study, investigating 1-step and 
2-step HT TSL based treatments in terms of in vitro cytotoxicity, drug uptake by cells, 
therapeutic efficacy and quantitative TSL uptake by B16 melanoma and BFS-1 sarcoma 
tumors. Furthermore, extensive ex vivo investigation provide data giving more insights 
into microenvironmental factors that could play a role in TSL accumulation for B16 and 
BFS-1 tumors and the influence of HT on these factors.
MATeriALS AND MeThoDS
Materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-(amino(polyethylene glycol)-2000) (DSPE-PEG2000) were purchased from Lipoid 
(Ludwigshafen, Germany). DSPE-diethylenetriaminepentaacetic acid (DTPA) was 
obtained from Avanti Polar Lipids Inc. (Alabaster, AL). Doxorubicin-hydrochloride 
solution (2 mg/ml) was ordered from Accord Healthcare. 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES), (NH4)2SO4, DMEM culture medium, fetal bovine 
serum (FBS), sulphorhodamine B (SRB), poly(2-hydroxyethylmethacrylate; HEMA), 
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris), NaCl, glycerol, Mayer’s hematoxy-
lin, eosin Y, Martius yellow, crystal scarlet and methyl blue were from Sigma Aldrich 
(St. Louis, MO). Nonyl phenoxypolyethoxylethanol (NP40) was purchased from ICN 
Biomedicals (Irvine, CA). Penicillin-streptomycin (Pen-Strep) solution was from Lonza 
(Breda, Netherlands). PD-10 desalting columns were bought from GE Healthcare Life 
Sciences (Buckinghamshire, UK). Entallan and rabbit-anti mouse Collagen IV antibody 
were from EMD Millipore (Billerica, MA). CD31 antibody (rat anti-mouse) was bought 
from Abcam (Cambridge, UK) and AlexaFluor 594 (goat anti-rat) and AlexaFluor 488 
(goat anti-rabbit) from Invitrogen (Carlsbad, CA). Matrigel was acquired from BD (San 
Jose, CA). Cryo compound was from Klinipath (Duiven, Netherlands). Fluoromount-
G was provided by Southern Biotech (Birmingham, AL). Cell death detection kit was 
obtained from Roche (Woerden, Netherlands). Weigert’s hematoxylin was purchased 
from Boom Chemicals (Meppel, Netherlands).
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Liposome preparation
DPPC:DSPC:DSPE-PEG2000 at a molar ratio of 70:25:5 were dissolved in 9:1 (vol:vol) 
chloroform/methanol. Solvent was evaporated using a rotary evaporator and the result-
ing lipid film was flushed under a stream of nitrogen. The lipid film was hydrated with a 
250 mM solution of (NH4)2SO4 buffer pH 5.5 and extruded five times through 200 nm, 
100 nm, 80 nm and 50 nm polycarbonate membrane filters. A pH gradient was estab-
lished using a PD-10 column and eluting the liposomes with a pH 7.4 HEPES buffered 
saline (10 mM HEPES, 135 mM NaCl). Phosphate concentration was determined by 
ammonium molybdate assay351. Doxorubicin was loaded into the liposomes by mixing 
doxorubicin and lipid at a ratio of 0.15:1 (mol:mol) and incubating it for 1 h at 39°C 
in a thermoshaker. Liposomes were concentrated by ultracentrifugation (193,000 g, 
2 h, 4°C) and resuspended in 10 mM HEPES buffered saline pH 7.4 yielding the final 
formulation of doxorubicin-loaded TSLs (TSLDox).
radiolabeled liposome preparation
For radiolabeled TSLs (111In-TSL), 0.1 mol% DSPE-DTPA was added to the formulation 
described above and produced in a similar fashion as the regular TSLs, with the excep-
tion that the liposomes were not loaded with doxorubicin. 1 µmol TSLs was incubated 
with 30 MBq indium-111 for 15 min at room temperature after the pH was set at 5.0 
with 2.5 M sodium acetate. After incubation, labeling efficiency was determined by 
ITLC-SG (Varian Inc.) and the final volume was adjusted to 200 µL with HEPES buff-
ered saline (10 mM HEPES, 135 mM NaCl, pH 7.4).
cellular toxicity assay
B16 or BFS-1 cells were seeded in 96-well plates and allowed to grow till 50% confluency 
in DMEM medium enriched with 10% FBS and 1% Pen-Strep. The medium was removed 
and fresh medium with a desired amount of free doxorubicin or TSLDox was brought onto 
the cells and incubated according to Scheme 1. NT: incubation with doxorubicin for 1 h 
at 37°C; HT42: incubation with doxorubicin for 1 h at 42°C; HT41-NT: Preheating cells 1 h 
at 41°C, 4 h recovery at 37°C and a 1 h incubation with doxorubicin at 37°C; HT41-HT42: 
Preheating cells for 1 h at 41°C, 4 h recovery at 37°C and a 1 h incubation doxorubicin at 
42°C. For a TSLDox treatments on cells, 10 µM doxorubicin was used. To apply HT, plates 
were put into a water bath set at the required temperature. After incubation, the doxoru-
bicin containing medium was removed and cells were given fresh medium for 24 h or 48 
h incubation at 37°C. Cells were fixed using 10% (w:v) trichloroacetic acid (TCA). After 
fixation, the plates were washed with water and 0.5% SRB solution was added to stain 
the fixed cells for 20 min. When staining was completed, cells were washed with 1% 
acetic acid and left to dry. In the end, 10 mM Tris was added to resuspend the SRB and 
absorbance was measured at 590 nm by spectrophotometry (Wallac Victor 2 Counter).
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Cellular doxorubicin uptake in 2D and 3D models
B16 or BFS-1 cells were seeded into 75 cm² flasks and grown under similar conditions as 
mentioned above until 80% confluency was reached. The cells were subjected to 40 µM 
doxorubicin under four different treatment conditions as stated in Scheme 1. Exposing 
cells to elevated temperatures was done by submerging the 75 cm² culture flask into 
a water bath. After incubation, the cells were washed with ice cold PBS, scraped from 
the flask and centrifuged at 200 g at 4°C. The pellets were resuspended in 150 µL lysis 
buffer (20 mM Tris, 150 mM NaCl, 0.2% NP40, 10% glycerol, pH 7.4), followed by 30 
min incubation on ice and centrifugation at 14,000 g. The pellets were resuspended 
and homogenized in 500 µL PBS by brief probe sonication and doxorubicin concentra-
tion was measured by fluorometry at 485 nm excitation and 580 nm emission (Wallac 
Victor 2 Counter). Tumor spheroids were made according to a previously described 
method352. In short, conical shaped 96-well plates were coated with poly-HEMA and 1 x 
105 cells which were centrifuged at 1,000 g for 10 min in the presence of 2.5% Matrigel 
and incubated overnight at 37°C. After incubation, spheroids were handpicked and 
exposed to identical treatments as in the 2D model in a thermoshaker (no shaking). 
After incubation, the spheroids were washed in PBS, embedded into Fluoromount-G 
and imaged by confocal microscopy (Zeiss LSM 510 Meta; Oberkochen, Germany). A 
5 µm Z-stack was made over the surface of the spheroid to determine total doxorubicin 
fluorescence. For each optical slice, the amount of saturated doxorubicin fluorescence 
pixels were counted. The sum of saturated pixels of all tumor slices was used as an 
indicator for doxorubicin uptake. For cryosectioning, spheroids were embedded into 
Cryo Compound and snap frozen in liquid nitrogen. 10 µm slices were made using 
a Cryostat (Leica CM1850 UV; Wetzlar, Germany), and afterwards embedded into 
1 h 42 ºC
NT HT42
1 h 41 ºC 4 h 37 ºC 1 h 37 ºC
HT41-NT
Dox added
1 h 41 ºC 4 h 37 ºC 1 h 42 ºC
HT41-HT42
1 h 37 ºC
Scheme 1. Overview of different in vitro doxorubicin uptake treatments. Cells were ex-
posed to doxorubicin at 37°C (NT) or 42°C (HT42). In two additional groups, cells were pre-
heated for 1 h at 41°C (HT41) with a 4 h recovery at 37°C before doxorubicin uptake under 
NT or HT42 conditions (HT41-NT and HT41-HT42, respectively).
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Fluoromount-G and imaged using fluorescence microscopy (Zeiss Axiovert 100M; 
Hamamatsu Photonics C4742-98 camera controller).
B16 and BFS-1 tumor generation
Murine B16 melanoma or BFS-1 sarcoma cells (1 x 106) were subcutaneously injected 
into the flank of C57BL6 mice (Harlan) to grow bulk tumors. After reaching volumes of 
approximately 700 mm³, animals were sacrificed and tumor pieces were transplanted 
to the animals of the therapeutic studies. All animal experiments were approved by the 
Erasmus MC animal research committee, Rotterdam, the Netherlands.
Therapeutic efficacy studies in a B16 and BFS-1 model
1 mm³ B16 or BFS-1 tumor pieces were transplanted subcutaneously onto the hind 
limb of C57BL6 mice and allowed to grow to 200 mm³ after which treatments were 
initiated as shown in Scheme 2. NT: 1-step with 100 µL i.v. PBS injection and 1 h 
anesthesia at body temperature; HT42: 1-step with 100 µL i.v. PBS injection and 1 h 
anesthesia with heated tumor at 42°C; TSLDox NT: 1-step with 100 µL 5 mg/kg TSLDox 
i.v. injection and 1 h anesthesia at body temperature; TSLDox HT42: 1-step with 100 µL 
5 mg/kg TSLDox i.v. injection and 1 h anesthesia with heated tumor at 42°C; HT41-HT42: 
2-step with 1 h preheating tumor at 41°C under anesthesia, 100 µL i.v. PBS injection, 
4 h waiting period and 1 h anesthesia with heated tumor at 42°C; TSLDox NT-HT42: 
2-step with 1 h anesthesia at body temperature, 100 µL 5 mg/kg TSLDox i.v. injection, 
4 h waiting period and 1 h anesthesia with heated tumor at 42°C; TSLDox HT41-HT42: 
2-step with 1 h preheating tumor at 41°C under anesthesia, 100 µL 5 mg/kg TSLDox 
1 h 42 ºC
NT HT42
1 h 35 ºC 4 h 1 h 42 ºC
NT-HT42
1 h 35 ºC
1 h 41 ºC 4 h 1 h 42 ºC
HT41-HT42
TSLDox or PBS injection
Anesthesia
Scheme 2. Overview of 1-step and 2-step treatments in vivo. For 1-step, i.v. TSLDox admin-
istration was conducted at body temperature (NT) or when the tumor was brought to 42°C 
(HT42). Two-step treatments were composed of keeping the mouse under anesthesia at body 
temperature for 1 h (NT-HT42) or preheating the tumor at 41°C for 1 h (HTDox injection, 4h 
rest and a second tumor heating at 42°C.
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i.v. injection, 4 h waiting period and 1 h anesthesia with heated tumor at 42°C. In 
the 1-step treatment protocol, the tumor was submerged into a 42.5°C water bath for 
heating to 42°C for 10 min, followed by an i.v. injection of TSL (5 mg/kg doxorubicin) 
and further heating for another hour. The 2-step treatment procedure included heating 
of the tumor to 41°C for 1 h and an i.v. injection of TSL (5 mg/kg doxorubicin) 10 min 
after heating. Afterwards, the animal was allowed to rest for 4 h, followed by a second 
HT treatment for 1 h at 42°C. In control groups normothermic (NT; 35°C) conditions 
were used, where the animal was put under anesthesia for 1 h and kept at 35°C on a 
37°C heating plate while covering the animal with tin foil. During both HT and NT 
experiments, the tumor bearing limb, with exception of the tumor itself, was coated in 
vaseline to prevent possible skin burns. Body temperatures of the mice were measured 
using a rectal probe.
SPECT/CT imaging of TSL accumulation in a B16 and BFS-1 model
1 x 106 cells were subcutaneously injected on the hind limb of C57BL6 mice and tumors 
were allowed to grow to volumes of 200 mm³. Tumors were either heated for 1 h at 
41°C prior to injection or kept at 35°C in a similar fashion as for the therapeutic study. 
111In-TSL were i.v. injected (200 µL per mouse with an average activity of 33 ± 2 MBq 
indium-111) and scans were made 4, 8, 24 and 48 h after injection. Scans were acquired 
using the nanoSPECT/CT (Mediso Medical Imaging Systems) with the following set-
tings for the SPECT scans: 20 projections, 60 s per projection, and a quality factor of 
0.8. APT1 apertures were used with 1.4 mm diameter pinholes (FOV 24 + 16 mm). CT 
scans were acquired with 240 projections, 45 kVp tube voltage and 500 ms exposure. 
Data analysis was performed using InVivoScope/VivoQuant software (inviCRO, Bos-
ton, MA), where three-dimensional regions of interest were drawn over the tumor to 
calculate uptake of 111In-TSL at the selected time points. After the last scan, the animals 
were sacrificed and tumors and organs were harvested, weighed and radioactivity was 
determined using a γ counter to calculate percentage injected dose per gram (%ID/g). 
All data were corrected for radioactive decay.
Pharmacokinetic modelling
The blood kinetics and pharmacokinetic parameters of the TSLDox formulation were 
determined in an earlier study353. Results from that study showed that the blood half-
life of liposomal carrier Clip(t) can be described with a mono-exponential function:
Clip(t) = Clip(t = 0) · Exp(−ln2 / t1/2,TSL · t) Eq. 1
with Clip(0)=100%ID at time point of injection and t1/2,TSL = 5.6 ± 0.4 h being the circula-
tion half-life of the liposomes. Upon injection, a fraction of doxorubicin is instantaneous 
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released (Burst = 8 ± 3%) followed by a slow leakage of doxorubicin from the liposomal 
carrier with a half-life of t1/2,leak = 2.7 ± 0.3 h. The concentration of intraliposomal dox 
CDox,TSL(t) can be described with the following equation:
CDox,TSL(t) = (1 − Burst/100) · Exp(−ln2/t1/2,leak · t) · Clip(t) Eq. 2
The concentration of (radiolabeled) liposomes in the tumor, CTSL,tumor(t), can be de-
scribed with a simple two compartment model:
∂CTSL,tumor(t)
= kin · Clip(t) − kout · CTSL,tumor(t) + kret Eq. 3
dt
where kin, kout and kret describe the rates of uptake, washout and retention of TSL in the 
tumor compartment.
Concentration of intraliposomal doxorubicin within the tumor is subsequently 
numerically calculated assuming the same burst and leakage of doxorubicin from the 
liposomal carrier as found for TSLDox in the blood compartment.
Numerical integration of Eq. 3 and fitting of the SPECT data was performed using 
Mathematica® (version 10.2, Wolfram Research).
histology
After the SPECT/CT experiments, the excised tumors were snap frozen in liquid 
nitrogen. Hereafter 5 µm slices were cut and tumors were stained for vessels with an 
anti-CD31 antibody and AlexaFluor 594 or collagen with anti-collagen IV antibody and 
AlexaFluor 488. The TUNEL staining was performed with a cell death detection kit. The 
CD31 and TUNEL stains were quantified using ImageJ (version 1.48) software and by 
setting a manual threshold. A second set of frozen slices was stained with Maier’s he-
matoxylin and Eosin (H&E) or by Weigert’s hematoxylin, Martius yellow, crystal scarlet 
and methyl blue (MSB), followed by mounting in Entallan. The slices were imaged 
for fluorescence by confocal microscopy (CD31, collagen IV & TUNEL) or bright field 
microscopy (Leica DM 4000B) for H&E and MSB stained sections.
Statistics
All statistical tests were carried out using Graphpad Prism 5 software. All figures were 
subjected to unpaired two tailed t-test or one-way ANOVA Bonferroni test with signifi-
cant difference at p < 0.05.
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reSuLTS
Preparation of TSLDox
Loading of TSL with the formulation DPPC:DSPC:DSPE-PEG2000 at a molar ratio of 
70:25:5 with doxorubicin was achieved with 100% efficacy. Dynamic light scattering 
of the resulting TSLDox indicated an average hydrodynamic diameter of 83 ± 3 nm and 
a zeta-potential of −7.9 ± 0.9 mV. Stability at 37°C and release kinetics at 42°C were 
tested in culture medium (10% FBS and 1% Pen-Strep) and were found to be similar to 
results obtained with 100% FBS as described in our previous work (Figure 1)353.
Figure 1. Doxorubicin release from TSL at 37°C and 42°C in DMEM culture medium with 
10% FBS and 1% Pen-Strep using fluorescence readout. All experiments have been per-
formed 3 times.
Cytotoxic assays on B16 melanoma and BFS-1 sarcoma cells
In an in vitro study, murine B16 melanoma and BFS-1 sarcoma cells were exposed to 
various doxorubicin concentrations for 1 h under the conditions depicted in Scheme 1. 
Both cell lines showed an increased sensitivity to doxorubicin when the drug exposure 
was performed at hyperthermic temperatures (Figure 2). For B16 (Figure 2A, 2B) 
and BFS-1 (Figure 2C, 2D), the doxorubicin sensitivity increased 8-fold. Additional 
pre-heating (HT41-HT42) did not result in a further increase in doxorubicin sensitiv-
ity for B16. However, the 18-fold increase for BFS-1 was significantly higher than the 
single HT treatment. In this case direct HT-induced cytotoxicity could have played a 
predominant role (Figure 3). B16 and BFS-1 cells were furthermore tested for survival 
after incubation with TSL (empty), 10 µM TSLDox or 10 µM free doxorubicin under 
normothermic (NT; 37°C) and HT42 conditions for 1 h. After the treatment, the cells 
were kept in culture medium for 24 h or 48 h. At 37°C, TSLDox induced little toxicity to 
the cells, while at 42°C the release of doxorubicin was sufficient to cause high cell death 
(Figure 4). The TSL by itself had no inhibitory effect on cell growth, while HT did show 
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some direct cytotoxicity, which was only significant for B16 24 h after incubation with 
72 ± 11% viable cells compared to the NT group (Figure 4A). The addition of 10 µM 
TSLDox to a 1 h incubation with HT42 resulted in an immediate cytotoxic effect 24 h after 
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Figure 2. Doxorubicin cytotoxicity assay and IC50 values for B16 (A, B) and BFS-1 cells (C, 
D) 48 h after treatment with different hyperthermia protocols. N = 3 for each data set. Curves 
were fit by non-linear regression and statistical analysis by one-way ANOVA Bonferroni test. 
The significance scores of all treatments versus NT groups are indicated with asterisks. * = p 
< 0.05, ** = p < 0.01, *** = p < 0.005.
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Figure 3. Analysis on HT induced cytotoxicity on B16 (A) and BFS-1 cells (B) in the experi-
mental groups of Figure 1. Survival of experimental groups is normalized to the NT group. 
N = 3 per group and one-way ANOVA Bonferroni test was used for statistical analysis of the 
data. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.
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the incubation (Figure 4A) with 25 ± 6% for B16 and 57 ± 7% cell survival for BFS-1. 
This cytotoxic effect became even more apparent 48 h after incubation, showing an al-
most complete cell death for both cell types (Figure 4B). The TSLDox HT42 group showed 
similar results as where 10 µM free doxorubicin was used (Dox HT42), suggesting a total 
doxorubicin release from TSLDox in these experimental conditions. A cytotoxicity assay 
using a 2-step heating protocol was not performed, as the main cytotoxic effect was 
caused by the increased uptake of free or released doxorubicin during HT42.
In vitro doxorubicin uptake in 2D and 3D models
Next, the effect of HT on doxorubicin uptake was studied in B16 and BFS-1 cells. Both 
cell lines exhibited a linear uptake of doxorubicin over time at body temperature (Figure 
5A, 5B). Incubation of both cell lines with doxorubicin at HT42 significantly increased 
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Figure 4. Cytotoxicity assay on B16 and BFS-1 cells 24 h (A) and 48 h (B) after a 1 h incu-
bation with 10 μM TSLDox or free doxorubicin under NT (37°C) or HT42 (42°C) conditions. 
N = 3 for each data set. Statistical analysis was carried out using one way ANOVA Bonferroni 
test comparing the treatment groups with the NT group separately at 24 h and 48 h. The 
significance scores of all treatments versus NT groups are indicated with asterisks. * = p < 
0.05, ** = p < 0.01, *** = p < 0.005.
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doxorubicin uptake 9-fold for B16 (Figure 5A) and 6-fold for BFS-1 cells (Figure 5B). 
Groups were added where the cells were preheated at 41°C for 1 h followed by 4 h at 
37°C to mimic a 2-step approach therapy. Preheating of the cells before incubation 
with doxorubicin at NT (HT41-NT) or HT42 (HT41-HT42) conditions did not result in a 
significant difference compared to doxorubicin uptake without preheating. Next, we 
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Figure 5. Two-dimensional doxorubicin uptake in B16 (A) and BFS-1 (B) cell cultures and 
BFS-1 spheroids (C-E). Cells or spheroids were exposed to 40 μM doxorubicin for 1 h at 37°C 
(NT), 42°C (HT42), or preheated at 41°C followed by 4 h at 37°C before a 1 h exposure to 40 
μM doxorubicin. Images of the spheroids made by confocal microscopy (C) were summed up 
to determine the Σ saturated pixels (red) per spheroid (D). Cryosections of 10 μm (E) of the 
BFS-1 spheroids show spatial distribution of doxorubicin fluorescence (red). All data sets are 
composed of an n = 3 experiment and compared by one way ANOVA Bonferroni test, * = p 
< 0.05, ** = p < 0.01, *** = p < 0.005. Asterisks show significance compared to NT groups. 
Scale bars = 100 μm.
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used multicellular spheroids of BFS-1 cells to determine the doxorubicin uptake as 
well as spatial distribution under the different temperature protocols in a 3D model. 
After performing similar incubation protocols as described before, the BFS-1 spheroids 
showed a similar pattern in doxorubicin uptake than BFS-1 cells in the 2D standard 
culture conditions (Figure 5C). When the doxorubicin fluorescence intensity was 
quantified (Figure 5D), HT42 and HT41-HT42 presented significantly more doxorubicin 
positive areas than NT spheroids with a 6-fold and 10-fold increase in the summation 
of saturated doxorubicin fluorescence pixels, respectively. HT41-NT treatment did not 
result in a significantly enhanced uptake. Doxorubicin did not penetrate farther than 
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Figure 6. Therapeutic efficacy study in C57BL6 mice with s.c. B16 or BFS-1 tumors. After 
treatment, results for B16 tumors were plotted for growth (A) and survival (B) with NT 
(black), HT42 (red), HT41-HT42 (orange), TSLDoxNT (green), TSLDoxHT42 (purple), TSLDoxNT-
HT42 (pink) and TSLDoxHT41-HT42 (blue). Survival (B) was based on a size cutoff at 300% 
tumor size increase. Error bars in growth curve (A) represent SEM and one way ANOVA Bon-
ferroni test was used to determine differences in survival in B (* = p < 0.05, ** = p < 0.01, *** 
= p < 0.005). Asterisks above bars show significance versus NT. Data for BFS-1 is presented 
similarly in C and D. N = 4 for NT, TSL42 groups; n = 5 for all other groups.
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the first few cell layers into the spheroid, despite the heating protocol used (Figure 
5E). B16 cells did not form spheroids and could therefore not be studied in the 3D 
doxorubicin uptake model.
one-step and two-step therapeutic study
A therapeutic study with B16 (Figure 6A, 6B) and BFS-1 (Figure 6C, 6D) tumors were 
subjected to 1-step or 2-step therapies (Scheme 2). We chose 41°C as preheating tem-
perature since it has been shown that an intratumoral increase of TSLDox accumulation 
can be established322 without risking significant vascular damage354. In both B16 and 
BFS-1 tumors, TSLDox with HT42 significantly outperformed all other treatments with 
an average improvement of survival of 7.1 ± 1.4 d for B16 and 14.6 ± 2.8 d for BFS-1 
when compared to the NT group. The body temperature differed significantly between 
NT and HT42 treated mice (Figure 7). Nevertheless, it remained at a physiological level 
with 35.0 ± 0.4°C and 36.9 ± 1.1°C, respectively.
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Figure 7. Body temperature readings of mice under anesthesia, on a 37°C heating plate, 
covered with tin foil (NT), or mice under anesthesia with the tumor bearing limb submerged 
in a 42.5°C water bath (HT42). n = 6 per group. Temperature readings were performed rec-
tally with a probe thermometer every 10 min. For every time point, statistical analysis was 
performed by unpaired two-tailed t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.
Quantitative SPecT/cT imaging of TSL accumulation in solid tumors
A SPECT/CT study with 111In-TSL (labeling efficiency > 99%) was carried out to visual-
ize the particle uptake in B16 and BFS-1 tumor bearing mice, comparing NT conditions 
versus tumor preheating for 1 h at 41°C prior to injection (HT41). SPECT imaging over 
time showed that the majority of the injected 111In-TSL were cleared by liver and spleen 
(Figure 8A, 8B) with tumor uptake over time. For all tumors, a maximum uptake was 
observed approx. 4 h post injection followed by a slight reduction over time leveling off 
at 48 h post injection. Under NT conditions, plateau values of 3.2 ± 0.5 and 1 ± 0.3% 
injected dose per cm³ were reached for B16 and BFS1 tumors respectively. Applying 
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Figure 8. SPECT-CT study on 111In-TSL distribution in B16 (A, C, E) and BFS-1 (B, D, F) 
tumor bearing mice. After i.v. administration, scans were made at 4 h, 8 h, 24 h and 48 h 
for all groups. B16 (A, C) and BFS-1 (B, D) tumors showed 111In-TSL accumulation after i.v. 
administration at NT, which could be significantly enhanced (unpaired two-tailed t-test; p < 
0.05) by pre-heating the tumor for 1 h at 41°C prior to 111In-TSL administration (HT41). The 
green line shows the 4 h time point where a second HT treatment would have taken place in 
case of a 2-step therapy. Biodistribution of excised organs and tumors (E, F) 48 h after injec-
tion. Every group consisted of three animals (n = 3).
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HT41 before injection increased uptake in both tumors, leading to higher maximum as 
well as plateau concentrations (B16: 6.2 ± 1.5% injected dose per cm³, BFS1: 3.3 ± 2.8% 
injected dose per cm³ at 48 h p.i.) (Figure 8A-D). Biodistribution studies at t = 48 h p.i. 
were consistent with data derived from SPECT showing an uptake of 111In-TSL in B16 
tumors 2.8 ± 0.5% injected dose per gram compared to a considerable lower uptake of 
0.9 ± 0.2% injected dose per gram in BFS-1 tumors for NT experiments (Figure 8E, 8F). 
Applying HT41 before injection resulted in a significantly increased 
111In-TSL accumula-
tion measured after 48 h in B16 tumors (5.0 ± 1.0% injected dose per gram; Figure 8C, 
8E) and BFS-1 tumors (2.6 ± 1.0% injected dose per gram; Figure 8D, 8F).
SPECT data were used to fit the liposomal tumor uptake according to a simple two 
compartment model, deriving the rates for uptake, washout and retention, kin, kout, 
kret, in the two different tumors under NT and HT41 conditions (Table 1). Taking the 
earlier determined pharmacokinetic properties of the here used TSLDox formulation 
into account, the model also allowed to calculate the concentration of intraliposomal 
doxorubicin present in the tumors as a function of time (Figure 8C, 8D). Maximum 
concentrations of intraliposomal doxorubicin were reached approximately 2 h p.i. In 
contrast to the liposomal concentrations, intraliposomal doxorubicin concentrations 
decreased to zero 15-20 h p.i. due to the leakage from the liposomal carrier.
The uptake as well as the retention rate of liposomes in B16 tumors was circa 2 times 
higher compared to BFS-1 tumors, while washout was comparable for both tumors. 
Notably, HT41 induced in both tumors a comparable effect with increasing the kin, and 
kret by a factor of 1.66 ± 0.13 leading to a more rapid and higher uptake of liposomes 
and consequently a high doxorubicin peak concentration.
Table 1. Pharmacokinetic parameters describing the tumor uptake and retention in B16 
and BFS-1 tumors
Tumor type Condition kin / (1/h) kout / (1/h) kret / (1/h)
B16 NT 0.0157 ± 0.004 0.39 ± 0.16 1.4 ± 0.63
HT41 0.0233 ± 0.007 0.36 ± 0.22 2.5 ± 1.64
BFS-1 NT 0.0074 ± 0.003 0.69 ± 0.34 0.7 ± 0.38
HT41 0.0127 ± 0.001 0.36 ± 0.07 1.2 ± 0.24
histology
After the SPECT-CT study, the tumors were used for H&E, MSB, TUNEL, CD31 and 
collagen IV staining (Figure 9 & 10). H&E staining indicated that B16 tumors have 
less strong cellular interactions as can be seen by the gaps in the tissue (Figure 9A), 
whereas BFS-1 has a much more compact morphology. Furthermore, the H&E suggests 
that the B16 tumors are more apoptotic (Figure 9A, arrows). Yet after HT41, apoptotic 
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areas could be seen in both tumor types. MSB staining showed that B16 tumors have 
a very low presence of extracellular fibers (Figure 9B), whereas BFS-1 showed a more 
mature extracellular matrix (Figure 9C). Quantitative TUNEL staining (Figure 10A) 
showed high apoptosis of 14.4 ± 10.0% for B16 when compared to BFS-1 with 0.4 ± 
0.1%. HT41 caused an increase of apoptosis, showing 24.5 ± 13.2% for B16 and 1.2 
± 0.4% for BFS-1, which was a significant increase for the latter. The vessel staining 
using CD31 indicated a comparable mean vessel density for both tumor models (Figure 
10B). The quantitative collagen IV staining confirmed the result of the MSB staining 
with 3.6 ± 0.3% for B16 and 14.8 ± 1.2% mean density for BFS-1 (Figure 10C). The 
B16 vessels were relatively large with collagen almost solely associated with the vessels 
(Figure 10D), whereas BFS-1 vessels were smaller and the interstitium consisted of 
more extracellular collagen matrix (Figure 10E).
A
B
16
B
FS
-1
NT HT41
B C
Figure 9. 5 μm H&E stained sections of B16 and BFS-1 tumors 48 h after NT or HT41 (A). 
Black arrows indicate apoptotic areas. MSB stained B16 (B) and BFS-1 (C) tumors showing 
collagen in blue. Scale bars = 200 μm in A and 20 μm in B and C.
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DiScuSSioN
In the field of nanomedicine, substantial research has been performed throughout the 
last decades on HT-triggered drug release from TSLs for treatment of solid tumors. In 
this context, mainly 1-step intravascular drug delivery schemes were employed, where 
tumors are heated to hyperthermic temperatures and drug loaded TSL are injected at 
the start of the HT treatment. In a previous study conducted by Li et al.350, a 2-step 
treatment scheme was investigated as a possible alternative in a BLM melanoma 
xenograft, where first HT41 is applied to enhance vascular permeability, then a TSLDox 
formulation was injected that subsequently accumulated in the tumor, followed by a 
second HT42 step to release the drug from its carrier in order to ensure bioavailability. 
The aforementioned study showed in contrast to the 1-step therapy, that the 2-step ap-
proach was not effective in causing a therapeutic response. In our experimental design 
we chose for a B16 melanoma and BFS-1 sarcoma cell line because tumors from these 
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Figure 10. Quantification of cryo-section staining with TUNEL (A), CD31 (B) and collagen 
IV (C) was analyzed by unpaired two tailed t-test (* = p < 0.05). B16 (D) and BFS-1 (E) blood 
vessels colored red for CD31. Collagen IV stained in green. Scale bars = 50 μm. N = 3 for all 
groups.
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cell lines have been previously reported to show high and low EPR-mediated uptake 
of TSL, respectively322. We tested how these tumors respond to a 1-step versus 2-step 
therapy, expanded the knowledge on how the tumor models responded to single versus 
multiple HT treatments in combination with local chemotherapy and provide extensive 
information on what factors can cause the differences in TSL accumulation between 
these tumors and which of these factors could be influenced by HT to increase TSL 
accumulation.
B16 and BFS-1 cells showed a significant increase in doxorubicin sensitivity when 
the drug exposure happened during HT42. The reduced IC50 with HT correlated with 
the increase doxorubicin uptake by the cells discussed hereafter. Previously published 
data on this correlation showed that the outcome of these experiments depend on cell 
type and specific experimental conditions, e.g. exact temperature and duration of HT 
exposure343,355-357. Testing TSLDox on these cells showed that at 37°C the cytotoxic effect 
is minimal, whereas at 42°C, the TSLDox released all drug and therefore cytotoxicity was 
comparable to free doxorubicin. The small cytotoxic effect at 37°C could be caused by 
cellular uptake of TSLDox or by doxorubicin leaking from the liposomes into culture 
medium (Figure 1). Next, we investigated the presence of a synergistic effect of doxo-
rubicin and HT for different heating schemes in a 2D and 3D cellular model. In a 2D 
model, it was shown that HT42 induces a faster cellular uptake of doxorubicin leading 
to a 6-9 times higher rate of uptake in B16 and BFS-1 cells than at 37°C. Preheating the 
cells for 1 h with HT41 followed by incubation for 4 h at 37°C before adding doxorubicin 
did not show any improvement of doxorubicin uptake, indicating that HT-induced 
effects at 41°C were reversible in nature and could only improve drug uptake during 
the heating and not thereafter. As the doxorubicin uptake is caused by passive diffu-
sion across the cell membrane, increase of cellular membrane fluidity and permeability 
during HT is the most likely explanation, since these effects are temporal in nature 
and fully reversible343,344. Other studies have shown that preheating to slightly higher 
temperatures of 43-45.5°C lead to a reduced doxorubicin uptake most likely due to a 
more permanent and irreversible temperature of thermal dose induced damage355,358. 
However, HT41 used for preheating in this study did not induce this effect and has also 
been reported by others359. Spheroids mimic a solid tumor in terms of cell physiology, 
presence of extracellular matrix and an apoptotic core360. For this reason, we employed 
this model to investigate whether doxorubicin penetration depth into a dense structure 
of cells is influenced by different heating conditions361,362. BFS-1 spheroids showed a 
similar response in doxorubicin uptake as the 2D model when different HT protocols 
were applied. However, it also showed that if cells are closely packed, the drug does not 
penetrate deep into the structure beyond the first few layers of cells. Neither the spatial 
distribution nor the penetration depth could be improved by HT in tumor spheroids. A 
comparative study using B16 cells was not possible since B16 cells did not form spher-
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oids. The latter might be caused by the lack of a substantial cell-cell adherence, which 
was also observed in ex vivo examination of B16 tumors described later in this section.
At this stage we have only shown the potential of local chemotherapy and HT in vitro. 
However, the described features are only a small part of the factors that have to be con-
sidered for drug delivery to solid tumors. Therefore, we performed a therapeutic study 
as well as in vivo imaging and extensive ex vivo investigation on B16 and BFS-1 tumors 
to better understand the factors that could have played a role in various therapeutic 
responses. For both tumor types, a 1-step approach where TSLDox is i.v. administered 
during HT42 gave a significant therapeutic response, whereas a 2-step approach which 
relied on TSLDox accumulation in a preheated (HT41) tumor followed by a second HT42 
step to induce drug release did not show a therapeutic effect. The SPECT/CT imaging 
in this case was particularly valuable to follow the TSL accumulation in B16 and BFS-1 
tumors. The SPECT data were used for fitting a two compartment model which de-
scribes tumor uptake of the liposomal carrier as well as the intraliposomal doxorubicin 
concentration in the tumor taking the blood kinetic and pharmacokinetic parameters 
of TSLDox into account353. For both tumors and regardless of applying HT41 beforehand, 
the maximum concentration of liposomes was reached approximately 4 h p.i., when the 
second HT42 step was applied. The B16 tumors showed a significantly higher liposomal 
uptake compared to the BFS-1 tumor with circa two fold higher kin and kret parameters 
reflecting a higher intrinsic EPR effect for the B16 model. Interestingly, 1 h of HT41 
induced the same effect in both tumors leading to a 1.66 times increase in kin and kret 
and thus maintaining the two fold higher uptake of TSLs in B16 compared to BFS1 
tumors.
However, calculations suggested that maximum intraliposomal doxorubicin con-
centrations were already reached 2 h p.i., and declining to zero within 20 h due to 
leakage from the TSLs. These data imply that a more favorable time point for the second 
HT42 step is circa 2-3 h post injection350. Based on our calculations, the intraliposomal 
doxorubicin reached concentrations of 1.7% injected dose per cm³ for B16 and 0.6% 
injected dose per cm³ doxorubicin for BFS-1 at the moment of the second HT42 step (i.e. 
after 4 h) at normal temperature conditions, and 3.0% injected dose per cm³ and 1.5% 
injected dose per cm³ doxorubicin with a preceding HT41 treatment. These concen-
trations are lower compared to typical values found for a 1-step delivery approach363, 
which provides an explanation for the lack of a significant therapeutic response in a 
2-step drug delivery protocol.
Finally, we performed histological analysis of excised tumors and investigated factors 
that may cause the differences in TSL uptake and the intrinsically higher EPR effect 
found in B16 and BFS-1 tumors. B16 tumors grew more aggressively than BFS-1, 
reaching volumes of 200 mm³ in 7-14 d and 14-21 d after inoculation, respectively. 
Especially in preclinical models, fast growing tumors show higher structural and func-
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tional abnormalities of the vasculature, thereby increasing the odds for a high EPR 
effect150,288,323. The mean vessel density was similar for B16 and BFS-1, however the 
morphology of B16 vessels appeared more tortuous and overall larger in size. Next to 
the growth rate and vascular properties, we also observed noticeable differences in cell 
packing and organization, which is important for the penetration depth of extravasated 
compounds into the tumor interstitium291,361,364. H&E staining showed less dense cel-
lular packing with gaps in the B16 tumor tissue, whereas BFS-1 showed a higher density 
and no gaps. Therefore, the finding that BFS-1 cells could form spheroids while B16 
cells did not, might be indicative for cell packing and organization in an actual tumor. 
In vivo, cell packing density and organization is, among other reasons, depends on the 
presence of a well-defined extracellular matrix. Analysis on the extracellular matrix by 
MSB staining and quantitative collagen IV immunostaining showed that B16 tumors 
have an almost completely absent extracellular matrix, whereas BFS-1 tumors had a 
more mature extracellular matrix. These findings suggest that the immature intersti-
tium of the B16 tumor could have played a role in facilitating a higher EPR, confirming 
previously published results157. Histological analysis and quantitative TUNEL staining 
also indicated a much higher amount of apoptosis in the B16 tumors than in the BFS-1 
tumors, which is typically associated with a more pronounced EPR effect365,366. The 
HT41 induced increase of apoptosis was significant for the sectioned BFS-1 tumors. 
While our study is in line with earlier findings showing that HT increases vascular 
permeability and promotes extravasation of nanoparticles322,345,346, our histology data 
also suggest that substantial HT41 induced apoptosis can further aid EPR.
In summary, we have shown that HT can aid in drug delivery by making cells more 
susceptible for doxorubicin uptake, increasing the EPR-mediated uptake of liposomal 
drugs and by providing a trigger for drug release from TSLDox. All above factors play a 
pivotal role in the here employed 2-step delivery scheme. However, the actual amount 
of doxorubicin delivered in a 2-step approach is determined by liposomal uptake 
and stability of the formulation and can therefore never exceed the liposomal uptake 
(in%ID/g). This study has shown that preheated B16 and BFS-1 tumors accumulated 
a maximum of 9.8% injected dose per cm³ and 5.0% injected dose per cm³ of the 
injected TSL dose, while the intraliposomal doxorubicin concentration only reached 3 
and 1.5% injected dose per cm³ at 4 h p.i. respectively. These doxorubicin concentra-
tions appeared insufficient to induce a noticeable therapeutic response. The 1-step 
intravascular drug release seems to be advantageous, since the injected TSLDox provide 
a high plasma concentration of doxorubicin exposing the tumor to a high area under 
the curve (AUC) over the time span of HT. Furthermore, the HT induced increase 
in doxorubicin uptake by tumor cells may lead in both delivery schemes to a higher 
intracellular concentration.
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curreNT STATuS of NANoMeDiciNe
Anticancer nanomedicine containing chemotherapeutics were developed to cope 
with drug solubility problems in vivo and severe side effects limiting use in patients367. 
For example, doxorubicin is an important anticancer drug used against various can-
cers368,369, but unfortunately it is associated with severe cardiotoxicity and potential 
heart failure370. Liposomal doxorubicin, Doxil, was successfully formulated to increase 
accumulation in the tumor and reduce cardiotoxicity. Other well known FDA approved 
nanomedicines are liposomal daunorubicin (DaunoXome), liposomal vincristine 
(Marqibo), and albumin-bound paclitaxel (Abraxane). These nanomedicines success-
fully reduce side effects and have shown therapeutic effects in certain tumor types. In 
addition, nanomedicines with cytarabine, mifamurtide, iron oxide particles, asparagi-
nase, DAB389IL-2, and SMANCS have been clinically approved371.
Most chemotherapeutics are encapsulated in lipid (liposomes) or polymer-based 
vesicles (micelles or polymersomes). Liposomes can encapsulate both hydrophilic and 
hydrophobic drugs, although the latter associates with the lipid bilayer which has a 
relatively small volume. Polymeric micelles have a hydrophilic shell and a hydrophobic 
core, which enables more efficient encapsulation of hydrophobic drugs372,373. Due to 
their relatively small size and effective tumor penetration374, several formulations are 
showing improved therapeutic responses and reduced side effects in clinical trials375. 
The chemotherapeutic drug paclitaxel causes severe adverse effects, in addition to 
hypersensitivity to its often used solubilizing excipient Kolliphor EL376. Genexol-PM, a 
Kolliphor EL-free polymeric formulation, is currently in Phase II trials, where it seems 
highly effective and tolerable in combination with cisplatin377. The FDA approved 
co-condensate of albumin and paclitaxel, ABI-007, demonstrated increased tumor 
response rates and delayed tumor progression in patients with metastatic breast can-
cer378. Irinotecan, a camptothecin derivative, is lipophilic and has an unstable structure 
on its own, yet it can be encapsulated in polymeric micelles (NK012) and has proven to 
be tolerated well and showed antitumor activity379. The platinum-based chemothera-
peutic, cisplatin380, has also been encapsulated in polymeric micelles (Nanoplatin or 
NC-6004), and a Phase I study is currently underway where it is being used as first line 
treatment in combination with 5-FU and cetuximab for metastatic squamous cell carci-
noma of the head and neck. This formulation was developed after disappointing results 
with liposomal cisplatin (SPI-77)381,382, where despite high tumor uptake, a limited ef-
fect was observed possibly due to incomplete drug release383. All the above mentioned 
formulations rely on passive accumulation in the tumor, which unfortunately is not 
often effective, and numerous nanomedicine have failed to get into the clinic or mainly 
received approval due to the reduction in drug related adverse effects.
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The variability in therapeutic efficacy can have various reasons, yet in general it comes 
down to inter- and intratumoral heterogeneity within the patient population384. It has 
been shown that tumor accumulation can range from 1-10% injected dose per gram 
in various mouse models depending on the formulation and pharmacokinetics of the 
nanomedicine385. Furthermore, the formulation of liposomes has a major effect on its 
biodistribution and interactions with the tumor microenvironment. Clinically used 
nanomedicines have sizes ranging from dozens to hundreds of nanometers, which 
results in different pharmacokinetic profiles. It has been implied that the large size 
of nanoparticles often compromises penetration and homogeneous distribution in 
tumors386. In 1995, a study with adenocarcinoma transplanted in dorsal skin chambers 
showed an inverse correlation between microvascular permeability and the size of 
macromolecules148. Further research led to the observation that tumor penetration is 
severely hampered by the composition, structure and distribution of the extracellular 
matrix387. As a result, nanoparticles primarily concentrate in the perivascular space of 
the tumor and often do not penetrate the tumor any further388,389. This was supported 
by a study which showed that increasing molecular weight of dextrans decreased pen-
etration of tumor tissue to only 5 μm from the nearest vessel for the largest dextrans 
of 2 MDa390. Luckily, the penetration of nanomedicines can be improved by using 
compounds that remove or weaken barriers present in the tumor, via loosening of the 
extracellular matrix with MMPs, such as collagenase391, hyaluronidase392, and other 
proteases393, although some of these molecules play important roles in tumor invasion 
and metastasis which limits their usability in the clinic394.
A more subtle way of increasing efficacy is by the addition of targeting ligands which 
can bind specifically to tumor cells, or in their vicinity via targeting of endothelial or 
stromal cells. Unfortunately, only a small number of targeted formulations are currently 
in Phase II/III clinical trials out of at least 36 anticancer nanomedicines371,395. In this 
thesis, we tried to develop diagnostic and therapeutic nanomedicines which use target-
ing ligands to enhance their specificity to the tumor and augment the beneficial effects 
of encapsulated drugs.
PerSoNALizeD MeDiciNe: TArGeTiNG or No TArGeTiNG?
Targeting tumor specific antigens is crucial for diagnostics, therapeutics, and evalua-
tion of drugs. Targeting moieties are in constant development to enhance specificity 
and decrease side effects in patients. As a novel moiety in the search for more targeted 
anticancer drugs, nanobodies have slowly become established as biotechnological 
tools and imaging modalities396, although their use as a therapeutic agent is still under 
development397. After their discovery78, their small size, high solubility and affinity, and 
cost-efficient production have made them the ideal tool for an ever increasing number 
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of applications108. Several nanobodies have been developed as targeting ligands against 
EGFR121, HER2398, c-MET and HGF122,399, VEGF and VEGFR-2124,400, DR5401, CXCR4402, 
CXCR7 and CXCL11/12123,403, and the vasculature via PlexinD1132. Nanobodies are ideal 
for imaging, due to their short half-life, although for therapeutic applications various 
modifications are used to increase their half-life in blood. Hydrophilic PEG chains can 
be conjugated to the nanobodies via cysteine chemistry, which has no effect on the 
nanobodies’ affinity404. The avidity of nanobodies can be enhanced by combining the 
number of nanobodies in one complex structure, in essence increasing the valency401. 
To take it one step further, a nanoparticle can conjugate hundreds of nanobodies on its 
surface, thereby increasing the specificity of nanomedicine and enhancing therapeutic 
efficacy. To this end, nanobody functionalized liposomes405, micelles406, and albumin-
based nanomedicine against EGFR were generated407, in addition to polymersomes 
targeted to HER2131.
In nanomedicine, targeting moieties can increase target cell specificity, reduce 
aspecific cell binding and potentially be internalized via receptor mediated endocyto-
sis151,408,409. The internalization of HER2-targeted Doxil liposomes has been shown with 
both monoclonal antibodies and antibody fragments as targeting ligands52,68. After suc-
cessful extravasation, ligand binding of tumor antigens will prevent diffusion back into 
circulation, which over time can lead to a higher concentration in the tumor. By using a 
different route of approach, targeted nanomedicines can circumvent drug resistance410. 
In addition, intrinsically active targeting moieties can have synergistic or additive effects 
in combination with drug loaded nanomedicine130. Targeted nanomedicines can use 
any overexpressed cancer cell surface marker as a potential target, although many such 
markers are not exclusively expressed by tumor cells276. Targeted nanomedicines have 
been generated using all types of targeting moieties, such as monoclonal antibodies48, 
antibody fragments, peptides411, aptamers412, and other small targeting molecules. 
When using targeting moieties, the nanomedicine first needs to accumulate in the 
tumor tissue via the EPR effect, before tumor-specific targeting can take place. Ideally, 
targeting ligands also improve cellular internalization via endocytosis, and commonly 
used receptors include folate65,413, and transferrin414,415. Receptors overexpressed on an-
giogenic endothelial cells can be targeted to reduce blood supply and starve the tumor 
of nutrients. Among the most common targets are integrins, targeted by derivatives of 
the oligopeptide RGD and NGR416. In the last year, a number of very interesting pre-
clinical studies have been performed which gives an insight into the future of targeted 
nanomedicine. For example, ICAM-1 targeted immunoliposomes were used to target 
triple-negative breast cancer and contained siRNA targeting lipocalin 2 (breast cancer 
progression promoter) to significantly reduce angiogenesis in vivo417. One of the first 
clinically tested targeted nanomedicine, BIND-014, a docetaxel containing polymer-
based nanomedicine targeted against PSMA, recently entered Phase II clinical trials 
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for the treatment of metastatic castration-resistant prostate cancer63,279. The targeting 
of this nanomedicine is based on a small hydrophilic molecule, S,S-2-(3-[1-carboxy-5-
amino-pentyl]-ureido)-pentanedioic acid, capable of targeting PSMA with high speci-
ficity280. Another study showed the use of CD44, identified as a cancer stem cell marker, 
as a targeting moiety for Doxil418. In addition to passive targeted doxorubicin formula-
tions, targeted liposomes with single chain variable fragments against HER2 (MM-302) 
in combination with trastuzumab are currently being tested in a Phase II clinical trial 
against locally advanced/metastatic breast cancer61. In one study, glutathione-targeted 
liposomes were designed to cross the blood brain barrier where encapsulated nanobod-
ies against amyloid beta could have its effect as treatment against neurodegenerative 
disorders such as Alzheimer’s419. These studies indicate that the optimal combination 
of nanoparticle formulation and targeting ligand can facilitate improved drug delivery 
and enhance therapeutic efficacy.
Whether the use of targeting ligands translates into effective therapeutic or diagnostic 
tools is dependent on several factors. Firstly, the ratio between antigen expression in the 
target tissue compared to non-target tissues determines the signal-to-background ratio 
in imaging and the amount of adverse effects in targeted nanomedicines. Secondly, the 
availability of the receptor at the target site, which depends on receptor density, degree 
of shedding and the rate of internalization, determines the degree of binding of targeted 
nanomedicines. Thirdly, the expression of the receptors might not be homogeneous 
throughout the tumor and may change over time, both naturally or as a reaction to recep-
tor binding drugs. Due to complications with conventional antibodies, smaller antibody 
fragments are often chosen for either targeting of nanoparticles or imaging. In this the-
sis, we have generated heavy-chain antibodies against MUC1, which contain a human 
variable fragment to facilitate clinical translation at a later stage (Chapter 2). MUC1 
is overexpressed in breast and ovarian cancer198,200, and is associated with metastatic 
potential and poor prognosis202. The generated antibodies showed increased avidity to 
MUC1 expressing cell lines and can be used as a novel targeting moiety for nanomedi-
cine. In addition, we developed a PMSA-specific imaging tracer by conjugating a nano-
body with indium-111 (Chapter 3). In this instance, the composition of the nanobody 
with the radionuclide was determining the biodistribution and modifications had to 
be made to optimize functionality. The nanobodies used have much shorter circulation 
times compared to formerly used monoclonal antibodies. The small size of nanobodies 
does increase the retention in the kidneys, due to glomerular filtration or trapping of 
metabolites in the lysosomes of renal tubular cells. The aspecific uptake in the kidneys 
might be problematic for therapeutic and imaging purposes, since it can cause toxicity 
in the kidney or interfere with visualization of small tumor lesions in the vicinity. The 
nanobody described in Chapter 3 was targeted against PSMA and produced using a 
His-tag, which showed high binding to PSMA-expressing PC-310 tumors. Co-injection 
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with gelofusin and lysine efficiently reduced renal uptake, as described elsewhere237. 
The His-tag can also increase renal uptake of radiolabeled nanobodies117, which led to 
the choice of a SUMO3 expression vector which can be used to produce proteins with 
minimal additions to its original amino acid sequence. This enabled the production of 
nanobodies with a C-terminal cysteine to facilitate conjugation to indium-111. The re-
sulting radionuclide-nanobody conjugates showed similar binding to PSMA-expressing 
tumors compared to His-tag produced nanobodies, and renal uptake was reduced to 3% 
injected dose per gram tissue at 4 h. These results show that nanobodies can be made 
that are ideal for imaging purposes, by reducing renal uptake as much as possible, and 
opening the way to therapeutic applications with these nanobodies.
Further, to make a direct comparison between targeted and non-targeted liposomes, 
we investigated cancer cell binding, tumor accumulation, and efficacy of both formula-
tions (Chapter 4). PSMA was chosen as a target, which is abundantly present on most 
prostate cancer cells. After conjugation of the PSMA-specific nanobodies to liposomes, 
binding was tested using flow cytometry and in vivo localization studies using SPECT/
CT imaging. The liposomes were highly specific in vitro, yet seemed to lose their ad-
vantage to non-targeted liposomes in vivo when patient-derived xenografts were used. 
It has been suggested that patient-derived xenografts develop a more organized and 
less permeable tumor vasculature, comparable to clinical tumors, than cell line xeno-
grafts420. PSMA-positive cell line xenografts showed accumulation comparable to the 
results found in vitro with flow cytometry, although PMSA-positive patient-derived xe-
nografts did not show an enhanced accumulation of targeted liposomes. To determine 
cytotoxicity, liposomes were loaded with doxorubicin and used for in vitro cytotoxicity 
experiments and an in vivo efficacy study. In vitro cytotoxicity showed that EC50 values 
were enhanced in PSMA-positive cell lines. The efficacy study showed that tumor in-
hibition was not significantly different between targeted and non-targeted liposomes 
in both PSMA-positive and negative xenografts. To find a possible explanation for the 
lack of efficacy of targeted liposomes, we performed reflectance microscopy on whole 
tumor xenografts injected with PSMA-targeted liposomes. We observed that while 
some liposomes did extravasate from tumor vessels, the majority remained confined in 
and around the tumor vessels. In addition, the coverage of liposomes after diffusion was 
extremely heterogenous, and several areas showed no liposomal presence. The tumor 
morphology is clearly a restrictive factor and it is plausible that the vasculature might 
not have gaps with a size suitable for liposomal extravasation. Additionally, liposomes 
that extravasated from the tumor vasculature may have been stopped by the first layer of 
antigen-positive cells, the so-called binding barrier effect207,421. While these experiments 
show that the use of targeted liposomes clearly enhances specificity and is advantageous 
over free drug, several issues such as effective biodistribution and bioavailability remain 
to be addressed and future studies should aim to further clarify these issues.
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THE EPR EFFECT, AN oNgoINg DEBATE
The EPR effect describes the accumulation of macromolecules in tumors142, and has 
been one of the major contributors to the success of nanomedicines in the clinic. Long-
circulating molecules have a better chance of using the leaky tumor vasculature de-
scribed by the EPR effect, hence nanomedicine research initially focused on more stable 
formulations. Clinical trials with liposomal doxorubicin have shown that the EPR effect 
is present in patients, although the accumulation of nanomedicine is dependent on the 
formulation of the nanomedicine and the tumor type being treated422. Nanoparticle 
extravasation relies on the presence of gaps in the endothelial layer, and tumors have 
an increased number of leaky cell-to-cell junctions due to an increased expression of 
angiogenic factors during the transition into the vascular phase of tumor growth146,423. 
Recently, a dynamic phenomenon has been characterized where vascular bursts take 
place which eject fluid into the interstitial space of tumors424. Together with the sus-
ceptibility of the tumor vasculature to permeability enhancing substances and external 
stimuli, it shows that blood vessels of the tumor are highly dynamic. Unfortunately, 
leakage from vessels is slow and nanomedicine can be cleared during circulation, which 
is one of the reasons that some nanomedicines do not find their way into the clinic284.
Efficacy of anticancer nanomedicines is often constrained by impaired blood flow, 
restricted extravasation from the blood vessels, and limited intratumoral penetration. 
These factors are dependent on the type and pathological state of the cancer, and 
patient-specific factors, including previous antitumor treatment425. The heterogeneous 
vasculature in the tumors causes nutrient poor and rich regions426, where tumor cells are 
packed closely around blood vessels, which inhibits drug penetration into the tumor427. 
Furthermore, the high interstitial fluid pressure created by a poor and heterogeneous 
perfusion, and the absence of a proper lymphatic drainage system, complicates pen-
etration deeper into the tumor428. Extracellular matrix components, such as collagen429, 
glycoprotein, proteoglycan, elastin, and hyaluronan, and fast proliferating tumor cells 
can contribute to a high tumor density, which restricts perfusion and penetration of 
nanomedicine430. The extracellular matrix is a major contributor to the heterogeneity 
within the tumor through upregulated secretion of matrix metalloproteinases, col-
lagen fibers, and hyaluronan151,431. In contrast to liposomes, smaller nanoparticles are 
confronted with a lesser degree of restrictions from the tumor matrix and are given the 
chance to penetrate deeply within the tumor tissue432, although these smaller particles 
are more susceptible to clearance. To enable larger nanomedicine to penetrate the tu-
mor, it is possible to alleviate solid stress by targeting stromal cells and thus priming the 
tumor for drug delivery433,434. The blood flow in tumor vessels can be normalized with 
vasodilators, such as nitroglycerin, that have reported clinical benefits435. Normaliza-
tion of the tumor vasculature is predominantly advantageous for smaller nanomedicine, 
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since normalized vessels tend to decrease the size of fenestrations436. Extravasation 
from tumor blood vessels can be enhanced with a large number of strategies, including 
sonoporation437, exogenous VEGF438, TNF439, and hyperthermia182. Hyperthermia can 
be applied relatively easily on superficial tumors and it has been shown to increase 
extravasation of liposomes specifically from tumor vessels182. Developments with high 
intensity focused ultrasound (HIFU) to heat the tumor have been effective and can 
reduce off-target effects by heating the tumor region more specifically440. Despite these 
strategies, the EPR effect remains a heterogeneous and rate-limiting step in the success-
ful application of nanomedicines441.
Due to the variable success rate of nanomedicines, we wanted to investigate the 
restrictions of the EPR effect on liposomal accumulation in tumors (Chapter 5). We 
tried to eliminate variations in liposomal formulation by using stable long-circulating 
liposomes similar to clinically used Doxil. Tumor size was kept comparable between 
tumor types, since it is known that small tumors lack the necessary vascular system 
and large tumors risk the development of hypoxic or necrotic cores. We observed that 
tumor accumulation can range from < 2% to > 10% injected dose per gram, which 
in addition to a heterogeneous uptake, can lead to very different clinical outcomes. 
Further investigations into morphological parameters, such as blood vessel density 
and hypoxia, did not result in significant correlations, although it was observed that 
liposomal uptake correlates with tumor growth. Others have shown that mean vessel 
density strongly correlates with liposomal accumulation308, but our study suggests that 
the EPR effect is most likely regulated by a combination of morphological parameters, 
which determine the degree of accumulation and distribution of nanomedicine within 
the tumor.
The EPR effect has been proven to be a major bottleneck for drug delivery, and there-
fore the inclusion of imaging modalities remains crucial for determining the true accu-
mulation and distribution of liposomes within the patient and tumor, and to elucidate 
the presence and degree of EPR. As reviewed recently, radiolabeling nanomedicines to 
determine drug distribution is relatively easy and can be achieved with a number of 
radionuclides442. With the help of SPECT imaging of indium-111, liposomal distribu-
tion has been investigated and shows large differences in tumor uptake, confirming the 
heterogeneous nature of the EPR effect in different tumors299.
eNhANciNG The ePr effecT wiTh MiLD hyPerTherMiA
The EPR effect can be very restrictive in a number of tumor types, which often results in 
rejection of nanomedicine as a viable therapeutic candidate. To this end, a number of 
approaches have been evaluated to enhance permeability, extravasation or intracellular 
drug uptake443. To enhance liposomal biodistribution, liposomal formulations with 
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increased stability were developed, which however impeded content release. To circum-
vent this issue, liposomes sensitive to pH variations and other environmental factors 
such as levels of reducing agents or enzymes have been developed, which enable drug 
release upon uptake by cancer cells444,445. In contrast to environmental stimuli, external 
triggers can be used to facilitate drug release, such as photoactivation446, ultrasound447, 
and hyperthermia448,449. Here we will focus on hyperthermia as a tool to increase tumor 
vessel permeability and trigger drug release from thermosensitive liposomes. In Chap-
ter 4, hyperthermia was used to increase permeability of the tumor vasculature and 
enhance liposomal extravasation into the tumor interstitium. This approach proved 
to be quite successful, increasing the accumulation of targeted liposomes in the tumor 
more than three-fold compared to their non-treated counterparts.
The main issue with most external stimuli is related to the location of the tumor, 
and as can be expected, most of these applications have a limited tissue penetration 
depth. Even when using HIFU, deep seated neoplastic tissues remain difficult to reach. 
This is also true for metastatic disease, which have small lesions spread around the 
body for which detection methods remain to be elucidated. Thermosensitive liposomes 
have shown enhanced tumor accumulation after hyperthermia application in sarcoma-
bearing cats347, although it has been suggested that redistribution into the circulation 
and premature drug release remain issues that need to be solved450. The addition of 
targeting moieties, against endothelial and tumor cells, to thermosensitive nanomedi-
cine can be used to increase accumulation in the tumor451,452.
To circumvent some of the limitations of the EPR effect, such as restricted extrava-
sation from tumor vessels, nanoparticles have been developed with triggered release 
capabilities. Stability and manufacturing consistency remain issues that impede rapid 
clinical applications, although more effective nanomedicines for triggered drug deliv-
ery are being developed453,454. The application of mild hyperthermia to trigger release 
of drugs from thermosensitive formulations has shown moderate success and has 
advanced to clinical trials455. Chapter 6 shows the combination of mild hyperthermia 
and thermosensitive liposomes on two morphologically different murine tumors, B16 
melanoma and BFS-1 sarcoma, which show high and low uptake of thermosensitive 
liposomes, respectively322. Thermosensitive liposomes released all drug at 42°C and 
achieved high cytotoxicity compared to liposomes at 37°C, and it was also observed 
that hyperthermia enabled a faster cellular uptake. An interesting observation was that 
the hyperthermia induced permeability is transient343, since preheating followed by 
4 h incubation at 37°C did not improve uptake of doxorubicin. It has been reported 
that it is possible to achieve more permanent permeability changes, although a higher 
temperature has to be used358. Between the two tumor types used, the B16 tumors 
showed a higher uptake of liposomes and intratumoral doxorubicin. These tumors have 
a higher growth rate, a lower cell density and almost no collagen IV matrix. This may 
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have facilitated an enhanced tumor penetration and hence an increased therapeutic 
efficacy364. This study shows that despite major advances in liposome formulations and 
the application of external stimuli, such as hyperthermia, the morphology and hetero-
geneity of the tumor are still major factors determining accumulation and therapeutic 
efficacy of liposomes.
coNcLuDiNG reMArkS
The increased effort in the development of nanomedicines, including antibody con-
jugates, as potential tools for diagnosis and therapy of cancer, has led to an increased 
number of clinical trials and FDA approved drugs. The majority of these approaches 
rely on passive accumulation of the nanomedicine via the EPR effect, although ligand-
mediated targeted nanomedicine is increasingly being investigated.
The biological drivers that disqualify the use of nanomedicine in the clinic, due to 
low efficaciousness or side effects, are multifactorial and often difficult to elucidate. 
Moreover, these factors are heavily tumor and patient dependent, and correlate to the 
stage of tumor development, presence of metastasis, and previous treatment received. 
This disease heterogeneity, in a highly variable patient population, makes it challenging 
to design effective nanomedicine and build the case towards clinically approved drugs.
As shown in this thesis, drug-free nanoparticles can be used in combination with 
imaging to predict therapeutic benefit in various models. This can be extrapolated 
to the clinical setting, wherein patients prior to treatment get a low dose of empty 
nanoparticles, to determine the biodistribution and observe possible complications 
due to aspecific targeting to other organs or resistance in the tumor.
With nanomedicine research, insight into biological barriers, pharmacokinetics, 
(cyto)toxicity, and tumor biology is ever expanding and in combination with sophis-
ticated design strategies, targeting modalities and powerful tools in imaging, enables 
us to study biodistribution in depth. Eventually, this will lead to the required level of 
insight to be able to circumvent (patho)physiological barriers and cope with tumor/
patient heterogeneity to generate truly personalized treatments.
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SuMMAry
Advances in molecular biology have changed the field of cancer therapy dramatically 
over the past few decades by providing tools for the discovery and understanding of 
molecular features that determine and dictate therapeutic responses. Conventional 
chemotherapeutic regimens are associated with a small therapeutic window, limita-
tions in optimal dosing, the development of drug resistance and high-grade toxicities, 
which often lead to the withdrawal of patients from treatment.
To address these problems, several adapted and novel drugs have been developed. 
Firstly, an ever increasing number of therapies are focused on specifically targeted 
drugs, using peptides or antibodies to deliver the drug to the desired target. Secondly, 
with the help of lipid or other nanoparticles the drug can be encapsulated, thereby 
favoring an enhanced biodistribution and preventing interaction with the immune 
system or healthy tissues. This approach has been shown to decrease adverse effects re-
lated to anticancer drugs. Finally, the combination of targeting and nanoparticles may 
have the added benefit of an enhanced internalization of the drug and/or drug-carrying 
nanoparticle, leading to an increase in therapeutic efficacy.
Despite successes in (targeted) nanomedicine, several issues remain to be solved. 
Biodistribution of nanomedicine is highly dependent on tumor morphology and the 
ability of nanoparticles to extravasate from blood vessels and accumulate in the tumor 
tissue. It has been stated that the structurally chaotic vasculature in solid tumors shows 
an enhanced permeability where nanoparticles can extravasate and remain in the 
tumor tissue due to a diminished clearing. This principle is called the enhanced perme-
ability and retention effect and has been observed in many solid tumors, although the 
degree of tumor accumulation varies. Understandably, this has a major effect on all 
nanomedicines, including targeted nanoparticles. Moreover, the targeting modalities 
alone can often lead to complications. It is known that large structures, like liposomes 
or antibodies can elicit immune reactions leading to adverse effects. To minimize such 
effects, stealth-liposomes and nanobodies have been developed which are known 
to escape detection in the body and thus do not trigger an immune response. These 
liposomes are stable and long circulating, although the increased stability has led to 
an impaired drug release. To this end, thermosensitive formulations have been created 
which remain stable in circulation yet can be heat-activated to release their chemo-
therapeutic content at the target site.
Anticancer therapies require continuous development of nanomedicines to counter-
act the challenges provided by the tumor and its microenvironment. Challenges such as 
impaired biodistribution, adverse drug-related effects and drug resistance remain, yet 
the benefit of using multifunctional nanomedicine facilitates the rapid adjustment to 
any challenge that may arise.
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This thesis describes research into the development of antibodies, nanomedicine and 
solutions to complications of in vivo application. A general introduction to these topics 
is presented in Chapter 1.
In Chapter 2 we describe the development of novel heavy chain antibodies against 
MUC1, a tumor antigen present on various cancers. After immunization of a transgenic 
mouse able to express antibodies containing human variable domains, a number of 
antibodies were successfully produced. These heavy chain antibodies showed specific-
ity to MUC1-positive cancer cells, making this the first step towards novel targeted 
nanomedicines.
In Chapter 3 we produced novel PSMA-specific nanobodies for imaging of prostate 
cancer. Purified camelid-derived nanobodies were produced with the addition of only 
one single cysteine, to ensure stable conjugation to the radionuclide indium-111. This 
antibody-radionuclide conjugate enabled imaging of PSMA positive tumors in vivo 
with high specificity.
In Chapter 4 we continued with the nanobodies described in Chapter 3 and conju-
gated these to liposomes containing the drug doxorubicin. We observed an increased 
binding in vitro with PSMA positive cells and an enhanced uptake in PSMA positive tu-
mors in vivo. Determination of the efficacy of targeted versus non-targeted doxorubicin 
liposomes did not result in significant differences. To explore this issue, we investigated 
the distribution of the liposomes within the tumor and observed that the liposomes re-
mained in and around the vasculature. Penetration of the tissue was limited, although 
the use of mild hyperthermia significantly increased extravasation and accumulation of 
liposomes in the tumor.
In Chapter 5 we further investigated the issue of limited extravasation and accumu-
lation of liposomes in solid tumors. We followed the biodistribution of radiolabeled 
non-targeted liposomes to evaluate the influence of the enhanced permeability and re-
tention effect in various human tumor xenografts. Numerous morphological variables 
were investigated, such as blood vessel density, tumor growth, intratumoral hypoxia, 
infiltrating macrophages and lymphatic vessel density. In the end, no clear biological 
determinants could be found, although there was a significant correlation of liposomal 
accumulation with tumor growth. We concluded that the EPR effect varies profoundly 
between tumor types and that it can be highly constrictive in the application of nano-
medicine.
In Chapter 6 we tried to increase nanoparticle accumulation and anti-tumor efficacy 
by using hyperthermia in combination with thermosensitive liposomes. The applica-
tion of mild hyperthermia (41-42°C) increased liposomal accumulation in the tumor 
and thermosensitive liposomes were able to release the drug specifically at the tumor 
site.
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Taken together, this thesis shows drug development from antibody production and 
characterization, to conjugation with liposomes and eventually, the application of drug-
loaded liposomes in vivo with or without hyperthermia to increase efficacy. Chapter 7 
discusses the implication of these results and reviews the advantages and drawbacks of 
targeted nanomedicine.
fuTure PerSPecTiveS
The field of nanomedicine progressed rapidly since the discovery of liposomes in the 
sixties. Since then, numerous lipid, polymer-based, inorganic and viral nanoparticles, 
and drug-conjugates have been developed and known formulations have been improved 
upon. Any kind of anticancer drug can be loaded into a nanoparticle for increased target 
specificity and efficacy, and decreased drug-related adverse effects and drug resistance.
As indicated in this thesis, despite all developments in and outside of nanomedicine, 
cancer remains one of the most challenging diseases of our time. Several issues such as 
tumor heterogeneity, tumor cell plasticity and treatment of metastases remain to be 
solved. Collectively, the results in this thesis address challenges in current nanomedi-
cine and propose solutions to combat these problems. That nanomedicine continues to 
remain one of the focal points of anticancer therapy indicates that much progress will 
still be made.
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SAMeNvATTiNG
Het onderzoek naar kanker therapie heeft de afgelopen jaren veel veranderingen 
doorgemaakt met de realisatie dat moleculaire eigenschappen van de tumorcellen de 
therapeutische respons bepalen. Conventionele chemotherapeutica worden geassoci-
eerd met een beperkt therapeutisch venster, beperkingen aan een optimale dosering, 
de ontwikkeling van medicijnresistentie en hoge toxiciteit. Dit alles leidt vaak tot het 
stoppen van de behandeling door deze groep patiënten. Om deze problemen aan te 
pakken, worden veel nieuwe medicijnen ontwikkeld en deze worden continu geopti-
maliseerd. Allereerst is er een steeds groter wordend aantal therapieën die gericht zijn 
tegen specifieke doelen, waar met behulp van peptides of antilichamen de medicijnen 
worden afgeleverd. Ten tweede, kunnen medicijnen worden ingesloten in nanodeeltjes, 
zoals liposomen, zodat deze een verbeterde biodistributie krijgen en interactie met het 
immuunsysteem en gezond weefsel wordt tegengegaan. Deze methode is zeer succesvol 
in het beperken van nadelige effecten gerelateerd aan antikanker medicijnen. Uitein-
delijk kan de combinatie van een gerichte therapie met liposomen een positief effect 
hebben op de opname van het medicijn in kankercellen, wat een verhoogde effectiviteit 
tot gevolg kan hebben.
Ondanks recente successen in (gerichte) nanomedicijnen zijn er verscheidene pro-
blemen die nog opgelost moeten worden. Zo is de biodistributie van nanomedicijnen 
zeer afhankelijk van de morfologie van de tumor en de mate van extravasatie uit de 
bloedvaten en opname in het tumorweefsel. Onderzoek heeft uitgewezen dat de bloed-
vaten in solide tumoren een zeer chaotische architectuur hebben, waardoor ze zeer 
permeabel voor nanodeeltjes zijn. Deze kunnen dan uit de bloedvaten treden, waarna 
ze door beperkte (lymfatische) afvoer achterblijven in de tumor. Dit principe heet het 
‘enhanced permeability and retention’ effect en is in veel solide tumoren vastgesteld, 
hoewel de mate van deze zeer kan variëren. Het is dan ook begrijpelijk dat dit een groot 
effect heeft op alle nanomedicijnen, dus ook op gerichte nanodeeltjes. Daarnaast kan 
het gebruik van gerichte liganden ook tot problemen leiden. Grote structuren, zoals 
liposomen en antilichamen, kunnen een immuunrespons oproepen wat uiteindelijk tot 
nadelige effecten kan leiden. Om dit zoveel mogelijk te beperken, zijn zogenaamde 
‘stealth’-liposomen en ‘nanobodies’ ontwikkeld die detectie in het lichaam ontlopen en 
zo geen immuunrespons opwekken. Deze liposomen zijn zeer stabiel en hebben een 
lange circulatietijd, maar helaas beperkt dit het vrijkomen van het ingesloten medicijn. 
Om dit probleem op te lossen zijn er thermosensitieve liposomen ontwikkeld die stabiel 
zijn tijdens circulatie, maar op commando bij een bepaalde temperatuur de medicijnen 
in de tumor kunnen vrijgeven.
Het vergt een continue ontwikkeling van nanomedicijnen om alle aspecten van de 
tumor en zijn omgeving tegen te gaan. Uitdagingen blijven bestaan in de beperkte 
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biodistributie van de medicijnen, nadelige bijwerkingen en de ontwikkeling van medi-
cijnresistentie, maar gelukkig zijn nanomedicijnen zeer flexibel inzetbaar en kunnen ze 
aangepast worden op het specifieke doel.
In dit proefschrift wordt onderzoek beschreven aan de ontwikkeling van antilicha-
men, nanomedicijnen en de complicaties van in vivo gebruik van deze. Een globale 
introductie die deze onderwerpen behandelt is weergegeven in Hoofdstuk 1.
In Hoofdstuk 2 is de ontwikkeling van nieuwe ‘heavy chain’ antilichamen tegen 
MUC1, een tumor antigeen, beschreven. Na immunisatie van een transgene muis 
hebben we verscheidene antilichamen geproduceerd die humane variabele domeinen 
bevatten. Deze heavy chain antilichamen zijn succesvol geconjugeerd aan liposomen, 
wat dit de eerste stap richting een nieuw antikanker medicijn maakt.
In Hoofdstuk 3 hebben we nieuwe PMSA-specifieke antilichamen gebruikt voor 
visualisatie van prostaatkanker. Nanobodies waren afgeleid na immunisatie van een 
lama en deze zijn geproduceerd met een enkele cysteine voor conjugatie aan radionu-
clide indium-111. Het antilichaam-radionuclide conjugaat zorgt voor zeer specifieke 
visualisatie van PSMA positieve tumoren.
Hoofdstuk 4 gaat verder met de nanobodies, zoals beschreven in hoofdstuk 3, die 
hier geconjugeerd werden met liposomen die geladen zijn met het chemotherapeuticum 
doxorubicine. Dit leidde tot een verhoogde binding met PSMA positieve cellen in vitro 
en een verhoogde opname in PSMA positieve tumoren in vivo. Echter de werkzaam-
heid van gerichte en ongerichte liposomen verschilde niet van elkaar, wat mogelijk te 
verklaren valt door een ophoping van beide liposomen in en om de bloedvaten. Om de 
opname in de tumor de verhogen hebben we uiteindelijk milde hyperthermie toegepast, 
die zowel extravasatie als ophoping verhoogde in de PSMA positieve tumoren.
In Hoofdstuk 5 zijn we dieper ingegaan op het beperkte binnendringen en ophopen 
van liposomen in solide tumoren. Hiervoor volgden we de biodistributie van radionu-
clide-gelabelde liposomen om de invloed van het enhanced permeability and reten-
tion effect op verschillende tumoren te bepalen. Variabelen, zoals bloedvatdichtheid, 
tumorgroei, intratumorale hypoxie, infiltrerende macrofagen en lymfevatdichtheid, 
zijn vergeleken tussen de verschillende tumoren. Uiteindelijk is er geen eenduidige 
biologische determinant gevonden, hoewel er een duidelijk verband was tussen de snel-
heid van tumorgroei en opname van liposomen. We concludeerden dat het enhanced 
permeability and retention effect zeer variabel is tussen de verschillende tumortypes en 
dat het zeer beperkend kan werken op het gebruik van nanomedicijnen.
Hoofdstuk 6 beschrijft het gebruik van thermosensitieve liposomen voor een 
verhoogde ophoping en groter antitumor effect. Door een verhoogde temperatuur van 
41-42°C in de tumor kunnen de liposomen de ingesloten medicijnen gelokaliseerd 
vrijgeven.
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Dit proefschrift laat de ontwikkeling van een kankermedicijn zien, beginnend bij de 
ontwikkeling en validatie van antilichamen tot aan de conjugatie met liposomen en 
uiteindelijk de toepassing van doxorubicine-geladen liposomen in vivo met of zonder 
hyperthermie. Dit alles met het uiteindelijk doel voor een verbeterd antitumor effect. 
Hoofdstuk 7 bediscussieert de gevolgen van deze resultaten en beschrijft de voor- en 
nadelen van doelgerichte nanomedicijnen en de huidige ontwikkelingen in antikanker 
medicijnen.
ToekoMSTPerSPecTief
De ontwikkeling van nanomedicijnen heeft niet stilgestaan sinds de ontdekking van 
liposomen in de jaren zestig. Sindsdien heeft menig lipide, polymeer, inorganisch en 
viraal nanodeeltje of medicijnconjugaat zijn opwachting gemaakt en er worden continu 
nieuwe deeltjes ontwikkeld. Voor ieder soort antikankermedicijn kan een passend na-
nodeeltje gemaakt worden met als voordelen, een verhoogde specificiteit en werkzaam-
heid en verminderde nadelige effecten en medicijnresistentie.
Zoals in dit proefschrift is beschreven, blijft kanker een van de meest uitdagende 
ziekten van onze tijd. Tumorheterogeniteit, tumorcel plasticiteit en de behandeling van 
metastase blijven uitdagingen in het kankeronderzoek. De medicijnontwikkelingen 
binnen de nanotechnologie geven hoop en de verwachting is dat er nog veel vooruit-
gang zal worden geboekt.
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